GenCore version 5.1.6 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2005, 08:40:57; Search time 11.4389 Seconds

(without alignments)

1690.542 Million cell updates/sec

Title: US-10-624-932-2_COPY_246_295

Perfect score: 290

Sequence: 1 STWTEWSVCSASCGRGWQKR.....NGGAFCEGQNVQKTACATLC 50

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A Geneseq 16Dec04:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

3: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

R	esult		* Query							
	No.	Score		Length	DB	ID	Description			
	1	290	100.0	330	8	ADH71620	Adh71620 Hur	man pro		
	. 2	290	100.0	336	8	ADH71614	Adh71614 Hur	man pro		
	3	290	100.0	898	2	AAW78898	Aaw78898 Ra	UNC-5		
	4	290	100.0	898	5	AAU10543	Aau10543 Rat	t netri		
	5	290	100.0	898	5	AAU85403	Aau85403 Hur	man pro		
	6	290	100.0	898	5	AAU97899	Aau97899 Hur	nan net		
	7	290	100.0	898	5	AAU97900	Aau97900 Ra	t netri		
	8	290	100.0	898	7	ADG42580	Adg42580 Rat	trans		
	9	290	100.0	898	8	ADH71618	Adh71618 Hur			

10	290	100.0	943	4	AAM79128	Aam79128 Human pro
11	249	85.9	636	8	ADR99262	Adr99262 Splice va
12	249	85.9	669	8	ADR99252	Adr99252 Human sRO
13	249	85.9	929	7	ADG42583	Adg42583 Human tra
14	249	85.9	931	4	AAB50691	Aab50691 Human UNC
15	249	85.9	931	7	ADE63098	Ade63098 Human Pro
16	249	85.9	931	7	ADG42582	Adg42582 Mouse tra
17	249	85.9	931	7	ADG42584	Adg42584 Human tra
18	249	85.9	931	7	ABU64297	Abu64297 Human thr
19	249	85.9	931	8	ADR99258	Adr99258 Human unc
20	249	85.9	964	8	ADR99250	Adr99250 Human 1RO
21	249	85.9	982	4	ABG11551	Abg11551 Novel hum
22	243	83.8	331	8	ADH71612	Adh71612 Human pro
23	243	83.8	898	8	ADH71626	Adh71626 Human pro
24	243	83.8	899	5	AAU79939	Aau79939 Human UNC
25	243	83.8	899	7	ADG42569	Adg42569 Novel hum
26	243	83.8	899	8	ADH71636	Adh71636 Human pro
27	243	83.8	899	8	ADH71642	Adh71642 Human pro
28	243	83.8	899	8	ADH71648	Adh71648 Human pro
29	243	83.8	899	8	ADH71632	Adh71632 Human pro
30	243	83.8	.899	8	ADH71610	Adh71610 Human pro
31	243	83.8	899	8	ADH71628	Adh71628 Human pro
32	243	83.8	899	8	ADH71640	Adh71640 Human pro
33	243	83.8	899	8	ADH71630	Adh71630 Human pro
34	243	83.8	899	8	.ADH71650	Adh71650 Human pro
35	243	83.8	899	8	ADH71644	Adh71644 Human pro
36	243	83.8	899	8	ADH71634	Adh71634 Human pro
37	243	83.8	899	8	ADH71646	Adh71646 Human pro
38	243	83.8	899	8	ADH71638	Adh71638 Human pro
39	239	82.4	56	7	ADC77400	Adc77400 Human tra
40	239	82.4	321	8	ADQ65811	Adq65811 Novel hum
41	239	82.4	679	6	ABU52369	Abu52369 Human GPC
42	239	82.4	679	8	ADL24073	Adl24073 Human NOV
43	239	82.4	887	7	ADC77422	Adc77422 Human tra
44	239	82.4	924	6	ABU11210	Abull210 Human G-p
45	239	82.4	933	5	AA018734	Aao18734 Human NOV

ALIGNMENTS

```
RESULT 1
ADH71620
ID
    ADH71620 standard; protein; 330 AA.
XX
AC
    ADH71620;
XX
DT
     25-MAR-2004 (first entry)
XX
DE
     Human protein of the invention NOV21f SEQ ID NO:516.
XX
KW
     human; cytostatic; immunomodulator; neuroprotective; nootropic;
KW
     anorectic; antidiabetic; antimicrobial; antilipaemic; gene therapy;
     vaccine; cancer; cachexia; Alzheimer's disease; Parkinson's disease;
KW
KW
     obesity; diabetes; infectious disease; metabolic syndrome X;
KW
     dyslipidaemia.
XX
```

```
os
     Homo sapiens.
XX
PN
     WO2003102155-A2.
XX
     11-DEC-2003.
PD
XX
PF
     03-JUN-2003; 2003WO-US017430.
XX
PR
     03-JUN-2002; 2002US-0385120P.
PR
     04-JUN-2002; 2002US-0385784P.
PR
     05-JUN-2002; 2002US-0386041P.
PR
     05-JUN-2002; 2002US-0386047P.
     06-JUN-2002; 2002US-0386376P.
PR
     06-JUN-2002; 2002US-0386453P.
PR
PR
     06-JUN-2002; 2002US-0386864P.
PR
     06-JUN-2002; 2002US-0387016P.
PR
     07-JUN-2002; 2002US-0386796P.
PR
     07-JUN-2002; 2002US-0386816P.
PR
     07-JUN-2002; 2002US-0386931P.
PR
     07-JUN-2002; 2002US-0386942P.
PR
     07-JUN-2002; 2002US-0386971P.
PR
     07-JUN-2002; 2002US-0387262P.
PR
     08-JUN-2002; 2002US-0296960P.
PR
     10-JUN-2002; 2002US-0387400P.
PR
     10-JUN-2002; 2002US-0387535P.
PR
     11-JUN-2002; 2002US-0387610P.
     11-JUN-2002; 2002US-0387625P.
PR
     11-JUN-2002; 2002US-0387634P.
PR
PR
     11-JUN-2002; 2002US-0387668P.
PR
     11-JUN-2002; 2002US-0387696P.
PR
     11-JUN-2002; 2002US-0387702P.
PR
     11-JUN-2002; 2002US-0387836P.
PR
     11-JUN-2002; 2002US-0387859P.
PR
     12-JUN-2002; 2002US-0387933P.
PR
     12-JUN-2002; 2002US-0387934P.
PR
     12-JUN-2002; 2002US-0387960P.
PR
     12-JUN-2002; 2002US-0388022P.
PR
     12-JUN-2002; 2002US-0388096P.
PR
     13-JUN-2002; 2002US-0389123P.
PR
     14-JUN-2002; 2002US-0389118P.
     14-JUN-2002; 2002US-0389120P.
PR
     14-JUN-2002; 2002US-0389144P.
PR
     14-JUN-2002; 2002US-0389146P.
PR
     17-JUN-2002; 2002US-0389729P.
PR
     17-JUN-2002; 2002US-0389742P.
P.R
     18-JUN-2002; 2002US-0389884P.
PR
     19-JUN-2002; 2002US-0390006P.
PR
     19-JUN-2002; 2002US-0390209P.
PR
     21-JUN-2002; 2002US-0390763P.
     17-JUL-2002; 2002US-0396706P.
PR
     06-AUG-2002; 2002US-0401628P.
PR
PR
     09-AUG-2002; 2002US-0402156P.
PR
     09-AUG-2002; 2002US-0402256P.
PR
     09-AUG-2002; 2002US-0402389P.
PR
     12-AUG-2002; 2002US-0402786P.
     12-AUG-2002; 2002US-0402816P.
PR
     12-AUG-2002; 2002US-0402821P.
PR
```

```
12-AUG-2002; 2002US-0402832P.
PR
     13-AUG-2002; 2002US-0403448P.
PR
     13-AUG-2002; 2002US-0403459P.
PR
     13-AUG-2002; 2002US-0403531P.
PR
     13-AUG-2002; 2002US-0403532P.
PR
PR
     13-AUG-2002; 2002US-0403563P.
PR
     13-AUG-2002; 2002US-0406317P.
     15-AUG-2002; 2002US-0403617P.
PR
     26-AUG-2002; 2002US-0406182P.
PR
     26-AUG-2002; 2002US-0406355P.
PR
     27-AUG-2002; 2002US-0406240P.
PR
     12-SEP-2002; 2002US-0410084P.
     20-SEP-2002; 2002US-0412528P.
PR
     23-SEP-2002; 2002US-0412731P.
PR
     30-SEP-2002; 2002US-0414801P.
PR
     30-SEP-2002; 2002US-0414839P.
PR
PR
     30-SEP-2002; 2002US-0414840P.
PR
     30-SEP-2002; 2002US-0414954P.
PR
     09-OCT-2002; 2002US-0417186P.
PR
     09-OCT-2002; 2002US-0417406P.
     23-OCT-2002; 2002US-0420639P.
PR
PR
     28-OCT-2002; 2002US-0421156P.
PR
     31-OCT-2002; 2002US-0422690P.
PR
     01-NOV-2002; 2002US-0423130P.
PR
     05-NOV-2002; 2002US-00423798.
     05-NOV-2002; 2002US-0423798P.
PR
     12-NOV-2002; 2002US-0425453P.
XX
PA
     (CURA-) CURAGEN CORP.
XX
PΙ
     Alsobrook JP, Alvarez E, Anderson DW, Boldog FL, Casman SJ;
     Catterton E, Chapoval A, Crabtree-Bokor JR, Edinger SR, Ellerman K;
PΙ
PΙ
     Ettenberg S, Gangolli EA, Gerlach VL, Gorman L, Gunther E, Guo X;
     Gusev VY, Herrmann JL, Ji W, Kekuda R, Li L, Liu X, Macdougall JR;
     Maclachlan T, Malyankar UM, Mezick AJ, Millet I, Mishra VS;
PΙ
     Padigaru M, Patturajan M, Pena CEA, Peyman JA, Raha D, Rastelli L; Rieger DK, Rothenberg ME, Sciore P, Shenoy SG, Shimkets RA;
ΡI
PΙ
PΙ
     Smithson G, Spytek KA, Stone DJ, Vernet CAM, Voss EZ, Zhong M;
PΙ
     Zhong H;
XX
DR
     WPI; 2004-081935/08.
DR
     N-PSDB; ADH71619.
XX
PT
     New NOVX polypeptides and nucleic acid molecules useful for preventing or
PT
     treating NOVX-associated disorders, e.g. cancer, diabetes, infection or
PT
     obesity, and in chromosome mapping, tissue typing or pharmacogenomics.
XX
PS
     Example 21; SEQ ID NO 516; 1880pp; English.
XX
CC
     The invention relates to a novel isolated polypeptide (NOVX). A
CC
     polypeptide of the invention has cytostatic, immunomodulator,
CC
     neuroprotective, nootropic, anorectic, antidiabetic, antimicrobial, and
CC
     antilipaemic activity, and may have a use in gene therapy, and as a
CC
     vaccine. The polypeptides are encoded by NOVX polynucleotides comprising
CC
     any of the 303 fully defined nucleotide sequences given in the
CC
     specification. The polypeptide is useful in the manufacture of a
CC
     medicament for treating a syndrome associated with a human disease. The
```

```
polypeptide, polynucleotide and antibody are useful in diagnosing,
CC
     treating or preventing NOVX-associated disorders, e.g. cancer, cachexia,
CC
     Alzheimer's disease, Parkinson's disease, obesity, diabetes, infectious
CC
     diseases, metabolic syndrome X or dyslipidaemias. The nucleic acids are
CC
     further used as hybridisation probes, in chromosome mapping, tissue
     typing, preventive medicine, and pharmacogenomics. The present sequence
CC
CC
     represents a NOVX polypeptide of the invention.
XX
SO
     Sequence 330 AA;
  Query Match
                          100.0%;
                                  Score 290; DB 8;
                                                      Length 330;
  Best Local Similarity
                                  Pred. No. 8.4e-25;
                          100.0%;
  Matches
            50; Conservative
                                0; Mismatches
                                                       Indels
                                                                 0;
                                                                     Gaps
                                                                             0;
QУ
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db ]
          221 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 270
RESULT 2
ADH71614
ID
     ADH71614 standard; protein; 336 AA.
XX
AC
     ADH71614;
XX
DT
     25-MAR-2004
                  (first entry)
XX
DE
     Human protein of the invention NOV21c SEQ ID NO:510.
XX
KW
     human; cytostatic; immunomodulator; neuroprotective; nootropic;
KW
     anorectic; antidiabetic; antimicrobial; antilipaemic; gene therapy;
KW
     vaccine; cancer; cachexia; Alzheimer's disease; Parkinson's disease;
KW
     obesity; diabetes; infectious disease; metabolic syndrome X;
KW
     dyslipidaemia.
XX
os
     Homo sapiens.
XX
PN
     WO2003102155-A2.
XX
PD
     11-DEC-2003.
XX
PF
     03-JUN-2003; 2003WO-US017430.
XX
PR
     03-JUN-2002; 2002US-0385120P.
PR
     04-JUN-2002; 2002US-0385784P.
PR
     05-JUN-2002; 2002US-0386041P.
PR
     05-JUN-2002; 2002US-0386047P.
PR
     06-JUN-2002; 2002US-0386376P.
PR
     06-JUN-2002; 2002US-0386453P.
     06-JUN-2002; 2002US-0386864P.
PR
     06-JUN-2002; 2002US-0387016P.
PR
     07-JUN-2002; 2002US-0386796P.
PR
PR
     07-JUN-2002; 2002US-0386816P.
     07-JUN-2002; 2002US-0386931P.
PR
PR
     07-JUN-2002; 2002US-0386942P.
PR
     07-JUN-2002; 2002US-0386971P.
     07-JUN-2002; 2002US-0387262P.
PR
```

CC

```
08-JUN-2002; 2002US-0296960P.
PR
     10-JUN-2002; 2002US-0387400P.
PR
PR
     10-JUN-2002; 2002US-0387535P.
PR
     11-JUN-2002; 2002US-0387610P.
PR
     11-JUN-2002; 2002US-0387625P.
PR
     11-JUN-2002; 2002US-0387634P.
     11-JUN-2002; 2002US-0387668P.
PR
     11-JUN-2002; 2002US-0387696P.
PR
PR
     11-JUN-2002; 2002US-0387702P.
PR
     11-JUN-2002; 2002US-0387836P.
     11-JUN-2002; 2002US-0387859P.
PR
     12-JUN-2002; 2002US-0387933P.
     12-JUN-2002; 2002US-0387934P.
PR
     12-JUN-2002; 2002US-0387960P.
PR
     12-JUN-2002; 2002US-0388022P.
PR
PR
     12-JUN-2002; 2002US-0388096P.
PR
     13-JUN-2002; 2002US-0389123P.
PR
     14-JUN-2002; 2002US-0389118P.
PR
     14-JUN-2002; 2002US-0389120P.
PR
     14-JUN-2002; 2002US-0389144P.
     14-JUN-2002; 2002US-0389146P.
PR
PR
     17-JUN-2002; 2002US-0389729P.
PR
     17-JUN-2002; 2002US-0389742P.
PR
     18-JUN-2002; 2002US-0389884P.
PR
     19-JUN-2002; 2002US-0390006P.
     19-JUN-2002; 2002US-0390209P.
     21-JUN-2002; 2002US-0390763P.
PR
     17-JUL-2002; 2002US-0396706P.
PR
     06-AUG-2002; 2002US-0401628P.
PR
     09-AUG-2002; 2002US-0402156P.
PR
     09-AUG-2002; 2002US-0402256P.
PR
     09-AUG-2002; 2002US-0402389P.
PR
PR
     12-AUG-2002; 2002US-0402786P.
PR
     12-AUG-2002; 2002US-0402816P.
PR
     12-AUG-2002; 2002US-0402821P.
     12-AUG-2002; 2002US-0402832P.
PR
     13-AUG-2002; 2002US-0403448P.
PR
PR
     13-AUG-2002; 2002US-0403459P.
PR
     13-AUG-2002; 2002US-0403531P.
PR
     13-AUG-2002; 2002US-0403532P.
PR
     13-AUG-2002; 2002US-0403563P.
PR
     13-AUG-2002; 2002US-0406317P.
PR
     15-AUG-2002; 2002US-0403617P.
PR
     26-AUG-2002; 2002US-0406182P.
PR
     26-AUG-2002; 2002US-0406355P.
PR
     27-AUG-2002; 2002US-0406240P.
PR
     12-SEP-2002; 2002US-0410084P.
PR
     20-SEP-2002; 2002US-0412528P.
PR
     23-SEP-2002; 2002US-0412731P.
     30-SEP-2002; 2002US-0414801P.
PR
     30-SEP-2002; 2002US-0414839P.
PR
PR
     30-SEP-2002; 2002US-0414840P.
PR
     30-SEP-2002; 2002US-0414954P.
     09-OCT-2002; 2002US-0417186P.
PR
PR
     09-OCT-2002; 2002US-0417406P.
PR
     23-OCT-2002; 2002US-0420639P.
     28-OCT-2002; 2002US-0421156P.
PR
```

```
PR
     31-OCT-2002; 2002US-0422690P.
PR
     01-NOV-2002; 2002US-0423130P.
     05-NOV-2002; 2002US-00423798.
PR
     05-NOV-2002; 2002US-0423798P.
PR
PR
     12-NOV-2002; 2002US-0425453P.
XX
PA
     (CURA-) CURAGEN CORP.
XX
PΙ
     Alsobrook JP, Alvarez E, Anderson DW, Boldog FL, Casman SJ;
PΙ
     Catterton E, Chapoval A, Crabtree-Bokor JR, Edinger SR, Ellerman K;
PΙ
     Ettenberg S,
                  Gangolli EA, Gerlach VL, Gorman L, Gunther E, Guo X;
PΙ
     Gusev VY, Herrmann JL, Ji W, Kekuda R, Li L, Liu X, Macdougall JR;
     Maclachlan T, Malyankar UM, Mezick AJ, Millet I, Mishra VS;
PΙ
     Padigaru M, Patturajan M, Pena CEA, Peyman JA, Raha D,
                                                               Rastelli L;
     Rieger DK, Rothenberg ME, Sciore P, Shenoy SG,
PΙ
                                                      Shimkets RA;
PΙ
     Smithson G, Spytek KA, Stone DJ, Vernet CAM, Voss EZ, Zhong M;
PΙ
     Zhong H;
XX
DR
     WPI; 2004-081935/08.
DR
     N-PSDB; ADH71613.
XX
PT
     New NOVX polypeptides and nucleic acid molecules useful for preventing or
PT
     treating NOVX-associated disorders, e.g. cancer, diabetes, infection or
PT
     obesity, and in chromosome mapping, tissue typing or pharmacogenomics.
XX
PS
     Example 21; SEQ ID NO 510; 1880pp; English.
XX
CC
     The invention relates to a novel isolated polypeptide (NOVX). A
CC
     polypeptide of the invention has cytostatic, immunomodulator,
CC
     neuroprotective, nootropic, anorectic, antidiabetic, antimicrobial, and
CC
     antilipaemic activity, and may have a use in gene therapy, and as a
     vaccine. The polypeptides are encoded by NOVX polynucleotides comprising
CC
CC
     any of the 303 fully defined nucleotide sequences given in the
CC
     specification. The polypeptide is useful in the manufacture of a
CC
     medicament for treating a syndrome associated with a human disease. The
     polypeptide, polynucleotide and antibody are useful in diagnosing,
CC
CC
     treating or preventing NOVX-associated disorders, e.g. cancer, cachexia,
     Alzheimer's disease, Parkinson's disease, obesity, diabetes, infectious
CC
CC
     diseases, metabolic syndrome X or dyslipidaemias. The nucleic acids are
CC
     further used as hybridisation probes, in chromosome mapping, tissue
     typing, preventive medicine, and pharmacogenomics. The present sequence
CC
CC
     represents a NOVX polypeptide of the invention.
XX
SO
     Sequence 336 AA;
. Query Match
                         100.0%;
                                  Score 290; DB 8; Length 336;
  Best Local Similarity
                         100.0%;
                                  Pred. No. 8.6e-25;
 Matches
           50; Conservative
                                0; Mismatches
                                                 0; Indels
                                                                   Gaps
                                                                           0;
Qу
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
         224 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 273
RESULT 3
```

AAW78898

ID AAW78898 standard; protein; 898 AA.

```
XX
AC
     AAW78898;
XX
     25-MAR-2003
DT
                  (revised)
DT
     21-DEC-1998
                 (first entry)
XX
DΕ
     Rat UNC-5 homologue UNC5H-1.
XX
KW
     UNC-5; UNC5H-1; rat; netrin receptor; cell migration; axon guidance;
KW
     diagnosis; therapy.
XX
os
     Rattus sp.
XX
FH
     Key
                     Location/Qualifiers
FT
     Peptide
                     580. .594
FT
                     /note= "peptide used to raise rabbit polyclonal antisera"
XX
PN
     W09837085-A1.
XX
PD
     27-AUG-1998.
XX
     19-FEB-1998;
PF
                    98WO-US003143.
XX
PR
     19-FEB-1997;
                    97US-00808982.
XX
PΑ
     (REGC ) UNIV CALIFORNIA.
XX
ΡI
     Tessier-Lavigne M, Leonardo ED, Hinck L, Masu M, Keinomasu K;
XX
DR
     WPI; 1998-495364/42.
DR
     N-PSDB; AAV52940.
XX
PТ
     Netrin-binding, vertebrate proteins - useful for diagnosis, therapy and
PT
     the biopharmaceutical industry.
XX
PS
     Claim 1; Page 19-22; 32pp; English.
XX
CC
     UNC5H-1 and UNC5H-2 (see AAW78900) are rat homologues of Caenorhabditis
CC
     elegans UNC-5 protein. Their amino acid sequences were deduced from
CC
     isolated unc5h cDNA clones (see AAV52940 and AAV52942) isolated from an
CC
     E18 brain cDNA library. The predicted proteins show similarity with UNC-
     5, possess 2 predicted Ig-like domains and 2 predicted thrombospondin
CC
CC
     type-1 repeats; a predicted membrane spanning region, and a large
CC
     intracellular domain. They are predicted to be involved in cell migration
     and axon guidance, and are characterised as receptor proteins for
CC
CC
     netrins. Human UNC5H-1 (see AAW78899) and UNC5H-2 (see AAW78901) proteins
CC
     are also claimed. Vertebrate UNC-5 proteins may be produced recombinantly
CC
     from transfected host cells. The invention also provides unc-5
CC
     hybridisation probes and primers, vertebrate UNC-5-specific binding
CC
     agents such as specific antibodies, and methods of making and using the
CC
     subject compositions in diagnosis (e.g. genetic hybridisation screens for
CC
     vertebrate unc-5 transcripts), therapy (e.g. gene therapy to modulate
CC
     vertebrate unc-5 gene expression) and in the biopharmaceutical industry
CC
     (e.g. as immunogens, reagents for modulating cell quidance, reagents for
CC
     screening chemical libraries for lead pharmacological agents, etc.).
CC
     (Updated on 25-MAR-2003 to correct PI field.)
```

XX

```
SQ
     Sequence 898 AA;
  Query Match
                         100.0%; Score 290; DB 2; Length 898;
                         100.0%; Pred. No. 2.3e-24;
  Best Local Similarity
            50; Conservative
                                0; Mismatches
                                                      Indels
                                                                    Gaps
                                                                            0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
              Db
          246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 4
AAU10543
ID
     AAU10543 standard; protein; 898 AA.
XX
AC
     AAU10543;
XX
DT
     14-FEB-2002 (first entry)
XX
DE
     Rat netrin receptor UNC5H1 (YSG7) polypeptide.
XX
KW
     YSG; YSG7; schizophrenia; chronic animal model; LCGU; netrin receptor;
KW
     local cerebral glucose utilisation; phosphodiesterase 1-alpha; UNC5H1;
KW
     calcium-independent alpha-latrotoxin receptor; CIRL; trkE; synapsin 1A;
KW
     epithelial discoidin domain receptor 1; synapsin 1B; neuroleptic;
KW
     tumour necrosis factor alpha; TNF-alpha; rat.
XX
os
     Rattus sp.
XX
PN
     WO200175440-A2.
XX
PD
     11-OCT-2001.
XX
PF
     02-APR-2001; 2001WO-GB001486.
XX
PR
     31-MAR-2000; 2000GB-00007880.
PR
     26-MAY-2000; 2000GB-00012768.
XX
PA
     (WELF-) WELFIDE CORP.
XX
PΙ
     Cochran S, Paterson G, Ohashi Y, Morris B, Pratt J;
XX
DR
     WPI; 2002-010813/01.
DR
     N-PSDB; AAS16843.
XX
PT
     Novel chronic animal model of schizophrenia, useful for identifying anti-
PT
     psychotic drugs and genes that are associated with schizophrenia.
XX
PS
     Disclosure; Fig 8b; 79pp; English.
XX
CC
     The invention relates to YSG polynucleotide fragments for use in
CC
     diagnosing and/or developing treatments for schizophrenia using chronic
CC
     animal models. The polynucleotides and their encoded polypeptides are
CC
     used for identification of compounds which modulate the expression of YSG
CC
     molecules, leading to the manufacture of schizophrenia medicaments. The
CC
     sequences can also be used for testing candidate compounds for any effect
CC
     on the polypeptides. Anti-schizophrenic effects of a compound can be
```

```
CC
     determined by measuring local cerebral glucose utilisation (LCGU) or
CC
     comparing its expression level with that of a control group. The
CC
     sequences are useful in the identification of genes associated with
CC
     schizophrenic states and in the development of an antibody. The sequences
CC
     of the invention include phosphodiesterase 1-alpha, calcium-independent
CC
     alpha-latrotoxin receptors (CIRL)-1,2&3, epithelial discoidin domain
CC
     receptor 1 (trkE), netrin receptor (UNC5H1), synapsins 1A and AB and
CC
     tumour necrosis factor (TNF) alpha. This sequence represents rat netrin
CC
     receptor UNC5H1 (YSG7) polypeptide
XX
SQ
     Sequence 898 AA;
  Query Match
                          100.0%;
                                  Score 290; DB 5; Length 898;
  Best Local Similarity
                         100.0%; Pred. No. 2.3e-24;
 Matches
           50; Conservative
                                0; Mismatches
                                                  0; Indels
                                                                    Gaps
                                                                            0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
              246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 5
AAU85403
ID
     AAU85403 standard; protein; 898 AA.
XX
AC
     AAU85403;
XX
DT
     21-MAY-2002 (first entry)
XX
DΕ
     Human protein NOV1.
XX
KW
     Human; NOVX; cardiomyopathy; atherosclerosis; diabetes;
KW
     cell signal processing disorder; metabolic disorder; obesity; infection;
KW
     anorexia; cancer-associated cachexia; cancer; neurodegenerative disorder;
KW
     Alzheimer's disease; Parkinson's disease; immune disorder;
KW
     haematopoietic disorders; dyslipidaemia; pain; asthma; hypertension;
KW
     osteoporosis; Crohn's disease; multiple sclerosis; angina pectoris;
KW
     myocardial infarction; ulcer; allergy; benign prostatic hypertrophy;
KW
     psychosis; neurological disorder; anxiety; schizophrenia;
KW
     manic depression; dementia; dyskinesia; Huntington's disease;
KW
     Gilles de la Tourette's syndrome; gene therapy.
XX
os
     Homo sapiens.
XX
PN
     WO200210216-A2.
XX
PD
     07-FEB-2002.
XX
PF
     30-JUL-2001; 2001WO-US024225.
XX
     28-JUL-2000; 2000US-0221409P.
PR
PR
     04-AUG-2000; 2000US-0222840P.
PR
     04-AUG-2000; 2000US-0223752P.
     04-AUG-2000; 2000US-0223762P.
PR
PR
     04-AUG-2000; 2000US-0223769P.
     04-AUG-2000; 2000US-0223770P.
PR
     14-AUG-2000; 2000US-0225146P.
PR
```

```
PR
     15-AUG-2000; 2000US-0225392P.
PR
     15-AUG-2000; 2000US-0225470P.
     16-AUG-2000; 2000US-0225697P.
PR
PR
     01-FEB-2001; 2001US-0263662P.
PR
     05-APR-2001; 2001US-0281645P.
XX
PA
     (CURA-) CURAGEN CORP.
XX
     Padigaru M, Mezes P, Mishra V, Burgess C, Casman S, Grosse WM;
PΙ
PΙ
     Alsobrook JP, Lepley DM, Gerlach VL, Macdougall JR,
                                                            Smithson G;
XX
DR
     WPI; 2002-180074/23.
     N-PSDB; ABK37922.
DR
XX
PΤ
     New isolated cytoplasmic, nuclear, membrane bound, or secreted
     polypeptide, useful for treating cardiomyopathy, atherosclerosis,
РΤ
PT
     infections, cancer, neurodegenerative, metabolic, hematopoietic and
PT
     immune disorders.
XX
PS
     Claim 1; Page 11; 213pp; English.
XX
CC
     The invention relates to an isolated cytoplasmic, nuclear, membrane
CC
    bound, or secreted polypeptide (NOVX, x= 1-14) their variants or mature
CC
     form. Also included are the nucleic acids encoding the NOVX proteins, a
CC
     vector comprising the nucleic acid, a cell comprising the vector, an anti
CC
     -NOVX antibody and modulators of NOVX. NOVX, the nucleic acid and the
CC
     antibody are useful for treating or preventing a NOVX-associated
CC
     disorder, where the disorder is selected from cardiomyopathy,
CC
     atherosclerosis, diabetes, a disorder related to cell signal processing
CC
     and metabolic pathway modulation, metabolic disorders, obesity,
CC
     infectious disease, anorexia, cancer-associated cachexia, cancer,
CC
    neurodegenerative disorders, Alzheimer's disease, Parkinson's disease,
CC
    immune disorders, haematopoietic disorders, and the various
CC
    dyslipidaemias, metabolic disturbances associated with obesity, the
CC
    metabolic syndrome X and wasting disorders associated with chronic
CC
    diseases, bacterial, fungal, protozoal and viral infections, pain,
CC
    bulimia, asthma, hypertension, urinary retention, osteoporosis, Crohn's
    disease, multiple sclerosis, Albright Hereditary Osteodystrophy, angina
CC
    pectoris, myocardial infarction, ulcer, allergy, benign prostatic
CC
    hypertrophy, and psychotic and neurological disorders, including anxiety,
CC
CC
     schizophrenia, manic depression, delirium, dementia, and dyskinesias,
CC
     such as Huntington's disease and Gilles de la Tourette's syndrome. The
CC
    nucleic acid is useful in gene therapy. The present sequence represents a
CC
    NOVX protein
XX
SO
     Sequence 898 AA; ....
                         100.0%; Score 290; DB 5; Length 898;
 Best Local Similarity
                         100.0%; Pred. No. 2.3e-24;
 Matches
           50; Conservative
                                0; Mismatches
                                                 0; Indels 0; Gaps
                                                                            0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
```

246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGONVQKTACATLC 295

Db

```
AAU97899
     AAU97899 standard; protein; 898 AA.
ID
XX
AC
     AAU97899;
XX
DT
     27-AUG-2002 (first entry)
XX
DE
     Human netrin binding membrane receptor UNC5H-1 protein.
XX
KW
     Netrin binding membrane receptor; receptor; UNC5H-1; human; nootropic;
KW
     neuroprotective; cytostatic; antiparkinsonian; cerebroprotective; cancer;
KW
     central nervous system; CNS; stroke; Parkinson's disease;
KW
     multiple sclerosis; Alzheimer's disease.
XX
OS
     Homo sapiens.
XX
FH
                     Location/Qualifiers
     Key
FT
     Domain
                     152. .223
FT
                     /note= "Immunoglobulin domain "
FT
     Domain
                     247. .294
FT
                     /note= "Thrombospondine type 1 domain "
FT
     Domain
                     302. .348
\mathbf{FT}
                     /note= "Thrombospondine type 1 domain"
FT
     Region
                     361. .382
FT
                     /note= "Transmembrane region"
                     495. .598
FT
     Domain
FT
                     /note= "ZU5 domain"
FT
     Domain
                     817. .897
FT
                     /note= "Death domain"
XX
PN
     WO200233080-A2.
XX
PD
     25-APR-2002.
XX
PF
     15-OCT-2001; 2001WO-EP011891.
XX
PR
     16-OCT-2000; 2000US-0240061P.
XX
PA
     (FARB ) BAYER AG.
XX
ΡI
     Koehler RH;
XX
DR
     WPI; 2002-463314/49.
DR
     N-PSDB; ABK52891.
XX
PT
     Novel human netrin binding membrane receptor polypeptide and
PT
     polynucleotides for identifying modulating agents useful in treating
PT
     diseases e.g. Parkinson's disease, multiple sclerosis, stroke,
     Alzheimer's disease.
PT
XX
PS
     Claim 1; Fig 2; 94pp; English.
XX
CC
     This invention relates to the DNA and protein sequences of a novel
CC
     purified human netrin binding membrane receptor, UNC5H-1. The DNA
CC
     sequence of the invention is useful as a probe for detecting a nucleic
CC
     acid encoding the UNC5H-1 protein in a biological sample. The sequences
CC
     of the invention are useful to screen for agents which decrease the
```

```
screening agents which regulate (modulate) the activity of the protein of
CC
     the invention. A pharmaceutical composition containing the protein of the
CC
CC
     invention or a reagent that modulates the activity of the UNC5H-1 protein
CC
    may be useful for treating a UNC5H-1 dysfunction related disease such as
CC
    cancer or a central nervous system (CNS) disorders (e.g, Parkinson's
CC
     disease, multiple sclerosis, stroke and Alzheimer's disease). Fusion
CC
     proteins comprising the UNC5H-1 protein are useful for generating
     antibodies and for in various assay systems, and the protein can be used
CC
     as a bait protein in a two-hybrid assay or three-hybrid assay. The method
CC
     of the invention is useful for detecting a coding sequence for the UNC5H-
CC
     1 protein. The present sequence represents the human netrin binding
CC
    membrane receptor UNC5H-1 protein of the invention
XX
SO
     Sequence 898 AA;
                          100.0%;
                                  Score 290; DB 5; Length 898;
 Query Match
  Best Local Similarity
                          100.0%;
                                  Pred. No. 2.3e-24;
           50; Conservative
                                0; Mismatches
                                                  0;
                                                      Indels
                                                                0;
                                                                    Gaps
                                                                            0;
Qy
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
          246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 7
AAU97900
    AAU97900 standard; protein; 898 AA.
XX
AC
    AAU97900;
XX
DT
     27-AUG-2002 (first entry)
XX
DΕ
     Rat netrin binding membrane receptor UNC5H-1 protein.
XX
KW
     Netrin binding membrane receptor; receptor; UNC5H-1; Rat; nootropic;
KW
     neuroprotective; cytostatic; antiparkinsonian; cerebroprotective; cancer;
     central nervous system; CNS; stroke; Parkinson's disease;
KW
KW
     multiple sclerosis; Alzheimer's disease.
XX
os
     Rattus sp.
XX
FH
     Key
                    Location/Qualifiers
FT
     Domain
                    152. .223
FT
                     /note= "Immunoglobulin domain "
FT
                    247. .294
     Domain
                     /note= "Thrombospondine type 1 domain "
FT
FT
                     302. .348
     Domain
FT
                     /note= "Thrombospondine type 1 domain"
FT
                    361. .382
     Region
                     /note= "Transmembrane region"
FT
FT
                     495. .598
     Domain
FT
                     /note= "ZU5 domain"
FT
                     817. .897
     Domain
FT
                    /note= "Death domain"
XX
     WO200233080-A2.
PN
```

activity of the UNC5H-1 protein. The sequences are also useful for

CC

```
XX
PD
     25-APR-2002.
XX
PF
     15-OCT-2001; 2001WO-EP011891.
XX
PR
     16-OCT-2000; 2000US-0240061P.
XX
PΑ
     (FARB ) BAYER AG.
XX
ΡI
     Koehler RH;
XX
DR
     WPI; 2002-463314/49.
XX
PT
     Novel human netrin binding membrane receptor polypeptide and
PΤ
     polynucleotides for identifying modulating agents useful in treating
PT
     diseases e.g. Parkinson's disease, multiple sclerosis, stroke,
PT
     Alzheimer's disease.
XX
PS
     Disclosure; Fig 3; 94pp; English.
XX
CC
     This invention relates to the DNA and protein sequences of a novel
CC
     purified human netrin binding membrane receptor, UNC5H-1. The DNA
CC
     sequence of the invention is useful as a probe for detecting a nucleic
CC
     acid encoding the UNC5H-1 protein in a biological sample. The sequences
CC
     of the invention are useful to screen for agents which decrease the
CC
     activity of the UNC5H-1 protein. The sequences are also useful for
CC
     screening agents which regulate (modulate) the activity of the protein of
CC
     the invention. A pharmaceutical composition containing the protein of the
CC
     invention or a reagent that modulates the activity of the UNC5H-1 protein
CC
     may be useful for treating a UNC5H-1 dysfunction related disease such as
CC
     cancer or a central nervous system (CNS) disorders (e.g, Parkinson's
CC
     disease, multiple sclerosis, stroke and Alzheimer's disease). Fusion
CC
     proteins comprising the UNC5H-1 protein are useful for generating
CC
     antibodies and for in various assay systems, and the protein can be used
CC
     as a bait protein in a two-hybrid assay or three-hybrid assay. The method
CC
     of the invention is useful for detecting a coding sequence for the UNC5H-
CC
     1 protein. The present sequence represents the Rat netrin binding
CC
     membrane receptor UNC5H-1 protein of the invention
XX
SQ
     Sequence 898 AA;
  Query Match
                         100.0%; Score 290; DB 5; Length 898;
  Best Local Similarity
                         100.0%; Pred. No. 2.3e-24;
  Matches
            50; Conservative
                                0; Mismatches
                                                      Indels
                                                                    Gaps
                                                                            0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
              Db
          246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 8
ADG42580
     ADG42580 standard; protein; 898 AA.
ID
XX
AC
     ADG42580;
XX
DT
     26-FEB-2004 (first entry)
```

```
XX
DE
     Rat transmembrane receptor Unc5H1.
XX
KW
     cytostatic; gene therapy; NOVX-agonist; NOVX-antagonist; pharmaceutical;
KW
     NOVX-associated disorder; cancer; rat; transmembrane receptor; Unc5H1.
XX
os
     Rattus norvegicus.
XX
     US2003204052-A1.
PN
XX
PD
     30-OCT-2003.
XX
PF
     04-OCT-2001; 2001US-00970944.
XX
     04-OCT-2000; 2000US-0237862P.
PR
XX
PA
     (HERR/) HERRMANN J L.
PA
     (RAST/) RASTELLI L.
PA
     (SHIM/) SHIMKETS R A.
XX
PI
     Herrmann JL, Rastelli L,
                               Shimkets RA;
XX
DR
     WPI; 2003-900673/82.
XX
PT
     New NOVX gene or NOVX-specific antibody, useful for preparing a
     composition for treating or preventing a NOVX-associated disorder, e.g.,
PT
     cancer.
XX
PS
     Disclosure; SEQ ID NO 13; 118pp; English.
XX
CC
     The invention describes a new isolated polypeptide comprising: a
CC
     polypeptide or its mature form comprising a sequence not given in the
CC
     specification; or a variant of (A), where one or more amino acid residues
CC
     in the variant differs in no more than 15% from the amino acid sequence
CC
     of the mature form. The pharmaceutical composition may be administered
CC
     via oral, transdermal, rectal or parenteral route. The polypeptide,
CC
     nucleic acid or antibody is useful for preparing a composition for
CC
     treating or preventing a NOVX-associated disorder, e.g., cancer. This is
CC
     the amino acid sequence of a transmembrane receptor Unc5H1 used in a
CC
     comparison with the novel human proteins of the invention.
XX
SO
     Sequence 898 AA;
  Query Match
                         100.0%;
                                  Score 290; DB 7; Length 898;
  Best Local Similarity
                         100.0%; Pred. No. 2.3e-24;
 Matches
           50; Conservative
                                0; Mismatches
                                                      Indels
                                                                            0;
                                                  0;
                                                                0; Gaps
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
              Db
          246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 9
ADH71618
     ADH71618 standard; protein; 898 AA.
XX
    ADH71618;
AC
```

```
XX
DT
     25-MAR-2004
                 (first entry)
XX
DE
     Human protein of the invention NOV21e SEQ ID NO:514.
XX
     human; cytostatic; immunomodulator; neuroprotective; nootropic;
KW
KW
     anorectic; antidiabetic; antimicrobial; antilipaemic; gene therapy;
KW
     vaccine; cancer; cachexia; Alzheimer's disease; Parkinson's disease;
KW
     obesity; diabetes; infectious disease; metabolic syndrome X;
KW
     dyslipidaemia.
XX
os
     Homo sapiens.
XX
     WO2003102155-A2.
PN
XX
PD
     11-DEC-2003.
XX
PF
     03-JUN-2003; 2003WO-US017430.
XX
PR
     03-JUN-2002; 2002US-0385120P.
PR
     04-JUN-2002; 2002US-0385784P.
PR
     05-JUN-2002; 2002US-0386041P.
PR
     05-JUN-2002; 2002US-0386047P.
PR
     06-JUN-2002; 2002US-0386376P.
PR
     06-JUN-2002; 2002US-0386453P.
     06-JUN-2002; 2002US-0386864P.
PR
     06-JUN-2002; 2002US-0387016P.
     07-JUN-2002; 2002US-0386796P.
PR
PR
     07-JUN-2002; 2002US-0386816P.
PR
     07-JUN-2002; 2002US-0386931P.
PR
     07-JUN-2002; 2002US-0386942P.
PR
     07-JUN-2002; 2002US-0386971P.
PR
     07-JUN-2002; 2002US-0387262P.
PR
     08-JUN-2002; 2002US-0296960P.
PR
     10-JUN-2002; 2002US-0387400P.
     10-JUN-2002; 2002US-0387535P.
PR
PR
     11-JUN-2002; 2002US-0387610P.
PR
     11-JUN-2002; 2002US-0387625P.
PR
     11-JUN-2002; 2002US-0387634P.
PR
     11-JUN-2002; 2002US-0387668P.
     11-JUN-2002; 2002US-0387696P.
PR
     11-JUN-2002; 2002US-0387702P.
PR
     11-JUN-2002; 2002US-0387836P.
PR
     11-JUN-2002; 2002US-0387859P.
PR
     12-JUN-2002; 2002US-0387933P.
PR
     12-JUN-2002; 2002US-0387934P.
PR
     12-JUN-2002; 2002US-0387960P.
PR
     12-JUN-2002; 2002US-0388022P.
     12-JUN-2002; 2002US-0388096P.
PR
     13-JUN-2002; 2002US-0389123P.
PR
     14-JUN-2002; 2002US-0389118P.
PR
     14-JUN-2002; 2002US-0389120P.
PR
     14-JUN-2002; 2002US-0389144P.
PR
PR
     14-JUN-2002; 2002US-0389146P.
     17-JUN-2002; 2002US-0389729P.
PR
     17-JUN-2002; 2002US-0389742P.
PR
     18-JUN-2002; 2002US-0389884P.
PR
```

```
19-JUN-2002; 2002US-0390006P.
PR
     19-JUN-2002; 2002US-0390209P.
PR
     21-JUN-2002; 2002US-0390763P.
PR
PR
     17-JUL-2002; 2002US-0396706P.
     06-AUG-2002; 2002US-0401628P.
PR
PR
     09-AUG-2002; 2002US-0402156P.
PR
     09-AUG-2002; 2002US-0402256P.
     09-AUG-2002; 2002US-0402389P.
PR
     12-AUG-2002; 2002US-0402786P.
PR
     12-AUG-2002; 2002US-0402816P.
PR
     12-AUG-2002; 2002US-0402821P.
PR
     12-AUG-2002; 2002US-0402832P.
PR
     13-AUG-2002; 2002US-0403448P.
PR
     13-AUG-2002; 2002US-0403459P.
PR
     13-AUG-2002; 2002US-0403531P.
PR
     13-AUG-2002; 2002US-0403532P.
PR
PR
     13-AUG-2002; 2002US-0403563P.
PR
     13-AUG-2002; 2002US-0406317P.
PR
     15-AUG-2002; 2002US-0403617P.
     26-AUG-2002; 2002US-0406182P.
PR
PR
     26-AUG-2002; 2002US-0406355P.
PR
     27-AUG-2002; 2002US-0406240P.
PR
     12-SEP-2002; 2002US-0410084P.
PR
     20-SEP-2002; 2002US-0412528P.
PR
     23-SEP-2002; 2002US-0412731P.
PR
     30-SEP-2002; 2002US-0414801P.
PR
     30-SEP-2002; 2002US-0414839P.
     30-SEP-2002; 2002US-0414840P.
PR
PR
     30-SEP-2002; 2002US-0414954P.
PR
     09-OCT-2002; 2002US-0417186P.
PR
     09-OCT-2002; 2002US-0417406P.
PR
     23-OCT-2002; 2002US-0420639P.
PR
     28-OCT-2002; 2002US-0421156P.
PR
     31-OCT-2002; 2002US-0422690P.
PR
     01-NOV-2002; 2002US-0423130P.
     05-NOV-2002; 2002US-00423798.
PR
PR
     05-NOV-2002; 2002US-0423798P.
PR
     12-NOV-2002; 2002US-0425453P.
XX
PA
     (CURA-) CURAGEN CORP.
XX
PΙ
     Alsobrook JP, Alvarez E, Anderson DW, Boldog FL, Casman SJ;
ΡI
     Catterton E, Chapoval A, Crabtree-Bokor JR, Edinger SR, Ellerman K;
ΡI
     Ettenberg S, Gangolli EA, Gerlach VL, Gorman L, Gunther E, Guo X;
     Gusev VY, Herrmann JL, Ji W, Kekuda R, Li L, Liu X, Macdougall JR;
ΡI
ΡI
     Maclachlan T, Malyankar UM, Mezick AJ, Millet I, Mishra VS;
ΡI
     Padigaru M, Patturajan M, Pena CEA, Peyman JA, Raha D,
PΙ
     Rieger DK, Rothenberg ME,
                                 Sciore P, Shenoy SG, Shimkets RA;
PΙ
     Smithson G, Spytek KA, Stone DJ, Vernet CAM, Voss EZ,
PΙ
     Zhong H;
XX
DR
     WPI; 2004-081935/08.
DR
     N-PSDB; ADH71617.
XX
PT
     New NOVX polypeptides and nucleic acid molecules useful for preventing or
PT
```

treating NOVX-associated disorders, e.g. cancer, diabetes, infection or obesity, and in chromosome mapping, tissue typing or pharmacogenomics.

PT

```
XX
PS
     Example 21; SEQ ID NO 514; 1880pp; English.
XX
CC
     The invention relates to a novel isolated polypeptide (NOVX). A
CC
     polypeptide of the invention has cytostatic, immunomodulator,
CC
     neuroprotective, nootropic, anorectic, antidiabetic, antimicrobial, and
CC
     antilipaemic activity, and may have a use in gene therapy, and as a
CC
     vaccine. The polypeptides are encoded by NOVX polynucleotides comprising
CC
     any of the 303 fully defined nucleotide sequences given in the
CC
     specification. The polypeptide is useful in the manufacture of a
CC
     medicament for treating a syndrome associated with a human disease. The
CC
     polypeptide, polynucleotide and antibody are useful in diagnosing,
CC
     treating or preventing NOVX-associated disorders, e.g. cancer, cachexia,
     Alzheimer's disease, Parkinson's disease, obesity, diabetes, infectious
CC
CC
     diseases, metabolic syndrome X or dyslipidaemias. The nucleic acids are
CC
     further used as hybridisation probes, in chromosome mapping, tissue
     typing, preventive medicine, and pharmacogenomics. The present sequence
CC
CC
     represents a NOVX polypeptide of the invention.
XX
SO
     Sequence 898 AA;
  Query Match
                         100.0%;
                                  Score 290; DB 8;
                                                     Length 898;
  Best Local Similarity
                         100.0%;
                                  Pred. No. 2.3e-24;
 Matches
           50; Conservative
                                0; Mismatches
                                                  0;
                                                      Indels
                                                                0;
                                                                            0;
                                                                    Gaps
Qу
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
          246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 10
AAM79128
ID
     AAM79128 standard; protein; 943 AA.
XX
AC
    AAM79128;
XX
DT
     06-NOV-2001 (first entry)
XX
DE
     Human protein SEQ ID NO 1790.
XX
KW
     Human; cytokine; cell proliferation; cell differentiation; gene therapy;
     vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW
KW
     tissue growth factor; immunomodulatory; cancer; leukaemia;
KW
     nervous system disorder; arthritis; inflammation.
XX
os
     Homo sapiens.
XX
PN
     WO200157190-A2.
XX
PD
     09-AUG-2001.
XX
PF
     05-FEB-2001; 2001WO-US004098.
XX
PR
     03-FEB-2000; 2000US-00496914.
PR
     27-APR-2000; 2000US-00560875.
PR
     20-JUN-2000; 2000US-00598075.
     19-JUL-2000; 2000US-00620325.
PR
```

```
01-SEP-2000; 2000US-00654936.
    15-SEP-2000; 2000US-00663561.
PR
    20-OCT-2000; 2000US-00693325.
PR
    30-NOV-2000; 2000US-00728422.
PR
XX
PΑ
     (HYSE-) HYSEQ INC.
XX
    Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;
ΡI
    Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PΙ
    Xue AJ, Yang Y, Wejhrman T, Goodrich R;
PΙ
XX
DR
    WPI; 2001-476283/51.
DR
    N-PSDB; AAK52261.
XX
PT
    Nucleic acids encoding polypeptides with cytokine-like activities, useful
PT
    in diagnosis and gene therapy.
XX
PS
    Claim 20; Page 4148-4150; 6221pp; English.
XX
CC
    The invention relates to polynucleotides (AAK51456-AAK53435) and the
    encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to
CC
CC
    cytokine, cell proliferation or cell differentiation or which may induce
CC
    production of other cytokines in other cell populations. The
CC
    polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC
    peptide therapy. The polypeptides have various cytokine-like activities,
CC
    e.g. stem cell growth factor activity, haematopoiesis regulating
    activity, tissue growth factor activity, immunomodulatory activity and
CC
    activin/inhibin activity and may be useful in the diagnosis and/or
CC
    treatment of cancer, leukaemia, nervous system disorders, arthritis and
    inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111
CC
CC
    (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the
CC
    sequence listing were missing at the time of publication
XX
SQ
    Sequence 943 AA;
 Query Match
                         100.0%; Score 290; DB 4; Length 943;
                         100.0%; Pred. No. 2.4e-24;
 Best Local Similarity
 Matches 50; Conservative 0; Mismatches
                                                0; Indels
                                                               0; Gaps
                                                                           0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             291 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 340
RESULT 11
ADR99262
    ADR99262 standard; protein; 636 AA.
XX
AC
    ADR99262;
XX
DT
    16-DEC-2004 (first entry)
XX
DE
    Splice variant human uncoordinated 5C (sUNC5C) protein.
XX
KW
    RAR-like orphan receptor alpha 1-uncoordinated 5C; ROR-alpha-1-UNC5C;
    ROR-alpha-5; obesity; susceptibility; anorectic; antilipaemic;
    antiarteriosclerotic; hepatotropic; hypotensive; antidiabetic; cardiant;
KW
```

KW vasotropic; osteopathic; antiarthritic; cytostatic; gene therapy; hyperlipidaemia; human; sUNC5C. KW XX OS Homo sapiens. XX PN WO2004083371-A2. XX PD 30-SEP-2004. XX 16-MAR-2004; 2004WO-GB001124. ΡF XX PR 19-MAR-2003; 2003GB-00006185. XX PΑ (ASTR) ASTRAZENECA AB. PΑ (ASTR) ASTRAZENECA UK LTD. XX PΙ Dahl N; XX DR WPI; 2004-691032/67. DR N-PSDB; ADR99261. XX

New isolated nucleic acid molecule encoding a RAR-like orphan receptor alpha 1-uncoordinated 5C (RORapproximatelyal-UNC5C) polypeptide, useful in diagnosing or treating obesity and hyperlipidemia.

Disclosure; SEQ ID NO 14; 96pp; English.

PT

PΤ

PT

XX PS

XX CC

CÇ

CC

The invention relates to a novel isolated nucleic acid molecule, comprising a nucleotide sequence having at least 65% identity to a degenerate variant of a fully defined sequence of 2986, 2780 or 1821 bp (ADR99249, ADR99251 or ADR99255), or the complement of nucleotide sequence with ADR99249, ADR99251 or ADR99255. The invention further comprises: an isolated nucleic acid molecule encoding a RAR-like orphan receptor alpha 1-uncoordinated 5C (ROR-alpha-1-UNC5C) polypeptide; an isolated nucleic acid molecule encoding a ROR-alpha-5 polypeptide; a vector comprising any of the nucleic acid molecules as cited; a host cell comprising the vector; a purified fusion polypeptide of the ROR-alpha-1-UNC5C polypeptide; a purified polypeptide of the ROR-alpha-5 polypeptide; a method for producing a protein comprising culturing the host cell; a method for detecting a polynucleotide which encodes a ROR-alpha-1-UNC5C protein; a method for detecting the presence of an obesity susceptibility gene; a method for detecting the presence of a translocation junction between chromosome 4 at cytoband 4q 22.3 and chromosome 15 at cytoband 15q22.2; a method for identifying a test compound that modulates the expression of an obesity susceptibility gene identified in said method; a method for identifying a test compound that modulates the activity of an obesity protein encoded by the obesity susceptibility gene identified in said method; a method for treating a subject having obesity; a pharmaceutical composition comprising a compound identified in the previous methods, and an adjuvant, diluent or carrier; making a pharmaceutical composition; a method for determining if an obesity susceptibility gene identified in the appropriate method; and a method · for diagnosing obesity, or a susceptibility to it in a subject. The isolated nucleic acid molecules and compounds of the invention have the following activities: anorectic, antilipaemic, antiarteriosclerotic, hepatotropic, hypotensive, antidiabetic, cardiant, vasotropic, osteopathic, antiarthritic, and cytostatic. The isolated nucleic acid

```
CC
     molecules and compounds may be used in gene therapy. The compound
     modulating the activity of an obesity protein or the expression of an
CC
CC
     obesity susceptibility gene is useful in the preparation of a medicament
     for the treatment of obesity. The compound is also useful in treating or
CC
CC
     diagnosing hyperlipidaemia, and the consequences of obesity, such as
CC
     arteriosclerosis, fatty liver, hypertension, diabetes, coronary heart
CC
     disease, stroke, gallbladder disease, osteoarthritis and cancer. This
CC
     sequence represents the alternative splice version of the human
CC
     uncoordinated 5C (UNC5C) protein of the invention.
XX
SQ
     Sequence 636 AA;
                                 Score 249; DB 8; Length 636;
  Query Match
                         85.9%;
  Best Local Similarity
                                 Pred. No. 7.5e-20;
                         82.0%;
  Matches 41; Conservative
                                6; Mismatches
                                                 3; Indels
                                                                    Gaps
                                                                            0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
              264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 12
ADR99252
     ADR99252 standard; protein; 669 AA.
XX
AC
     ADR99252;
XX
DT
     16-DEC-2004 (first entry)
XX
DE
     Human sROR-alpha-1-UNC5C protein.
XX
KW
     RAR-like orphan receptor alpha 1-uncoordinated 5C; ROR-alpha-1-UNC5C;
KW
     ROR-alpha-5; obesity; susceptibility; anorectic; antilipaemic;
KW
     antiarteriosclerotic; hepatotropic; hypotensive; antidiabetic; cardiant;
KW
     vasotropic; osteopathic; antiarthritic; cytostatic; gene therapy;
KW
     hyperlipidaemia; human; sROR-alpha-1-UNC5C.
XX
os
     Homo sapiens.
XX
PN
     WO2004083371-A2.
XX
PD
     30-SEP-2004.
XX
PF
     16-MAR-2004; 2004WO-GB001124.
XX
PR
     19-MAR-2003; 2003GB-00006185.
XX
PA
     (ASTR ) ASTRAZENECA AB.
PA
     (ASTR ) ASTRAZENECA UK LTD.
XX
PΙ
     Dahl N;
XX
DR
     WPI; 2004-691032/67.
DR
     N-PSDB; ADR99251.
XX
PT
     New isolated nucleic acid molecule encoding a RAR-like orphan receptor
PT
     alpha 1-uncoordinated 5C (RORapproximatelya1-UNC5C) polypeptide, useful
```

The invention relates to a novel isolated nucleic acid molecule, comprising a nucleotide sequence having at least 65% identity to a degenerate variant of a fully defined sequence of 2986, 2780 or 1821 bp (ADR99249, ADR99251 or ADR99255), or the complement of nucleotide sequence with ADR99249, ADR99251 or ADR99255. The invention further comprises: an isolated nucleic acid molecule encoding a RAR-like orphan receptor alpha 1-uncoordinated 5C (ROR-alpha-1-UNC5C) polypeptide; an isolated nucleic acid molecule encoding a ROR-alpha-5 polypeptide; a vector comprising any of the nucleic acid molecules as cited; a host cell comprising the vector; a purified fusion polypeptide of the ROR-alpha-1-UNC5C polypeptide; a purified polypeptide of the ROR-alpha-5 polypeptide; a method for producing a protein comprising culturing the host cell; a method for detecting a polynucleotide which encodes a ROR-alpha-1-UNC5C protein; a method for detecting the presence of an obesity susceptibility gene; a method for detecting the presence of a translocation junction between chromosome 4 at cytoband 4q 22.3 and chromosome 15 at cytoband 15q22.2; a method for identifying a test compound that modulates the expression of an obesity susceptibility gene identified in said method; a method for identifying a test compound that modulates the activity of an obesity protein encoded by the obesity susceptibility gene identified in said method; a method for treating a subject having obesity; a pharmaceutical composition comprising a compound identified in the previous methods, and an adjuvant, diluent or carrier; making a pharmaceutical composition; a method for determining if an obesity susceptibility gene identified in the appropriate method; and a method for diagnosing obesity, or a susceptibility to it in a subject. The isolated nucleic acid molecules and compounds of the invention have the following activities: anorectic, antilipaemic, antiarteriosclerotic, hepatotropic, hypotensive, antidiabetic, cardiant, vasotropic, osteopathic, antiarthritic, and cytostatic. The isolated nucleic acid molecules and compounds may be used in gene therapy. The compound modulating the activity of an obesity protein or the expression of an obesity susceptibility gene is useful in the preparation of a medicament for the treatment of obesity. The compound is also useful in treating or diagnosing hyperlipidaemia, and the consequences of obesity, such as arteriosclerosis, fatty liver, hypertension, diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis and cancer. This sequence represents the human sROR-alpha-1-UNC5C protein of the invention.

SQ Sequence 669 AA;

```
85.9%;
                                  Score 249; DB 8; Length 669;
 Query Match
  Best Local Similarity
                          82.0%;
                                  Pred. No. 7.9e-20;
 Matches
           41; Conservative
                                 6; Mismatches
                                                                              0;
                                                       Indels
                                                                  0;
                                                                      Gaps
                                                   3;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
```

278 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 327

CC

22 CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

Db

```
ID
     ADG42583 standard; protein; 929 AA.
XX
AC
     ADG42583;
XX
DT
     26-FEB-2004 (first entry)
XX
DE
     Human transmembrane receptor Unc5 homologue #1.
XX
     cytostatic; gene therapy; NOVX-agonist; NOVX-antagonist; pharmaceutical;
KW
KW
     NOVX-associated disorder; cancer; human; transmembrane receptor;
KW
     Unc5 homologue.
XX
os
    Homo sapiens.
XX
PN
     US2003204052-A1.
XX
PD
     30-OCT-2003.
XX
PF
     04-OCT-2001; 2001US-00970944.
XX
PR
     04-OCT-2000; 2000US-0237862P.
XX
PA
     (HERR/) HERRMANN J L.
PA
     (RAST/) RASTELLI L.
PΑ
     (SHIM/) SHIMKETS R A.
XX
PΙ
     Herrmann JL, Rastelli L, Shimkets RA;
XX
DR
     WPI; 2003-900673/82.
XX
PT
     New NOVX gene or NOVX-specific antibody, useful for preparing a
PT
     composition for treating or preventing a NOVX-associated disorder, e.g.,
PT
     cancer.
XX
PS
     Disclosure; SEQ ID NO 16; 118pp; English.
XX
CC
     The invention describes a new isolated polypeptide comprising: a
     polypeptide or its mature form comprising a sequence not given in the
CC
CC
     specification; or a variant of (A), where one or more amino acid residues
CC
     in the variant differs in no more than 15% from the amino acid sequence
CC
     of the mature form. The pharmaceutical composition may be administered
CC
     via oral, transdermal, rectal or parenteral route. The polypeptide,
CC
     nucleic acid or antibody is useful for preparing a composition for
CC
     treating or preventing a NOVX-associated disorder, e.g., cancer. This is
CC
     the amino acid sequence of a transmembrane receptor homologue used in a
CC
     comparison with the novel human proteins of the invention.
XX
SQ
     Sequence 929 AA;
  Query Match
                          85.9%;
                                 Score 249; DB 7; Length 929;
  Best Local Similarity
                         82.0%;
                                 Pred. No. 1.1e-19;
  Matches
           41; Conservative
                                6; Mismatches
                                                  3; Indels
                                                                            0;
                                                                0;
                                                                    Gaps
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGONVQKTACATLC 50
Qу
              Db
          264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
```

```
RESULT 14
AAB50691
     AAB50691 standard; protein; 931 AA.
ID
XX
AC
     AAB50691;
XX
DT
     19-MAR-2001 (first entry)
XX
DE
     Human UNC5C protein SEQ ID NO:90.
XX
KW
     Human; Caenorhabditis elegans; UNC-5; splice variant; nematode worm;
KW
     protein-protein interaction; identification.
XX
os
     Homo sapiens.
XX
PN
     WO200073328-A2.
XX
PD
     07-DEC-2000.
XX
     02-JUN-2000; 2000WO-EP005108.
PF
XX
PR
     01-JUN-1999;
                    99GB-00012755.
XX
PΑ
     (DEVG-) DEVGEN NV.
XX
     Van Criekinge W, Roelens I, Bogaert T, Verwaerde P;
ΡI
XX
DR
     WPI; 2001-016508/02.
XX
PT
     Three variants of human unc-5C cDNAs (unc-5Cb, unc-5Cc and unc-5C8) and a
PT
     human unc-5HS1 cDNA, useful in yeast two hybrid experiments for
PT
     identifying unknown human cDNAs which encode proteins that interact with
PT
     the human unc-5C protein.
XX
PS
     Disclosure; Page 224-227; 246pp; English.
XX
CC
     The present invention describes 3 variants of human unc-5C cDNAs (unc-
CC
     5Cb, unc-5Cc and unc-5C8) which correspond to alternatively spliced unc-
CC
     5C transcripts, and a human unc-5HS1 cDNA which shares homology with the
     Rattus norvegicus unc-5HS1 cDNA. Also described are assays based on
CC
CC
     protein-protein-interactions between the unc-5 protein and a variety of
CC
     different interacting proteins. The unc-5C variant cDNAs and unc-5HS1
CC
     cDNA are useful in methods for identifying compounds which reduce or
CC
     inhibit the lethal phenotype associated with the expression of the unc-5
     death domain in yeast. They are also useful in yeast two hybrid
CC
CC
     experiments for identifying unknown human cDNAs which encode proteins
CC
     that interact with the human unc-5C protein. AAC90914 to AAC90971 and
CC
     AAB50646 to AAB50693 represent sequences used in the exemplification of
CC
     the present invention
XX
SQ
     Sequence 931 AA;
  Query Match
                          85.9%;
                                  Score 249; DB 4; Length 931;
  Best Local Similarity
                          82.0%; Pred. No. 1.1e-19;
  Matches
            41; Conservative
                                 6; Mismatches
                                                  3; Indels
                                                                  0; Gaps
                                                                              0;
```

```
1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGONVQKTACATLC 50
Qy
              264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
Db
RESULT 15
ADE63098
    ADE63098 standard; protein; 931 AA.
XX
AC
    ADE63098;
XX
    29-JAN-2004 (first entry)
DT
XX
DE
    Human Protein AAC67491, SEQ ID NO 9033.
XX
KW
    Human; pain; neuronal tissue; gene therapy;
KW
     spinal segmental nerve injury; chronic constriction injury; CCI;
KW
     spared nerve injury; SNI; Chung.
XX
OS
    Homo sapiens.
XX
PN
    WO2003016475-A2.
XX
PD
    27-FEB-2003.
XX
     14-AUG-2002; 2002WO-US025765.
PF
XX
     14-AUG-2001; 2001US-0312147P.
PR
PR
     01-NOV-2001; 2001US-0346382P.
PR
     26-NOV-2001; 2001US-0333347P.
XX
PΑ
     (GEHO ) GEN HOSPITAL CORP.
PA
     (FARB ) BAYER AG.
XX
ΡI
    Woolf C, D'urso D, Befort K, Costigan M;
XX
DR
    WPI; 2003-268312/26.
DR
     GENBANK; AAC67491.
XX
PT
    New composition comprising two or more isolated polypeptides, useful for
PT
    preparing a medicament for treating pain in an animal.
XX
PS
     Claim 1; Page; 1017pp; English.
XX
CC
     The invention discloses a composition comprising two or more isolated rat
CC
     or human polynucleotides or a polynucleotide which represents a fragment,
CC
     derivative or allelic variation of the nucleic acid sequence. Also
CC
     claimed are a vector comprising the novel polynucleotide, a host cell
CC
     comprising the vector, a method for identifying a nucleotide sequence
CC
     which is differentially regulated in an animal subjected to pain and a
     kit to perform the method, an array, a method for identifying an agent
CC
CC
     that increases or decreases the expression of the polynucleotide sequence
     that is differentially expressed in neuronal tissue of a first animal
CC
CC
     subjected to pain, a method for identifying a compound which regulates
CC
     the expression of a polynucleotide sequence which is differentially
```

expressed in an animal subjected to pain, a method for identifying a

compound that regulates the activity of one or more of the

CC

CC

```
CC
    polynucleotides, a method for producing a pharmaceutical composition, a
CC
    method for identifying a compound or small molecule that regulates the
CC
    activity in an animal of one or more of the polypeptides given in the
CC
    specification, a method for identifying a compound useful in treating
CC
    pain and a pharmaceutical composition comprising the one or more
CC
    polypeptides or their antibodies. The polynucleotide or the compound that
CC
    modulates its activity is useful for preparing a medicament for treating
CC
    pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
CC
    injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
    therapy). The sequence presented is a human protein (shown in Table 2 of
CC
CC
    the specification) which is differentially expressed during pain. Note:
CC
    The sequence data for this patent did not form part of the printed
CC
    specification, but was obtained in electronic form directly from WIPO at
CC
    ftp.wipo.int/pub/published pct sequences.
XX
SQ
    Sequence 931 AA;
  Query Match
                         85.9%;
                                Score 249; DB 7; Length 931;
  Best Local Similarity
                         82.0%;
                                Pred. No. 1.1e-19;
                                                                          0;
  Matches
           41; Conservative
                                6; Mismatches
                                                 3; Indels
                                                              0; Gaps
Qу
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
             Db
         264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
```

Search completed: March 1, 2005, 08:56:47

Job time : 11.4389 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2005, 08:42:47; Search time 2.99591 Seconds

(without alignments)

1245.848 Million cell updates/sec

Title: US-10-624-932-2 COPY 246 295

Perfect score: 290

Sequence: 1 STWTEWSVCSASCGRGWQKR.....NGGAFCEGQNVQKTACATLC 50

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Issued Patents AA:*

1: /cgn2 6/ptodata/1/iaa/5A COMB.pep:*

2: /cgn2 6/ptodata/1/iaa/5B COMB.pep:*

3: /cgn2 6/ptodata/1/iaa/6A COMB.pep:*

4: /cgn2 6/ptodata/1/iaa/6B_COMB.pep:*

5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*

6: /cgn2 6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		8				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	290	100.0	 898	 2	US-08-808-982-5	Seguence 5, Appli
2	290	100.0	898	3	US-09-306-902A-5	Sequence 5, Appli
3	249	85.9	769	4	US-09-949-016-10665	Sequence 10665, A
4	238	82.1	943	2	US-08-808-982-7	Sequence 7, Appli
5	238	82.1	943	3	US-09-306-902A-7	Sequence 7, Appli
6	147	50.7	939	4	US-09-854-845-16	Sequence 16, Appl
7	147	50.7	954	4	US-09-854-845-14	Sequence 14, Appl
8	147	50.7	1034	4	US-09-854-845-6	Sequence 6, Appli
9	147	50.7	1049	4	US-09-854-845-2	Sequence 2, Appli
10	147	50.7	1078	4	US-09-854-845-8	Sequence 8, Appli
11	147	50.7	1093	4	US-09-854-845-4	Sequence 4, Appli

12	147	50.7	1136	4	US-09-854-845-12	Sequence	12, Appl
13	147	50.7	1151	4	US-09-854-845-10	Sequence	10, Appl
14	139	47.9	1224	4	US-09-930-872-4	Sequence	4, Appli
15	139	47.9	1224	4	US-10-217-774-4	Sequence	4, Appli
16	137	47.2	584	1	US-08-313-288B-17		17, Appl
17	136	46.9	479	4	US-09-270-767-46823	Sequence	46823, A
18	136	46.9	481	4	US-09-130-491-8	-	8, Appli
19	132	45.5	239	5	PCT-US93-01652-1	Sequence	1, Appli
20	132	45.5	837	4	US-09-122-126B-2	Sequence	2, Appli
21	132	45.5	837	4	US-09-634-286A-2		2, Appli
22	132	45.5	837	4	US-10-247-685-2	Sequence	2, Appli
23	132	45.5	1170	4	US-09-657-472-2	Sequence	2, Appli
24	131	45.2	905	3	US-09-369-364A-9	Sequence	9, Appli
25	130	44.8	551	4	US-09-130-491-16	Sequence	16, Appl
26	130	44.8	608	4	US-09-130-491-13	Sequence	13, Appl
27	130	44.8	727	4	US-09-445-023A-1	Sequence	1, Appli
28	130	44.8	727	4	US-09-445-023A-12	Sequence	12, Appl
29	130	44.8	949	4	US-09-568-559-2	Sequence	2, Appli
30	130	44.8	950	4	US-09-321-987B-4	Sequence	4, Appli
31	130	44.8	967	4	US-09-130-491-2	Sequence	2, Appli
32	128.5	44.3	950	4	US-10-009-332-1	Sequence	1, Appli
33	128	44.1	1170	1	US-08-313-288B-20	Sequence	20, Appl
34	126	43.4	2150	4	US-09-321-987B-2	Sequence	2, Appli
35	126	43.4	2165	4	US-09-800-729-155	Sequence	155, App
36	122	42.1	321	4	US-09-969-532-24	Sequence	24, Appl
37	122	42.1	332	4	US-09-969-532-22	Sequence	22, Appl
38	122	42.1	335	4	US-09-969-532-20	Sequence	20, Appl
39	122	42.1	346	4	US-09-969-532 - 18		18, Appl
40	122	42.1	552	4	US-09-969-532-8		8, Appli
41	122	42.1	563	4	US-09-969-532-6		6, Appli
42	122	42.1	566	4	US-09-969-532-4	Sequence	4, Appli
43	122	42.1	577	4	US-09-969-532-2		2, Appli
44	122	42.1	655	4	US-09-969-532-32		32, Appl
45	122	42.1	666	4	US-09-969-532-30	Sequence	30, Appl

ALIGNMENTS

```
RESULT 1
US-08-808-982-5
; Sequence 5, Application US/08808982
; Patent No. 5939271
  GENERAL INFORMATION:
    APPLICANT: Tessier-Lavigne, Marc
    APPLICANT: Leonardo, E. David
    APPLICANT: Hink, Lindsay
    APPLICANT: Masu, Masayuki
    APPLICANT: Kazuko, Keino-Masu
     TITLE OF INVENTION: Netrin Receptors
    NUMBER OF SEQUENCES: 8
     CORRESPONDENCE ADDRESS:
      ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
      STREET: 268 BUSH STREET, SUITE 3200
      CITY: SAN FRANCISCO
      STATE: CALIFORNIA
      COUNTRY: USA
```

```
ZIP: 94104
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/808,982
      FILING DATE:
      CLASSIFICATION: 530
    ATTORNEY/AGENT INFORMATION:
      NAME: OSMAN, RICHARD A
      REGISTRATION NUMBER: 36,627
;
      REFERENCE/DOCKET NUMBER: UC96-217
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (415) 343-4341
      TELEFAX: (415) 343-4342
  INFORMATION FOR SEQ ID NO: 5:
;
    SEQUENCE CHARACTERISTICS:
      LENGTH: 898 amino acids
      TYPE: amino acid
      STRANDEDNESS: not relevant
      TOPOLOGY: not relevant
    MOLECULE TYPE: peptide
US-08-808-982-5
                         100.0%; Score 290; DB 2; Length 898;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 3.6e-25;
                             0; Mismatches
 Matches
           50; Conservative
                                              0;
                                                    Indels
                                                              0; Gaps
                                                                          0;
           1 STWTEWSVCSASCGRGWOKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qy
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 2
US-09-306-902A-5
; Sequence 5, Application US/09306902A
; Patent No. 6277585
   GENERAL INFORMATION:
        APPLICANT: Tessier-Lavigne, Marc
                   Leonardo, E. David
                   Hink, Lindsay
                  Masu, Masayuki
                   Kazuko, Keino-Masu
        TITLE OF INVENTION: Netrin Receptors
        NUMBER OF SEQUENCES: 9
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
             STREET: 268 BUSH STREET, SUITE 3200
             CITY: SAN FRANCISCO
             STATE: CALIFORNIA
             COUNTRY: USA
             ZIP: 94104
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
```

```
OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.30
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/09/306,902A
             FILING DATE: 07-May-1999
             CLASSIFICATION: <Unknown>
        ATTORNEY/AGENT INFORMATION:
             NAME: OSMAN, RICHARD A
             REGISTRATION NUMBER: 36,627
             REFERENCE/DOCKET NUMBER: UC96-217
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: (415) 343-4341
             TELEFAX: (415) 343-4342
    INFORMATION FOR SEQ ID NO: 5:
        SEQUENCE CHARACTERISTICS:
             LENGTH: 898 amino acids
             TYPE: amino acid
             STRANDEDNESS: not relevant
             TOPOLOGY: not relevant
        MOLECULE TYPE: peptide
        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-306-902A-5
  Query Match
                         100.0%; Score 290; DB 3; Length 898;
 Best Local Similarity 100.0%; Pred. No. 3.6e-25;
                             0; Mismatches 0; Indels
 Matches
           50; Conservative
                                                                           0;
                                                               0; Gaps
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
Db
RESULT 3
US-09-949-016-10665
; Sequence 10665, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
  TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
  TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES
THEREOF
; FILE REFERENCE: CL001307
  CURRENT APPLICATION NUMBER: US/09/949,016
  CURRENT FILING DATE: 2000-04-14
   PRIOR APPLICATION NUMBER: 60/241,755
   PRIOR FILING DATE: 2000-10-20
  PRIOR APPLICATION NUMBER: 60/237,768
  PRIOR FILING DATE: 2000-10-03
  PRIOR APPLICATION NUMBER: 60/231,498
  PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10665
   LENGTH: 769
   TYPE: PRT
   ORGANISM: Human
US-09-949-016-10665
```

```
85.9%; Score 249; DB 4; Length 769;
  Query Match
  Best Local Similarity 82.0%; Pred. No. 1.5e-20;
                               6; Mismatches 3; Indels 0; Gaps
                                                                        0;
 Matches 41; Conservative
Qу
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
             Db
         102 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 151
RESULT 4
US-08-808-982-7
; Sequence 7, Application US/08808982
; Patent No. 5939271
  GENERAL INFORMATION:
    APPLICANT: Tessier-Lavigne, Marc
    APPLICANT: Leonardo, E. David
    APPLICANT: Hink, Lindsay
    APPLICANT: Masu, Masayuki
    APPLICANT: Kazuko, Keino-Masu
;
    TITLE OF INVENTION: Netrin Receptors
    NUMBER OF SEQUENCES: 8
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
      STREET: 268 BUSH STREET, SUITE 3200
      CITY: SAN FRANCISCO
      STATE: CALIFORNIA
      COUNTRY: USA
;
      ZIP: 94104
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/808,982
      FILING DATE:
      CLASSIFICATION: 530
    ATTORNEY/AGENT INFORMATION:
      NAME: OSMAN, RICHARD A
      REGISTRATION NUMBER: 36,627
      REFERENCE/DOCKET NUMBER: UC96-217
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (415) 343-4341
      TELEFAX: (415) 343-4342
   INFORMATION FOR SEQ ID NO: 7:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 943 amino acids
      TYPE: amino acid
      STRANDEDNESS: not relevant
      TOPOLOGY: not relevant
    MOLECULE TYPE: peptide
US-08-808-982-7
                        82.1%; Score 238; DB 2; Length 943;
 Query Match
  Best Local Similarity 78.0%; Pred. No. 3.4e-19;
```

Matches 39; Conservative 4; Mismatches 7; Indels 0; Gaps

```
1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qy
             Db
         248 SSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQACQKTACTTVC 297
RESULT 5
US-09-306-902A-7
; Sequence 7, Application US/09306902A
; Patent No. 6277585
   GENERAL INFORMATION:
        APPLICANT: Tessier-Lavigne, Marc
                   Leonardo, E. David
                  Hink, Lindsay
                   Masu, Masayuki
                   Kazuko, Keino-Masu
        TITLE OF INVENTION: Netrin Receptors
        NUMBER OF SEQUENCES: 9
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
             STREET: 268 BUSH STREET, SUITE 3200
             CITY: SAN FRANCISCO
             STATE: CALIFORNIA
             COUNTRY: USA
             ZIP: 94104
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.30
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/09/306,902A
             FILING DATE: 07-May-1999
             CLASSIFICATION: <Unknown>
        ATTORNEY/AGENT INFORMATION:
             NAME: OSMAN, RICHARD A
             REGISTRATION NUMBER: 36,627
             REFERENCE/DOCKET NUMBER: UC96-217
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: (415) 343-4341
             TELEFAX: (415) 343-4342
   INFORMATION FOR SEQ ID NO: 7:
        SEQUENCE CHARACTERISTICS:
             LENGTH: 943 amino acids
             TYPE: amino acid
             STRANDEDNESS: not relevant
             TOPOLOGY: not relevant
        MOLECULE TYPE: peptide
        SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-306-902A-7
                         82.1%; Score 238; DB 3; Length 943;
 Query Match
 Best Local Similarity 78.0%; Pred. No. 3.4e-19;
 Matches
           39; Conservative
                                4; Mismatches
                                                7; Indels
                                                                   Gaps
                                                                           0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
```

```
RESULT 6
US-09-854-845-16
; Sequence 16, Application US/09854845
; Patent No. 6750054
; GENERAL INFORMATION:
; APPLICANT: Walke, D. Wade
  APPLICANT: Wang, Xiaoming
 APPLICANT: Scoville, John
  APPLICANT: Turner, C. Alexander Jr.
  TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
  FILE REFERENCE: LEX-0177-USA
  CURRENT APPLICATION NUMBER: US/09/854,845
  CURRENT FILING DATE: 2001-05-14
  PRIOR APPLICATION NUMBER: US 60/205,274
  PRIOR FILING DATE: 2000-05-18
  PRIOR APPLICATION NUMBER: US 60/208,893
  PRIOR FILING DATE: 2000-06-02
 NUMBER OF SEQ ID NOS: 50
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 16
   LENGTH: 939
    TYPE: PRT
   ORGANISM: homo sapiens
US-09-854-845-16
                         50.7%; Score 147; DB 4; Length 939;
  Query Match
  Best Local Similarity 54.2%; Pred. No. 9.1e-09;
           26; Conservative
                                6; Mismatches
                                                16; Indels
                                                               0; Gaps
                                                                          0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
Qу
              717 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 764
RESULT 7
US-09-854-845-14
; Sequence 14, Application US/09854845
; Patent No. 6750054
; GENERAL INFORMATION:
  APPLICANT: Walke, D. Wade
; APPLICANT: Wang, Xiaoming
; APPLICANT: Scoville, John
; APPLICANT: Turner, C. Alexander Jr.
; TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
; FILE REFERENCE: LEX-0177-USA
  CURRENT APPLICATION NUMBER: US/09/854,845
  CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/205,274
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: US 60/208,893
  PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 50
```

```
SOFTWARE: FastSEO for Windows Version 4.0
 ; SEQ ID NO 14
    LENGTH: 954
    TYPE: PRT
    ORGANISM: homo sapiens
 US-09-854-845-14
   Query Match
                         50.7%; Score 147; DB 4; Length 954;
  Best Local Similarity 54.2%; Pred. No. 9.2e-09;
  Matches 26; Conservative 6; Mismatches
                                               16; Indels
                                                             0; Gaps
                                                                        0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
 Qy
              717 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 764
 RESULT 8
 US-09-854-845-6
 ; Sequence 6, Application US/09854845
 ; Patent No. 6750054
 ; GENERAL INFORMATION:
 ; APPLICANT: Walke, D. Wade
 ; APPLICANT: Wang, Xiaoming
 ; APPLICANT: Scoville, John
 ; APPLICANT: Turner, C. Alexander Jr.
 ; TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
 Polynucleotides Encoding the Same
 ; FILE REFERENCE: LEX-0177-USA
 ; CURRENT APPLICATION NUMBER: US/09/854,845
 ; CURRENT FILING DATE: 2001-05-14
 ; PRIOR APPLICATION NUMBER: US 60/205,274
 ; PRIOR FILING DATE: 2000-05-18
 ; PRIOR APPLICATION NUMBER: US 60/208,893
 ; PRIOR FILING DATE: 2000-06-02
   NUMBER OF SEQ ID NOS: 50
   SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 6
    LENGTH: 1034
    TYPE: PRT
    ORGANISM: homo sapiens
 US-09-854-845-6
   Query Match
                         50.7%; Score 147; DB 4; Length 1034;
   Best Local Similarity 54.2%; Pred. No. 1e-08;
  Matches 26; Conservative 6; Mismatches 16; Indels
                                                             0; Gaps
                                                                        0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
 Qу
             Db
          812 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 859
 RESULT 9
 US-09-854-845-2
; Sequence 2, Application US/09854845
 ; Patent No. 6750054
 ; GENERAL INFORMATION:
 ; APPLICANT: Walke, D. Wade
```

```
; APPLICANT: Wang, Xiaoming
; APPLICANT: Scoville, John
; APPLICANT: Turner, C. Alexander Jr.
; TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
; FILE REFERENCE: LEX-0177-USA
  CURRENT APPLICATION NUMBER: US/09/854,845
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/205,274
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: US 60/208,893
; PRIOR FILING DATE: 2000-06-02
  NUMBER OF SEQ ID NOS: 50
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
   LENGTH: 1049
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-854-845-2
 Query Match
                        50.7%; Score 147; DB 4; Length 1049;
 Best Local Similarity 54.2%; Pred. No. 1e-08;
 Matches 26; Conservative 6; Mismatches
                                                             0; Gaps 0;
                                              16; Indels
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
Qу
             812 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 859
RESULT 10
US-09-854-845-8
; Sequence 8, Application US/09854845
; Patent No. 6750054
; GENERAL INFORMATION:
  APPLICANT: Walke, D. Wade
  APPLICANT: Wang, Xiaoming
; APPLICANT: Scoville, John
; APPLICANT: Turner, C. Alexander Jr.
  TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
; FILE REFERENCE: LEX-0177-USA
  CURRENT APPLICATION NUMBER: US/09/854,845
  CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/205,274
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: US 60/208,893
; PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 50
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
   LENGTH: 1078
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-854-845-8
  Query Match
                       50.7%; Score 147; DB 4; Length 1078;
 Best Local Similarity 54.2%; Pred. No. 1e-08;
```

```
26; Conservative 6; Mismatches 16; Indels
 Matches
                                                            0; Gaps
                                                                       0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
Qy
             856 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 903
RESULT 11
US-09-854-845-4
; Sequence 4, Application US/09854845
; Patent No. 6750054
; GENERAL INFORMATION:
  APPLICANT: Walke, D. Wade
  APPLICANT: Wang, Xiaoming
; APPLICANT: Scoville, John
; APPLICANT: Turner, C. Alexander Jr.
 TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
; FILE REFERENCE: LEX-0177-USA
  CURRENT APPLICATION NUMBER: US/09/854,845
  CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/205,274
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: US 60/208,893
; PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 50
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
   LENGTH: 1093
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-854-845-4
 Query Match
                        50.7%; Score 147; DB 4; Length 1093;
 Best Local Similarity 54.2%; Pred. No. 1.1e-08;
                              6; Mismatches
 Matches 26; Conservative
                                              16; Indels
                                                            0; Gaps
                                                                       0;
Qу
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
             856 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 903
RESULT 12
US-09-854-845-12
; Sequence 12, Application US/09854845
; Patent No. 6750054
; GENERAL INFORMATION:
; APPLICANT: Walke, D. Wade
  APPLICANT: Wang, Xiaoming
  APPLICANT: Scoville, John
; APPLICANT: Turner, C. Alexander Jr.
; TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
; FILE REFERENCE: LEX-0177-USA
; CURRENT APPLICATION NUMBER: US/09/854,845
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/205,274
```

```
PRIOR FILING DATE: 2000-05-18
  PRIOR APPLICATION NUMBER: US 60/208,893
 PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 50
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
   LENGTH: 1136
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-854-845-12
 Query Match
                        50.7%; Score 147; DB 4; Length 1136;
 Best Local Similarity 54.2%; Pred. No. 1.1e-08;
          26; Conservative
                            6; Mismatches
                                              16; Indels
                                                            0; Gaps
                                                                       0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
Qу
             914 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 961
RESULT 13
US-09-854-845-10
; Sequence 10, Application US/09854845
; Patent No. 6750054
; GENERAL INFORMATION:
 APPLICANT: Walke, D. Wade
  APPLICANT: Wang, Xiaoming
  APPLICANT: Scoville, John
; APPLICANT: Turner, C. Alexander Jr.
; TITLE OF INVENTION: No. 6750054el Human Semaphorin Homologs and
Polynucleotides Encoding the Same
; FILE REFERENCE: LEX-0177-USA
 CURRENT APPLICATION NUMBER: US/09/854,845
 CURRENT FILING DATE: 2001-05-14
  PRIOR APPLICATION NUMBER: US 60/205,274
  PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: US 60/208,893
; PRIOR FILING DATE: 2000-06-02
 NUMBER OF SEQ ID NOS: 50
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
   LENGTH: 1151
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-854-845-10
                        50.7%; Score 147; DB 4; Length 1151;
  Query Match
                        54.2%; Pred. No. 1.1e-08;
  Best Local Similarity
                              6; Mismatches
                                                            0; Gaps
                                                                       0;
 Matches
          26; Conservative
                                              16; Indels
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
Qу
             914 SCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCAT 961
Db
```

RESULT 14 US-09-930-872-4

```
; Sequence 4, Application US/09930872
; Patent No. 6448388
; GENERAL INFORMATION:
  APPLICANT: Friddle, Carl Johan
  APPLICANT: Hilbun, Erin
  TITLE OF INVENTION: No. 6448388el Human Proteases and Polynucleotides
Encoding the Same
; FILE REFERENCE: LEX-0219-USA
  CURRENT APPLICATION NUMBER: US/09/930,872
  CURRENT FILING DATE: 2001-08-14
; PRIOR APPLICATION NUMBER: US 60/225,852
  PRIOR FILING DATE: 2000-08-16
  NUMBER OF SEQ ID NOS: 5
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
   LENGTH: 1224
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-930-872-4
                        47.9%; Score 139; DB 4; Length 1224;
 Query Match
 Best Local Similarity 52.0%; Pred. No. 9.8e-08;
                               3; Mismatches
 Matches
          26; Conservative
                                                17;
                                                    Indels
                                                              4;
                                                                  Gaps
                                                                          1;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             ŀ
Db
         590 SDWSSWSPCSRTCGGGVSHRSRLCTNPKPSHGGKFCEG----STRTLKLC 635
RESULT 15
US-10-217-774-4
; Sequence 4, Application US/10217774
; Patent No. 6734007
; GENERAL INFORMATION:
  APPLICANT: Friddle, Carl Johan
  APPLICANT: Hilbun, Erin
  TITLE OF INVENTION: No. 6734007el Human Proteases and Polynucleotides
Encoding the
; TITLE OF INVENTION: Same
; FILE REFERENCE: LEX-0219-USA
; CURRENT APPLICATION NUMBER: US/10/217,774
  CURRENT FILING DATE: 2002-08-12
  PRIOR APPLICATION NUMBER: US/09/930,872
  PRIOR FILING DATE: 2001-08-14
  PRIOR APPLICATION NUMBER: US 60/225,852
  PRIOR FILING DATE: 2000-08-16
  NUMBER OF SEQ ID NOS: 5
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
   LENGTH: 1224
   TYPE: PRT
   ORGANISM: homo sapiens
US-10-217-774-4
 Query Match
                         47.9%; Score 139; DB 4; Length 1224;
  Best Local Similarity 52.0%; Pred. No. 9.8e-08;
 Matches 26; Conservative 3; Mismatches 17; Indels
                                                             4; Gaps
```

1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50 Qу 590 SDWSSWSPCSRTCGGGVSHRSRLCTNPKPSHGGKFCEG----STRTLKLC 635 Db

Search completed: March 1, 2005, 09:05:52 Job time: 3.99591 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2005, 08:46:18; Search time 1.95188 Seconds

(without alignments)

2464.715 Million cell updates/sec

Title: US-10-624-932-2 COPY 246 295

Perfect score: 290

Sequence: 1 STWTEWSVCSASCGRGWQKR.....NGGAFCEGQNVQKTACATLC 50

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: PIR 79:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

			75				
Re	sult		Query				
	No.	Score	Match	Length	DB	ID	Description
_	1	148	51.0	1074	 2	JC5928	semaphorin F precu
	2	138	47.6	584	1	C8HUA	complement C8 alph
	3	132	45.5	837	2	T00355	hypothetical prote
	4	130.5	45.0	1444	2	Т18856	angiogenesis inhib
	5	130	44.8	550	2	T47158	hypothetical prote
	6	130	44.8	951	2	T00017	gene ADAMTS-1 prot
	7	128	44.1	1170	1	TSHUP1	thrombospondin 1 p
	8	127	43.8	919	2	T32541	unc-5 protein - Ca
	9	127	43.8	947	1	B44294	unc-5 protein, lon
	10	126	43.4	1170	2	A40558	thrombospondin 1 p
	11	126	43.4	2165	2	T21371	hypothetical prote
	12	123	42.4	585	2	146686	complement compone
	13	119	41.0	1572	2	T00027	brain-specific ang

14	119	41.0	1584	2	T00026	brain-specific ang
.15	118.5	40.9	437	2.	S05478	properdin - mouse
16	118	40.7	254	2	T15952	hypothetical prote
17	117	40.3	654	2	T29247	hypothetical prote
18	116.5	40.2	984	2	T00326	hypothetical prote
19	116.5	40.2	1522	2	T00028	brain-specific ang
20	115	39.7	1178	1	A39804	thrombospondin pre
21	113.5	39.1	469	1	S29126	properdin precurso
22	111.5	38.4	934	1	A34372	complement C6 prec
23	110	37.9	1172	1	TSHUP2	thrombospondin 2 p
24	109.5	37.8	957	2	T15976	hypothetical prote
25	109	37.6	1172	2	A42587	thrombospondin 2 p
26	108	37.2	788	2	T25061	hypothetical prote
27	106	36.6	590	2	I46687	complement compone
28	106	36.6	843	1	A27340	complement C7 prec
29	104	35.9	1205	2	T18517	procollagen N-endo
30	99.5	34.3	805	2	T34212	hypothetical prote
31	96	33.1	860	2	T16892	hypothetical prote
32	94	32.4	591	1	C8HUB	complement C8 beta
33	92	31.7	2761	2	T21064	hypothetical prote
34	91	31.4	206	2	A45517	coccidiosis-relate
35	91	31.4	712	2	A45638	immunodominant mic
36	91	31.4	7,36	2	Т19366	hypothetical prote
37	90	31.0	807	2	A38152	F-spondin - rat
38	89	30.7	803	2	A47723	F-spondin precurso
39	89	30.7	1360	2	T33922	hypothetical prote
40	86.5	29.8	610	2	T16761	hypothetical prote
41	86.5	29.8	1184	2	T09484	cartilage intermed
42	84	29.0	898	2	T14764	hypothetical prote
43	84	29.0	1059	2	T22545	hypothetical prote
44	80	27.6	651	2	T19477	hypothetical prote
45	79	27.2	724	2	A48569	antigen Em100 - Ei

ALIGNMENTS

```
RESULT 1
JC5928
```

semaphorin F precursor - human C; Species: Homo sapiens (man)

C;Date: 10-Apr-1998 #sequence revision 08-May-1998 #text change 09-Jul-2004 C; Accession: JC5928

R; Simmons, A.D.; Pueschel, A.W.; McPherson, J.D.; Overhauser, J.; Lovett, M. Biochem. Biophys. Res. Commun. 242, 685-691, 1998

A; Title: Molecular cloning and mapping of human semaphorin F from the Cri-duchat candidate interval.

A; Reference number: JC5928; MUID: 98125554; PMID: 9464278

A; Accession: JC5928

A; Status: nucleic acid sequence not shown

A; Molecule type: mRNA A; Residues: 1-1074 <SIM>

A;Cross-references: UNIPROT:Q13591; GB:U52840; NID:g2772583; PIDN:AAC09473.1;

PID:g2772584

A; Experimental source: brain

C; Comment: This protein disrupts normal brain development and leads to some of the features of Cri-du-chat.

```
C; Genetics:
A:Gene: semaf
C; Superfamily: human semaphorin F; thrombospondin type 1 repeat homology
F;1-20/Domain: signal sequence #status predicted <SIG>
F;50-533/Domain: semaphorin #status predicted <SEM>
F;840-896/Domain: thrombospondin type 1 repeat homology <THR3>
F;971-993/Domain: transmembrane #status predicted <TMM>
                          51.0%; Score 148; DB 2; Length 1074;
  Query Match
  Best Local Similarity
                          54.5%; Pred. No. 6.6e-09;
  Matches
           24; Conservative
                                 6; Mismatches
                                                  14; Indels
                                                                 0; Gaps
                                                                             0;
Qу
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
              601 WTSWSPCSTTCGIGFQVRQRSCSNPTPRHGGRVCVGQNREERYC 644
RESULT 2
C8HUA
complement C8 alpha chain precursor [validated] - human
C; Species: Homo sapiens (man)
C;Date: 28-Dec-1987 #sequence revision 17-Nov-2000 #text change 17-Nov-2000
C; Accession: I37213; A26704
R; Michelotti, G.A.; Snider, J.V.; Sodetz, J.M.
Hum. Genet. 95, 513-518, 1995
A; Title: Genomic organization of human complement protein C8 alpha and further
examination of its linkage to C8 beta.
A; Reference number: I37213; MUID: 95278905; PMID: 7759071
A; Accession: I37213
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-584 <MIC>
A; Cross-references: EMBL: U08006; NID: q901862; PIDN: AAA82124.1; PID: q901864
R; Rao, A.G.; Howard, O.M.Z.; Ng, S.C.; Whitehead, A.S.; Colten, H.R.; Sodetz,
J.M.
Biochemistry 26, 3556-3564, 1987
A; Title: Complementary DNA and derived amino acid sequence of the alpha subunit
of human complement protein C8: evidence for the existence of a separate alpha
subunit messenger RNA.
A; Reference number: A26704; MUID: 88000560; PMID: 2820471
A; Accession: A26704
A; Molecule type: mRNA
A; Residues: 1-92, 'Q', 94-466, 'CCGTQAWASGGQ', 480-574, 'P', 576-584 < RAO>
A; Note: part of the sequence was confirmed by protein sequencing
R; Hofsteenge, J.; Blommers, M.; Hess, D.; Furmanek, A.; Miroshnichenko, O.
J. Biol. Chem. 274, 32786-32794, 1999
A; Title: The four terminal components of the complement system are C-
mannosylated on multiple tryptophan residues.
A; Reference number: A59362; MUID: 20020247; PMID: 10551839
A; Contents: annotation
A; Note: identification and location of C-mannosylation sites by mass-
spectroscopy
C; Genetics:
A; Gene: GDB: C8A
A; Cross-references: GDB:119735; OMIM:120950
A; Map position: 1p32-1p32
A; Introns: 26/2; 57/3; 106/1; 155/2; 218/3; 285/3; 366/1; 408/1; 460/3; 535/1
```

```
C; Complex: heterotrimer of C8 alpha chain (PIR: C8HUA), C8 beta chain
(PIR:C8HUB), and C8 gamma chain (PIR:C8HUG); the trimer associates with the C5b-
7 complex
C; Function:
A; Description: combines with complement C5b-7 complex to polymerize complement
component C9
A; Pathway: complement pathway
C; Superfamily: complement C9; EGF homology; LDL receptor ligand-binding repeat
homology; thrombospondin type 1 repeat homology
C; Keywords: complement pathway; cytolysis; glycoprotein; membrane attack
complex; plasma
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-30/Domain: propeptide #status predicted <PRO>
F;31-584/Product: complement C8 alpha chain #status predicted <MPT>
F;37-91/Domain: thrombospondin type 1 repeat homology <THR1>
F;96-130/Domain: LDL receptor ligand-binding repeat homology <LDL>
F;497-528/Domain: EGF homology <EGF>
F;538-584/Domain: thrombospondin type 1 repeat homology <THR2>
F;43/Binding site: carbohydrate (Asn) (covalent) #status absent
F;44,542,545,548/Modified site: 2'-mannosyl-tryptophan (Trp) #status
experimental
F;437/Binding site: carbohydrate (Asn) (covalent) #status predicted
  Query Match
                          47.6%; Score 138; DB 1; Length 584;
  Best Local Similarity
                          56.5%; Pred. No. 5.3e-08;
          26; Conservative
                                 3; Mismatches
                                                  13; Indels
                                                                      Gaps
                                                                              1;
Qу
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
              1 1: 1111 1
                            1 1:1 1 1 111 111 1 1: 11
          543 SCWSSWSVCRA----GIQERRRECDNPAPQNGGASCSGRKVQTQAC 584
RESULT 3
T00355
hypothetical protein KIAA0688 - human
C; Species: Homo sapiens (man)
C; Date: 01-Feb-1999 #sequence revision 01-Feb-1999 #text change 09-Jul-2004
C; Accession: T00355
R; Ishikawa, K.; Nagase, T.; Suyama, M.; Miyajima, N.; Tanaka, A.; Kotani, H.;
Nomura, N.; Ohara, O.
DNA Res. 5, 169-176, 1998
A; Title: Prediction of the coding sequences of unidentified human genes. X. The
complete sequences of 100 new cDNA clones from brain which can code for large
proteins in vitro.
A; Reference number: Z14142; MUID: 98403880; PMID: 9734811
A; Accession: T00355
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-837 <ISH>
A; Cross-references: UNIPROT: 075173; EMBL: AB014588; NID: q3327189;
PIDN:BAA31663.1; PID:g3327190
A; Experimental source: brain
C; Genetics:
A; Gene: KIAA0688
F;519-575/Domain: thrombospondin type 1 repeat homology <THR3>
  Query Match
                          45.5%; Score 132; DB 2; Length 837;
```

```
Best Local Similarity 47.8%; Pred. No. 3.4e-07;
           22; Conservative.
                                5; Mismatches 19; Indels
                                                               0; Gaps
                                                                           0;
Qу
           3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
                  Db
         526 WGPWGDCSRTCGGGVQFSSRDCTRPVPRNGGKYCEGRRTRFRSCNT 571
RESULT 4
T18856
angiogenesis inhibitor homolog - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 09-Jul-2004
C; Accession: T18856; T24653
R; McMurray, A.
submitted to the EMBL Data Library, July 1995
A; Reference number: Z19031
A; Accession: T18856
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-1444 <WIL>
A; Cross-references: UNIPROT: Q8MYA8; EMBL: Z50004; PIDN: CAA90293.1; GSPDB: GN00028;
CESP: C02B4.1
A; Experimental source: clone C02B4
R; McMurray, A.
submitted to the EMBL Data Library, July 1995
A; Reference number: Z19917
A; Accession: T24653
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-1444 <WI2>
A;Cross-references: EMBL:Z50006; PIDN:CAA90302.1; GSPDB:GN00028; CESP:C02B4.1
A; Experimental source: clone T07C5
C; Genetics:
A; Gene: CESP: C02B4.1
A; Map position: X
A; Introns: 25/3; 70/3; 96/3; 139/3; 187/1; 234/2; 282/3; 376/2; 422/2; 478/3;
509/3; 566/2; 625/1; 696/2; 786/3; 812/2; 878/3; 971/1; 1007/3; 1067/1; 1099/3;
1180/3; 1273/2; 1305/1; 1363/1; 1388/2
 Query Match
                         45.0%; Score 130.5; DB 2; Length 1444;
 Best Local Similarity
                         52.2%; Pred. No. 7.8e-07;
 Matches
           24; Conservative
                                6; Mismatches 15; Indels
                                                               1;
                                                                   Gaps
                                                                           1;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qу
             Db
        1311 STWSDWTPCSASCGFGVQTRDRSCSSPEP-KGGQSCSGLAHQTSLC 1355
RESULT 5
T47158
hypothetical protein DKFZp762C1110.1 - human (fragment)
C; Species: Homo sapiens (man)
C;Date: 20-Apr-2000 #sequence revision 20-Apr-2000 #text change 09-Jul-2004
C; Accession: T47158
R; Blum, H.; Bauersachs, S.; Mewes, H.W.; Weil, B.; Wiemann, S.
submitted to the Protein Sequence Database, March 2000
```

```
A: Reference number: Z24379
A; Accession: T47158
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-550 <AAA>
A; Cross-references: UNIPROT: Q9UHI8; EMBL: AL162080
A; Experimental source: adult melanoma (MeWo cell line); clone DKFZp762C1110
C; Genetics:
A; Note: DKFZp762C1110.1
                         44.8%; Score 130; DB 2; Length 550;
  Query Match
  Best Local Similarity
                         47.7%; Pred. No. 4e-07;
 Matches
           21; Conservative
                                5; Mismatches 18; Indels
                                                               0; Gaps
                                                                           0;
Qу
           3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
             Db
         148 WGPWGDCSRTCGGGVQYTMRECDNPVPKNGGKYCEGKRVRYRSC 191
RESULT 6
T00017
gene ADAMTS-1 protein - mouse
C; Species: Mus musculus (house mouse)
C;Date: 22-Jan-1999 #sequence revision 22-Jan-1999 #text change 15-Mar-2004
C; Accession: T00017
R; Kuno, K.; Lizasa, H.; Ohno, S.; Matsushima, K.
Genomics 46, 466-471, 1997
A; Title: The exon/intron organization and chromosomal mapping of the mouse
ADAMTS-1 gene encoding an ADAM family protein with TSP motifs.
A; Reference number: Z14055; MUID: 98110583; PMID: 9441751
A; Accession: T00017
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-951 <KUN>
A;Cross-references: EMBL:AB001735; NID:g2809056; PIDN:BAA24501.1; PID:g2809057
A; Experimental source: strain 129SVJ
C; Genetics:
A; Gene: ADAMTS-1
A; Introns: 228/1; 343/3; 388/1; 444/1; 539/3; 602/1; 660/3; 719/2
F;542-598/Domain: thrombospondin type 1 repeat homology <THR3>
  Query Match
                         44.8%; Score 130; DB 2; Length 951;
  Best Local Similarity
                         47.7%; Pred. No. 6.3e-07;
 Matches
           21; Conservative
                                5; Mismatches
                                                18; Indels
                                                                          0;
           3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qу
             Db
         549 WGPWGDCSRTCGGGVQYTMRECDNPVPKNGGKYCEGKRVRYRSC 592
RESULT 7
TSHUP1
thrombospondin 1 precursor - human
C; Species: Homo sapiens (man)
C;Date: 23-Aug-1987 #sequence revision 03-Aug-1995 #text change 09-Jul-2004
C; Accession: A26155; A34274; A30140; A25812; A05172; A42927
R; Lawler, J.; Hynes, R.O.
```

```
J. Cell Biol. 103, 1635-1648, 1986
A; Title: The structure of human thrombospondin, an adhesive glycoprotein with
multiple calcium-binding sites and homologies with several different proteins.
A; Reference number: A26155; MUID: 87057617; PMID: 2430973
A; Accession: A26155
A; Molecule type: mRNA
A; Residues: 1-1170 <LAW>
A; Cross-references: UNIPROT: P07996; GB: X04665; NID: q37137; PIDN: CAA28370.1;
PID: g37138
A; Note: parts of this sequence, including the amino end of the mature protein,
were determined by protein sequencing
R; Laherty, C.D.; Gierman, T.M.; Dixit, V.M.
J. Biol. Chem. 264, 11222-11227, 1989
A; Title: Characterization of the promoter region of the human thrombospondin
gene. DNA sequences within the first intron increase transcription.
A; Reference number: A34274; MUID: 89291870; PMID: 2544587
A; Accession: A34274
A; Molecule type: DNA
A; Residues: 1-166 <LAH>
A; Cross-references: GB: J04835
R; Hennessy, S.W.; Frazier, B.A.; Kim, D.D.; Deckwerth, T.L.; Baumgartel, D.M.;
Rotwein, P.; Frazier, W.A.
J. Cell Biol. 108, 729-736, 1989
A; Title: Complete thrombospondin mRNA sequence includes potential regulatory
sites in the 3' untranslated region.
A; Reference number: A30140; MUID: 89139590; PMID: 2918029
A; Accession: A30140
A; Molecule type: mRNA
A; Residues: 1-83, 'A', 85-522, 'A', 524-1170 < HEN>
A; Cross-references: EMBL: X14787; NID: q37464; PIDN: CAA32889.1; PID: q37465
A; Note: parts of this sequence, including the amino end of the mature protein,
were determined by protein sequencing
R; Kobayashi, S.; Eden-McCutchan, F.; Framson, P.; Bornstein, P.
Biochemistry 25, 8418-8425, 1986
A; Title: Partial amino acid sequence of human thrombospondin as determined by
analysis of cDNA clones: homology to malarial circumsporozoite proteins.
A; Reference number: A25812; MUID: 87157592; PMID: 3030396
A; Accession: A25812
A; Molecule type: mRNA
A; Residues: 1-83, 'A', 85-397 < KOB>
A;Cross-references: GB:M25631; NID:q538353; PIDN:AAA36741.1; PID:q538354
R; Dixit, V.M.; Hennessy, S.W.; Grant, G.A.; Rotwein, P.; Frazier, W.A.
Proc. Natl. Acad. Sci. U.S.A. 83, 5449-5453, 1986
A; Reference number: A05172; MUID: 86287276; PMID: 3461443
A; Accession: A05172
A; Molecule type: mRNA
A; Residues: 1-83, 'A', 85-374, 'RC' <DIX>
A;Cross-references: GB:M14326; NID:g340005; PIDN:AAA61237.1; PID:g553801
A; Note: parts of this sequence, including the amino end of the mature protein,
were determined by protein sequencing
R; Sun, X.; Skorstengaard, K.; Mosher, D.F.
J. Cell Biol. 118, 693-701, 1992
A; Title: Disulfides modulate RGD-inhibitable cell adhesive activity of
thrombospondin.
A; Reference number: A42927; MUID: 92348511; PMID: 1379247
A; Accession: A42927
A; Molecule type: protein
```

```
A; Residues: 987-1003 <SUN>
A; Note: Cys-992 is shown to have a free sulfhydryl
C; Genetics:
A; Gene: GDB: THBS1; TSP1; TSP
A; Cross-references: GDB:120438; OMIM:188060
A; Map position: 15q15-15q15
A; Introns: 23/1
A; Note: the list of introns may be incomplete
C; Complex: homotrimer, disulfide linked
C; Function:
A; Description: participates in cell migration and adhesion, and in platelet
aggregation
C; Superfamily: thrombospondin 1; EGF homology; thrombospondin type 1 repeat
homology; von Willebrand factor type C repeat homology
C; Keywords: beta-hydroxyasparagine; calcium binding; cell adhesion;
glycoprotein; trimer
F;1-18/Domain: signal sequence #status predicted <SIG>
F;19-1170/Product: thrombospondin 1 #status predicted <MAT>
F;317-375/Domain: von Willebrand factor type C repeat homology <VWC>
F;378-429/Domain: thrombospondin type 1 repeat homology <THR1>
F;434-490/Domain: thrombospondin type 1 repeat homology <THR2>
F;491-547/Domain: thrombospondin type 1 repeat homology <THR3>
F;551-586/Domain: EGF homology <EGF1>
F;650-689/Domain: EGF homology <EGF2>
F;926-928/Region: cell attachment (R-G-D) motif
F;171-232/Disulfide bonds: #status predicted
F;248,360,708,1067/Binding site: carbohydrate (Asn) (covalent) #status predicted
F;270,274/Disulfide bonds: interchain #status predicted
F;610/Modified site: erythro-beta-hydroxyasparagine (Asn) #status predicted
F;1051/Binding site: carbohydrate (Asn) (covalent) #status absent
  Query Match
                          44.1%; Score 128; DB 1; Length 1170;
  Best Local Similarity
                          47.7%; Pred. No. 1.2e-06;
                                4; Mismatches
          21; Conservative
                                                 19; Indels
                                                                0; Gaps
                                                                             0;
Qy
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
              498 WSPWDICSVTCGGGVQKRSRLCNNPTPQFGGKDCVGDVTENQIC 541
RESULT 8
T32541
unc-5 protein - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 29-Oct-1999 #sequence revision 29-Oct-1999 #text change 09-Jul-2004
C; Accession: T32541
R; Latreille, P.
submitted to the EMBL Data Library, December 1997
A; Description: The sequence of C. elegans cosmid B0273.
A; Reference number: Z21187
A; Accession: T32541
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-919 <LAT>
A;Cross-references: UNIPROT:044171; EMBL:AF036698; PIDN:AAB88355.1;
GSPDB:GN00022; CESP:B0273.4a
A; Experimental source: strain Bristol N2; clone B0273
```

```
C; Genetics:
A; Gene: unc-5; CESP: B0273.4a
A; Map position: 4
A; Introns: 41/3; 108/1; 142/3; 201/1; 323/2; 553/1; 858/3
C; Superfamily: unc-5 protein; immunoglobulin homology; SH3 homology;
thrombospondin type 1 repeat homology
                          43.8%; Score 127; DB 2; Length 919;
  Query Match
                          47.1%; Pred. No. 1.3e-06;
  Best Local Similarity
  Matches
           24; Conservative
                                 9; Mismatches
                                                  14; Indels
                                                                  4; Gaps
                                                                              2;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC-ATLC 50
Qу
              1:1::11 | 1:11 |
                                Db
          278 SSWSDWSACSSSCHR---YRTRACTVPPPMNGGQPCFGDDLMTQECPAQLC 325
RESULT 9
B44294
unc-5 protein, long form - Caenorhabditis elegans
N; Contains: unc-5 protein, short form
C; Species: Caenorhabditis elegans
C;Date: 30-Apr-1993 #sequence revision 28-Jul-1995 #text change 09-Jul-2004
C; Accession: B44294; T32540; A44294
R; Leung-Hagesteijn, C.; Spence, A.M.; Stern, B.D.; Zhou, Y.; Su, M.W.;
Hedgecock, E.M.; Culotti, J.G.
Cell 71, 289-299, 1992
A; Title: UNC-5, a transmembrane protein with immunoglobulin and thrombospondin
type 1 domains, guides cell and pioneer axon migrations in C. elegans.
A; Reference number: A44294; MUID: 93046629; PMID: 1384987
A; Contents: variety Bergerac
A; Accession: B44294
A; Molecule type: DNA
A; Residues: 1-947 <LEU>
A;Cross-references: UNIPROT:044171; GB:S47168; NID:g258527; PIDN:AAB23867.1;
PID:g258529
A; Note: sequence extracted from NCBI backbone (NCBIN:116668, NCBIN:116670,
NCBIN:116672, NCBIN:116674, NCBIN:116676, NCBIN:116678, NCBIN:116680,
NCBIN:116682, NCBIN:116685, NCBIP:118648)
A; Note: authors translated the codon CTA for residue 642 as Val; sequence shown
follows the authors' translation
A; Note: mRNA lacking the first exon is equally prevalent
R; Latreille, P.
submitted to the EMBL Data Library, December 1997
A; Description: The sequence of C. elegans cosmid B0273.
A; Reference number: Z21187
A; Accession: T32540
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-947 <LAT>
A;Cross-references: EMBL:AF036698; PIDN:AAB88356.1; GSPDB:GN00022; CESP:B0273.4b
A; Experimental source: strain Bristol N2; clone B0273
C; Genetics:
A; Gene: unc-5
A; Map position: 4
A; Introns: 28/1; 69/3; 136/1; 170/3; 229/1; 351/2; 581/1; 886/3
C; Function:
```

```
A; Description: required for quidance of pioneering axons and cells migrating
 dorsally along the body wall; proposed to be a receptor on the surface of the
 motile cells
 C; Superfamily: unc-5 protein; immunoglobulin homology; SH3 homology;
 thrombospondin type 1 repeat homology
 C; Keywords: alternative splicing; duplication; glycoprotein; receptor;
 transmembrane protein
 F;30-947/Product: unc-5 protein, short form #status predicted <ALT>
 F;46-116/Domain: immunoglobulin homology <IM1>
 F;153-211/Domain: immunoglobulin homology <IM2>
 F;229-300/Domain: thrombospondin type 1 repeat homology #status atypical <THR1>
 F;301-354/Domain: thrombospondin type 1 repeat homology <THR2>
 F;365-390/Domain: transmembrane #status predicted <TMM>
 F;512-559/Domain: SH3 homology <SH3>
 F;53-114,65-112,160-209/Disulfide bonds: #status predicted
F;206/Binding site: carbohydrate (Asn) (covalent) #status predicted
                           43.8%;
                                   Score 127; DB 1; Length 947;
   Best Local Similarity
                           47.1%; Pred. No. 1.4e-06;
 Matches
            24; Conservative
                                  9; Mismatches
                                                   14; Indels
                                                                  4; Gaps
                                                                              2;
 Qу
             1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC-ATLC 50
               Db
           306 SSWSDWSACSSSCHR---YRTRACTVPPPMNGGQPCFGDDLMTQECPAQLC 353
 RESULT 10
 A40558
 thrombospondin 1 precursor - mouse
 C; Species: Mus musculus (house mouse)
 C;Date: 05-Jun-1992 #sequence revision 05-Jun-1992 #text change 09-Jul-2004
 C; Accession: A40558; A37905; B42587; S68787
 R; Lawler, J.; Duquette, M.; Ferro, P.; Copeland, N.G.; Gilbert, D.J.; Jenkins,
 N.A.
 Genomics 11, 587-600, 1991
 A; Title: Characterization of the murine thrombospondin gene.
 A; Reference number: A40558; MUID: 92128941; PMID: 1774063
 A; Accession: A40558
 A; Status: preliminary
 A; Molecule type: DNA
 A; Residues: 1-1170 <LAW>
 A;Cross-references: UNIPROT:P35441; GB:M62449; GB:M62450; GB:M62451; GB:M62452;
 GB:M62453; GB:M62454; GB:M62455; GB:M62456; GB:M62457; GB:M62458; GB:M62459;
 GB:M62460; GB:M62461; GB:M62462; GB:M62463; GB:M62464; GB:M62465; GB:M62466;
 GB:M62467; GB:M62468; GB:M62469; GB:M62470; NID:g511867; PIDN:AAA50611.1;
 PID:q511869
 R; Bornstein, P.; Alfi, D.; Devarayalu, S.; Framson, P.; Li, P.
 J. Biol. Chem. 265, 16691-16698, 1990
 A; Title: Characterization of the mouse thrombospondin gene and evaluation of the
 role of the first intron in human gene expression.
 A; Reference number: A37905; MUID: 90375546; PMID: 2398070
 A; Accession: A37905
 A; Status: preliminary
 A; Molecule type: DNA
 A; Residues: 1-490 <BOR>
 A;Cross-references: GB:J05605; GB:J05606; NID:g201991; PIDN:AAA40431.1;
PID:g554390
```

```
R; Laherty, C.D.; O'Rourke, K.; Wolf, F.W.; Katz, R.; Seldin, M.F.; Dixit, V.M.
J. Biol. Chem. 267, 3274-3281, 1992
A; Title: Characterization of mouse thrombospondin 2 sequence and expression
during cell growth and development.
A; Reference number: A42587; MUID: 92147683; PMID: 1371115
A; Accession: B42587
A; Status: preliminary; not compared with conceptual translation
A; Molecule type: mRNA
A; Residues: 1-1152, 'P', 1154-1170 <LAH>
A; Cross-references: GB: M87276
A: Note: sequence extracted from NCBI backbone (NCBIP: 81501)
R; Chen, H.; Aeschlimann, D.; Nowlen, J.; Mosher, D.F.
FEBS Lett. 387, 36-41, 1996
A; Title: Expression and initial characterization of recombinant mouse
thrombospondin 1 and thrombospondin 3.
A; Reference number: S68787; MUID: 96234006; PMID: 8654563
A: Accession: S68787
A; Molecule type: protein
A; Residues: 19-26, 'X', 28-37 < CHE>
C; Complex: homotrimer, disulfide linked
C; Superfamily: thrombospondin 1; EGF homology; thrombospondin type 1 repeat
homology; von Willebrand factor type C repeat homology
C; Keywords: calcium binding; glycoprotein; homotrimer
F;1-18/Domain: signal sequence #status predicted <SIG>
F;19-1170/Product: thrombospondin 1 #status predicted <MAT>
F;317-375/Domain: von Willebrand factor type C repeat homology <VWC>
F;378-429/Domain: thrombospondin type 1 repeat homology <THR1>
F;434-490/Domain: thrombospondin type 1 repeat homology <THR2>
F;491-547/Domain: thrombospondin type 1 repeat homology <THR3>
F;551-586/Domain: EGF homology <EGF>
F;248,360,708,1067/Binding site: carbohydrate (Asn) (covalent) #status predicted
  Query Match
                          43.4%;
                                  Score 126; DB 2; Length 1170;
  Best Local Similarity
                          45.5%; Pred. No. 2.1e-06;
  Matches
            20; Conservative
                                 5; Mismatches
                                                                  0; Gaps
                                                  19; Indels
                                                                              0;
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qy
              Db
          498 WSPWDICSVTCGGGVQRRSRLCNNPTPQFGGKDCVGDVTENQVC 541
RESULT 11
T21371
hypothetical protein F25H8.3 - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 09-Jul-2004
C; Accession: T21371; T24896
R; Gajadsty, S.
submitted to the EMBL Data Library, February 1996
A; Reference number: Z19413
A; Accession: T21371
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2165 <WIL>
A; Cross-references: UNIPROT:Q19791; EMBL:Z69360; PIDN:CAA93287.1; GSPDB:GN00022;
CESP: F25H8.3
A; Experimental source: clone F25H8
```

```
R; Gajadsty, S.
submitted to the EMBL Data Library, February 1996
A: Reference number: Z19949
A; Accession: T24896
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2165 <WI2>
A; Cross-references: EMBL: 269361; PIDN: CAA93288.1; GSPDB: GN00022; CESP: F25H8.3
A; Experimental source: clone T13H10
C; Genetics:
A; Gene: CESP: F25H8.3
A; Map position: 4
A; Introns: 31/1; 52/1; 135/2; 193/3; 216/1; 266/1; 495/2; 547/3; 584/3; 634/2;
744/1; 814/1; 961/2; 1251/3; 1338/3; 1500/3; 1553/3; 1647/3; 1704/3; 1762/3;
1820/3; 1938/1; 1998/2; 2044/1; 2109/3
 Query Match
                         43.4%;
                                 Score 126; DB 2; Length 2165;
  Best Local Similarity
                         45.7%; Pred. No. 3.5e-06;
                                5; Mismatches
           21; Conservative
                                                 20; Indels
                                                                0;
                                                                    Gaps
                                                                            0:
Qу
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
                  Db
         609 WRSWGECSRTCGGGVQKGLRDCDSPKPRNGGKYCVGQRERYRSCNT 654
RESULT 12
I46686
complement component C8 alpha subunit - rabbit
C; Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 14-Feb-1997 #sequence revision 14-Feb-1997 #text change 09-Jul-2004
C; Accession: I46686
R; White, R.V.; Kaufman, K.M.; Letson, C.S.; Platteborze, P.L.; Sodetz, J.M.
J. Immunol. 152, 2501-2508, 1994
A; Title: Characterization of rabbit complement component C8: Functional evidence
for the species-selective recognition of C8 alpha by homologous restriction
factor (CD59).
A; Reference number: I46686; MUID: 94179833; PMID: 7510745
A; Accession: I46686
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-585 <WHI>
A; Cross-references: UNIPROT: P98136; GB: L26981; NID: q469060; PIDN: AAA31191.1;
PID:g469061
C; Superfamily: complement C9; EGF homology; LDL receptor ligand-binding repeat
homology; thrombospondin type 1 repeat homology
F;37-91/Domain: thrombospondin type 1 repeat homology <THR1>
F;96-130/Domain: LDL receptor ligand-binding repeat homology <LDL2>
F;498-529/Domain: EGF homology <EGF>
                         42.4%; Score 123; DB 2; Length 585;
  Query Match
                         52.2%; Pred. No. 2.6e-06;
  Best Local Similarity
 Matches
           24; Conservative
                                3; Mismatches
                                                 15; Indels
                                                               4;
                                                                    Gaps
                                                                            1;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qу
              1 1 11 1:1
                            Db
          544 SCWGSWSPCTA----GTRERRRECNNPAPQNGGAPCPGWRVQTQAC 585
```

```
RESULT 13
T00027
brain-specific angiogenesis inhibitor 2 - human
N; Alternate names: BAI2 protein
C; Species: Homo sapiens (man)
C; Date: 22-Jan-1999 #sequence revision 22-Jan-1999 #text change 09-Jul-2004
C; Accession: T00027
R; Shiratsuchi, T.; Nishimori, H.; Ichise, H.; Nakamura, Y.; Tokino, T.
Cytogenet. Cell Genet. 79, 103-108, 1997
A; Title: Cloning and characterization of BAI2 and BAI3, novel genes homologous
to brain-specific angiogenesis inhibitor 1 (BAI 1).
A; Reference number: Z14066; MUID: 98194217; PMID: 9533023
A; Accession: T00027
A; Status: translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-1572 <SHI>
A; Cross-references: UNIPROT: 060241; EMBL: AB005298; NID: q3021698;
PIDN:BAA25362.1; PID:q3021699
A; Experimental source: brain
C; Genetics:
A; Gene: GDB: BAI2
A; Cross-references: GDB:9838089; OMIM:602683
A; Map position: 1p35-1p35
  Query Match
                          41.0%; Score 119; DB 2; Length 1572;
  Best Local Similarity 46.7%; Pred. No. 1.6e-05;
 Matches
            21; Conservative
                               6; Mismatches
                                                  16; Indels
                                                                   2; Gaps
                                                                               1;
Qу
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACA 47
              | ||:|| ||||| : | |:|
                                        | | | | | | | | | | |
          358 WGSWSLCSRSCGRGSRSRMRTCV--PPQHGGKACEGPELQTKLCS 400
Db
RESULT 14
T00026
brain-specific angiogenesis inhibitor 1 - human
N; Alternate names: BAI1 protein
C; Species: Homo sapiens (man)
C; Date: 22-Jan-1999 #sequence revision 22-Jan-1999 #text change 09-Jul-2004
C; Accession: T00026
R; Nishimori, H.; Shiratsuchi, T.; Urano, T.; Kimura, Y.; Kiyono, K.; Tatsumi,
K.; Yoshida, S.; Ono, M.; Kuwano, M.; Nakamura, Y.
submitted to the EMBL Data Library, June 1997
A; Reference number: 214064
A; Accession: T00026
A; Status: translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-1584 < NIS>
A;Cross-references: UNIPROT:014514; EMBL:AB005297; NID:d1175078; PID:d1024528
A; Experimental source: brain
C; Genetics:
A; Gene: GDB: BAI1
A; Cross-references: GDB: 9838088; OMIM: 602682
A; Map position: 8q24-8q24
F;408-462/Domain: thrombospondin type 1 repeat homology <THR3>
```

```
41.0%; Score 119; DB 2; Length 1584;
 Query Match
 Best Local Similarity 47.7%; Pred. No. 1.6e-05;
           21; Conservative
                                7; Mismatches
                                                14; Indels
                                                                   Gaps
                                                                           1;
           3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qy
             1: || || || :| :| :| : |
                                        ||| |:| |:
Db
         473 WSSWSACSASCSQGRQQRTRECNGPS--YGGAECQGHWVETRDC 514
RESULT 15
S05478
properdin - mouse (fragment)
C; Species: Mus musculus (house mouse)
C;Date: 07-Sep-1990 #sequence revision 07-Sep-1990 #text change 09-Jul-2004
C:Accession: S05478
R; Goundis, D.; Reid, K.B.M.
Nature 335, 82-85, 1988
A; Title: Properdin, the terminal complement components, thrombospondin and the
circumsporozoite protein of malaria parasites contain similar sequence motifs.
A; Reference number: S05478; MUID:88318954; PMID:3045564
A; Accession: S05478
A; Molecule type: mRNA
A; Residues: 1-437 <GOU>
A;Cross-references: UNIPROT:P11680; EMBL:X12905; NID:g53786; PIDN:CAA31389.1;
PID:q53787
C; Complex: a mixture of homodimers, homotrimers and homotetramers
C; Function:
A; Description: protects C3 convertase (C3bBb) from rapid inactivation
A; Pathway: complement alternate pathway
C; Superfamily: human properdin precursor; thrombospondin type 1 repeat homology
C; Keywords: complement alternate pathway; glycoprotein; homodimer; homotetramer;
homotrimer; plasma
F;45-97/Domain: thrombospondin type 1 repeat homology <THR1>
F;104-160/Domain: thrombospondin type 1 repeat homology <THR2>
F:161-224/Domain: thrombospondin type 1 repeat homology <THR3>
F;225-282/Domain: thrombospondin type 1 repeat homology <THR4>
F;283-345/Domain: thrombospondin type 1 repeat homology <THR5>
F;346-408/Domain: thrombospondin type 1 repeat homology <THR6>
F;52,55,108,111,114,165,168,229,232,290,293,350,353,356/Modified site: 2'-
mannosyl-tryptophan (Trp) #status predicted
F;366,396/Binding site: carbohydrate (Asn) (covalent) #status predicted
  Query Match
                         40.9%; Score 118.5; DB 2; Length 437;
  Best Local Similarity
                         47.9%; Pred. No. 6.4e-06;
 Matches
           23; Conservative
                                3; Mismatches
                                                 21;
                                                      Indels
                                                                   Gaps
                                                                           1;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACAT 48
Qу
             109 SEWGPWGPCSVTCSKGTQIRQRVCDNPAPKCGG-HCPGEAQQSQACDT 155
```

Search completed: March 1, 2005, 09:07:20 Job time: 2.95188 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2005, 09:06:01; Search time 9.62324 Seconds

(without alignments)

1704.439 Million cell updates/sec

US-10-624-932-2_COPY_246_295 Title:

Perfect score:

Sequence: 1 STWTEWSVCSASCGRGWQKR.....NGGAFCEGQNVQKTACATLC 50

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

1385339 seqs, 328044528 residues Searched:

Total number of hits satisfying chosen parameters: 1385339

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Published Applications AA:* Database :

/cgn2 6/ptodata/1/pubpaa/US07 PUBCOMB.pep:*

/cgn2 6/ptodata/1/pubpaa/PCT NEW PUB.pep:* 2:

/cgn2 6/ptodata/1/pubpaa/US06 NEW PUB.pep:* 3:

/cgn2 6/ptodata/1/pubpaa/US06 PUBCOMB.pep:* 4:

/cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*

6: /cgn2 6/ptodata/1/pubpaa/PCTUS PUBCOMB.pep:*

7: /cgn2 6/ptodata/1/pubpaa/US08 NEW PUB.pep:*

8: /cgn2 6/ptodata/1/pubpaa/US08 PUBCOMB.pep:*

9: /cgn2 6/ptodata/1/pubpaa/US09A PUBCOMB.pep:*

10: /cgn2 6/ptodata/1/pubpaa/US09B PUBCOMB.pep:*

/cgn2 6/ptodata/1/pubpaa/US09C PUBCOMB.pep:* 11:

12: /cgn2 6/ptodata/1/pubpaa/US09 NEW PUB.pep:*

13: /cgn2_6/ptodata/1/pubpaa/US10A PUBCOMB.pep:* 14: /cgn2_6/ptodata/1/pubpaa/US10B PUBCOMB.pep:*

15: /cgn2 6/ptodata/1/pubpaa/US10C PUBCOMB.pep:*

16: /cgn2 6/ptodata/1/pubpaa/US10D PUBCOMB.pep:*

17: /cgn2 6/ptodata/1/pubpaa/US10 NEW PUB.pep:*

/cgn2 6/ptodata/1/pubpaa/US11 NEW PUB.pep:* 18:

/cgn2 6/ptodata/1/pubpaa/US60 NEW PUB.pep:* 19:

/cgn2 6/ptodata/1/pubpaa/US60 PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

		8				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
						
1	290	100.0	898	10	US-09-933-261-5	Sequence 5, Appli
2	290	100.0	898	10	US-09-918-779-2	Sequence 2, Appli
3	290	100.0	898	10	US-09-970-944-13	Sequence 13, Appl
4	290	100.0	898	14	US-10-256-702-5	Sequence 5, Appli
5	290	100.0	898	14	US-10-240-154-16	Sequence 16, Appl
6	290	100.0	898	15	US-10-624-932-2	Sequence 2, Appli
7	249	85.9	931	10	US-09-970-944-15	Sequence 15, Appl
8	249	85.9	931	10	US-09-970-944-16	Sequence 16, Appl
9	249	85.9	931	10	US-09-970-944-17	Sequence 17, Appl
10	249	85.9	931	11	US-09-972-211-121	Sequence 121, App
11	249	85.9	931	11	US-09-972-211-122	Sequence 122, App
12	249	85.9	931	11	US-09-972-211-125	Sequence 125, App
13	249	85.9	931	15	US-10-087-684-35	Sequence 35, Appl
14	249	85.9	931	15	US-10-087-684-36	Sequence 36, Appl
15	249	85.9	931	15	US-10-218-779-36	Sequence 36, Appl
16	249	85.9	931	15	US-10-037-417-117	Sequence 117, App
17	249	85.9	931	15	US-10-037-417-118	Sequence 118, App
18	249	85.9	931	15	US-10-037-417-119	Sequence 119, App
19	249	85.9	931	15	US-10-037-417-120	Sequence 120, App
20	249	85.9	931	15	US-10-096-625-121	Sequence 121, App
21	249	85.9	931	15	US-10-096-625-122	Sequence 122, App
22	249	85.9	931	15	US-10-096-625-125	Sequence 125, App
23	249	85.9	1010	15	US-10-218-779-35	Sequence 35, Appl
24	243	83.8	899	10	US-09-970-944-2	Sequence 2, Appli
25	239	82.4	56	17	US-10-872-681-32	Sequence 32, Appl
26	239	82.4	679	15	US-10-094-886-118	Sequence 118, App
27	239	82.4	887	17	US-10-872-681-54	Sequence 54, Appl
28	, 239	82.4	924	16	US-10-473-518-63	Sequence 63, Appl
29	239	82.4	933	15	US-10-087-684-2	Sequence 2, Appli
30	239	82.4	933	15	US-10-087-684-4	Sequence 4, Appli
31	239	82.4	933	15	US-10-218-779-2	Sequence 2, Appli
32	239	82.4	933	15	US-10-218-779-4	Sequence 4, Appli
33	239	82.4	945	14	US-10-028-072-146	Sequence 146, App
34	239	82.4	945	14	US-10-140-808-146	Sequence 146, App
35	239	82.4	945	14	US-10-121-049-146	Sequence 146, App
36	239	82.4	945	14	US-10-123-904-146	Sequence 146, App
37	239	82.4	945	14	US-10-140-470-146	Sequence 146, App
38	239	82.4	945	14	US-10-175-746-146	Sequence 146, App
39	239	82.4	945	14	US-10-176-918-146	Sequence 146, App
40	239	82.4	945	14	US-10-176-921-146	Sequence 146, App
41	239	82.4	945	14	US-10-137-865-146	Sequence 146, App
42	239	82.4	945	14	US-10-140-474-146	Sequence 146, App
43	239	82.4	945	14	US-10-142-431-146	Sequence 146, App
44	239	82.4	945	14	US-10-143-114-146	Sequence 146, App
45	239	82.4	945	14	US-10-142-419-146	Sequence 146, App

ALIGNMENTS

RESULT 1 US-09-933-261-5

[;] Sequence 5, Application US/09933261

```
; Publication No. US20030040046A1
   GENERAL INFORMATION:
        APPLICANT: Tessier-Lavigne, Marc
                   Leonardo, E. David
                   Hink, Lindsay
                   Masu, Masayuki
                   Kazuko, Keino-Masu
        TITLE OF INVENTION: Netrin Receptors
        NUMBER OF SEQUENCES: 8
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
             STREET: 268 BUSH STREET, SUITE 3200
             CITY: SAN FRANCISCO
             STATE: CALIFORNIA
             COUNTRY: USA
             ZIP: 94104
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.30
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/09/933,261
             FILING DATE: 20-Aug-2001
             CLASSIFICATION: <Unknown>
        PRIOR APPLICATION DATA:
             APPLICATION NUMBER: 08/808,982
             FILING DATE: <Unknown>
        ATTORNEY/AGENT INFORMATION:
             NAME: OSMAN, RICHARD A
             REGISTRATION NUMBER: 36,627
             REFERENCE/DOCKET NUMBER: UC96-217
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: (415) 343-4341
             TELEFAX: (415) 343-4342
   INFORMATION FOR SEQ ID NO: 5:
        SEQUENCE CHARACTERISTICS:
             LENGTH: 898 amino acids
             TYPE: amino acid
             STRANDEDNESS: No. US20030040046A1 Relevant
             TOPOLOGY: No. US20030040046A1 Relevant
        MOLECULE TYPE: peptide
        SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-933-261-5
 Query Match
                         100.0%; Score 290; DB 10;
                                                     Length 898;
 Best Local Similarity 100.0%; Pred. No. 9.9e-24;
                                                               0; Gaps
          50; Conservative 0; Mismatches
                                                                           0;
 Matches
                                                0;
                                                     Indels
           1 STWTEWSVCSASCGRGWOKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qy
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
Db
RESULT 2
US-09-918-779-2
; Sequence 2, Application US/09918779
```

```
; Publication No. US20030064369A1
; GENERAL INFORMATION:
  APPLICANT: Taupier, Raymond
  APPLICANT: Padigaru, Muralidhara
  APPLICANT: Rastelli, Luca
  APPLICANT: Spaderna, Steven
  APPLICANT: Shimkets, Richard APPLICANT: Zerhusen, Bryan
;
;
; APPLICANT: Spytek, Kimberly
  APPLICANT: Shenoy, Suresh
  APPLICANT: Li, Li
  APPLICANT: Gusev, Vladimir
  APPLICANT: Grosse, William APPLICANT: Alsobrook, John
;
  APPLICANT: Lepley, Denise
  APPLICANT: Burgess, Catherine
  APPLICANT: Gerlach, Valerie
  APPLICANT: Ellerman, Karen
;
  APPLICANT: MacDougall, John
  APPLICANT: Stone, David
APPLICANT: Smithson, Glennda
;
;
  TITLE OF INVENTION: Novel Proteins and Nucleic Acids Encoding Same
;
; FILE REFERENCE: 21402-074 US
  CURRENT APPLICATION NUMBER: US/09/918,779
  CURRENT FILING DATE: 2001-07-30
  PRIOR APPLICATION NUMBER: 60/221,409
   PRIOR FILING DATE: 2000-07-28
   PRIOR APPLICATION NUMBER: 60/222,840
   PRIOR FILING DATE: 2000-08-04
  PRIOR APPLICATION NUMBER: 60/223,752
   PRIOR FILING DATE: 2000-08-08
  PRIOR APPLICATION NUMBER: 60/223,762
  PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,770
   PRIOR FILING DATE: 2000-08-08
  PRIOR APPLICATION NUMBER: 60/223,769
  PRIOR FILING DATE: 2000-08-08
 PRIOR APPLICATION NUMBER: 60/225,146
  PRIOR FILING DATE: 2000-08-14
  PRIOR APPLICATION NUMBER: 60/225,392
  PRIOR FILING DATE: 2000-08-15
  PRIOR APPLICATION NUMBER: 60/225,470
   PRIOR FILING DATE: 2000-08-15
   PRIOR APPLICATION NUMBER: 60/225,697
   PRIOR FILING DATE: 2000-08-16
   PRIOR APPLICATION NUMBER: 60/263,662
   PRIOR FILING DATE: 2001-02-01
   PRIOR APPLICATION NUMBER: 60/281,645
; PRIOR FILING DATE: 2001-04-05
  NUMBER OF SEQ ID NOS: 61
  SOFTWARE: PatentIn Ver. 2.1
;
; SEQ ID NO 2
    LENGTH: 898
    TYPE: PRT
    ORGANISM: Homo sapiens
US-09-918-779-2
```

```
Query Match
                        100.0%; Score 290; DB 10; Length 898;
 Best Local Similarity 100.0%; Pred. No. 9.9e-24;
          50; Conservative 0; Mismatches
                                                  Indels
                                                            0; Gaps
                                                                       0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
Db
RESULT 3
US-09-970-944-13
; Sequence 13, Application US/09970944
; Publication No. US20030204052A1
; GENERAL INFORMATION:
; APPLICANT: Herrman, John L
 APPLICANT: Rastelli, Luca
 APPLICANT: Shimkets, Richard A
 TITLE OF INVENTION: No. US20030204052Alel Proteins and Nucleic Acids Encoding
Same and
; TITLE OF INVENTION: Antibodies Directed Against these Proteins
; FILE REFERENCE: 21402-138
  CURRENT APPLICATION NUMBER: US/09/970,944
  CURRENT FILING DATE: 2002-05-02
; PRIOR APPLICATION NUMBER: 60/237,862
; PRIOR FILING DATE: 2000-10-04
; NUMBER OF SEQ ID NOS: 62
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
   LENGTH: 898
   TYPE: PRT
   ORGANISM: Rattus norvegicus
US-09-970-944-13
                        100.0%; Score 290; DB 10; Length 898;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 9.9e-24;
         50; Conservative 0; Mismatches
                                              0;
                                                   Indels
                                                            0; Gaps
                                                                       0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 4
US-10-256-702-5
; Sequence 5, Application US/10256702
; Publication No. US20030059859A1
   GENERAL INFORMATION:
        APPLICANT: Tessier-Lavigne, Marc
                  Leonardo, E. David
                  Hink, Lindsay
                  Masu, Masayuki
                  Kazuko, Keino-Masu
        TITLE OF INVENTION: Netrin Receptors
        NUMBER OF SEQUENCES: 8
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP
             STREET: 268 BUSH STREET, SUITE 3200
```

```
CITY: SAN FRANCISCO
              STATE: CALIFORNIA
              COUNTRY: USA
              ZIP: 94104
         COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
         CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/10/256,702
              FILING DATE: 27-Sep-2002
              CLASSIFICATION: <Unknown>
         PRIOR APPLICATION DATA:
              APPLICATION NUMBER: US/09/933,261
              FILING DATE: 20-Aug-2001
              APPLICATION NUMBER: 08/808,982
              FILING DATE: <Unknown>
         ATTORNEY/AGENT INFORMATION:
              NAME: OSMAN, RICHARD A
              REGISTRATION NUMBER: 36,627
              REFERENCE/DOCKET NUMBER: UC96-217
         TELECOMMUNICATION INFORMATION:
              TELEPHONE: (415) 343-4341
              TELEFAX: (415) 343-4342
    INFORMATION FOR SEQ ID NO: 5:
         SEQUENCE CHARACTERISTICS:
;
              LENGTH: 898 amino acids
;
              TYPE: amino acid
;
              STRANDEDNESS: No. US20030059859A1 Relevant
              TOPOLOGY: No. US20030059859A1 Relevant
         MOLECULE TYPE: peptide
         SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-256-702-5

      Query Match
      100.0%;
      Score 290;
      DB 14;

      Best Local Similarity
      100.0%;
      Pred. No. 9.9e-24;

                                                         Length 898;
  Matches 50; Conservative 0; Mismatches
                                                    0;
                                                         Indels
                                                                    0:
                                                                        Gaps
                                                                                0;
Qу
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
               246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 5
US-10-240-154-16
; Sequence 16, Application US/10240154
; Publication No. US20030175741A1
; GENERAL INFORMATION:
; APPLICANT: Cochran et al.
   TITLE OF INVENTION: SCHIZOPHRENIA RELATED GENES
  FILE REFERENCE: CKFW-P01-006
; CURRENT APPLICATION NUMBER: US/10/240,154
; CURRENT FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: PCT/GB01/01486
; PRIOR FILING DATE: 2001-04-02
; NUMBER OF SEQ ID NOS: 34
```

```
SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
   LENGTH: 898
    TYPE: PRT
    ORGANISM: Rattus sp.
US-10-240-154-16
  Query Match
                          100.0%; Score 290; DB 14; Length 898;
  Best Local Similarity 100.0%; Pred. No. 9.9e-24;
  Matches 50; Conservative
                                0; Mismatches
                                                       Indels
                                                                      Gaps
                                                                              0;
Qy
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 6
US-10-624-932-2
; Sequence 2, Application US/10624932
; Publication No. US20040096877A1
; GENERAL INFORMATION:
; APPLICANT: Taupier, Raymond
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Rastelli, Luca
; APPLICANT: Spaderna, Steven
; APPLICANT: Shimkets, Richard
; APPLICANT: Zerhusen, Bryan
; APPLICANT: Spytek, Kimberly ; APPLICANT: Shenoy, Suresh ; APPLICANT: Li, Li
; APPLICANT: Gusev, Vladimir
; APPLICANT: Grosse, William
; APPLICANT: Alsobrook, John
; APPLICANT: Lepley, Denise
; APPLICANT: Burgess, Catherine
; APPLICANT: Gerlach, Valerie
; APPLICANT: Ellerman, Karen
; APPLICANT: MacDougall, John
; APPLICANT: Stone, David
; APPLICANT: Smithson, Glennda
; TITLE OF INVENTION: Novel Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-074 US
  CURRENT APPLICATION NUMBER: US/10/624,932
;
  CURRENT FILING DATE: 2003-07-21
; PRIOR APPLICATION NUMBER: 09/918,779
; PRIOR FILING DATE: 2001-07-03
; PRIOR APPLICATION NUMBER: 60/221,409
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/222,840
   PRIOR FILING DATE: 2000-08-04
   PRIOR APPLICATION NUMBER: 60/223,752
   PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,762
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,770
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,769
```

```
PRIOR FILING DATE: 2000-08-08
  PRIOR APPLICATION NUMBER: 60/225,146
  PRIOR FILING DATE: 2000-08-14
  PRIOR APPLICATION NUMBER: 60/225,392
  PRIOR FILING DATE: 2000-08-15
  PRIOR APPLICATION NUMBER: 60/225,470
  PRIOR FILING DATE: 2000-08-15
  Remaining Prior Application data removed - See File Wrapper or PALM.
  NUMBER OF SEQ ID NOS: 61
  SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 2
   LENGTH: 898
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-624-932-2
 Query Match
                        100.0%; Score 290; DB 15; Length 898;
                        100.0%; Pred. No. 9.9e-24;
  Best Local Similarity
                             0; Mismatches
                                               0;
                                                               Gaps
                                                                        0;
 Matches 50; Conservative
                                                   Indels
                                                             0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
Db
RESULT 7
US-09-970-944-15
; Sequence 15, Application US/09970944
; Publication No. US20030204052A1
; GENERAL INFORMATION:
; APPLICANT: Herrman, John L
 APPLICANT: Rastelli, Luca
 APPLICANT: Shimkets, Richard A
  TITLE OF INVENTION: No. US20030204052Alel Proteins and Nucleic Acids Encoding
Same and
  TITLE OF INVENTION: Antibodies Directed Against these Proteins
  FILE REFERENCE: 21402-138
  CURRENT APPLICATION NUMBER: US/09/970,944
  CURRENT FILING DATE: 2002-05-02
  PRIOR APPLICATION NUMBER: 60/237,862
  PRIOR FILING DATE: 2000-10-04
  NUMBER OF SEQ ID NOS: 62
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Caenorhabditis elegans
US-09-970-944-15
                        85.9%; Score 249; DB 10; Length 931;
  Query Match
  Best Local Similarity 82.0%; Pred. No. 3.5e-19;
  Matches 41: Conservative
                               6; Mismatches
                                               3; Indels
                                                                        0;
                                                             0; Gaps
           1 STWTEWSVCSASCGRGWOKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qу
             264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
Db
```

```
RESULT 8
US-09-970-944-16
; Sequence 16, Application US/09970944
; Publication No. US20030204052A1
; GENERAL INFORMATION:
  APPLICANT: Herrman, John L
; APPLICANT: Rastelli, Luca
; APPLICANT: Shimkets, Richard A
  TITLE OF INVENTION: No. US20030204052Alel Proteins and Nucleic Acids Encoding
  TITLE OF INVENTION: Antibodies Directed Against these Proteins
  FILE REFERENCE: 21402-138
  CURRENT APPLICATION NUMBER: US/09/970,944
  CURRENT FILING DATE: 2002-05-02
  PRIOR APPLICATION NUMBER: 60/237,862
  PRIOR FILING DATE: 2000-10-04
  NUMBER OF SEO ID NOS: 62
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Caenorhabditis elegans
US-09-970-944-16
 Query Match
                         85.9%; Score 249; DB 10; Length 931;
 Best Local Similarity 82.0%; Pred. No. 3.5e-19;
 Matches 41; Conservative
                                6; Mismatches
                                                 3;
                                                    Indels
                                                               0; Gaps
                                                                           0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             Db
         264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 9
US-09-970-944-17
; Sequence 17, Application US/09970944
; Publication No. US20030204052A1
; GENERAL INFORMATION:
; APPLICANT: Herrman, John L
; APPLICANT: Rastelli, Luca
  APPLICANT: Shimkets, Richard A
  TITLE OF INVENTION: No. US20030204052Alel Proteins and Nucleic Acids Encoding
Same and
  TITLE OF INVENTION: Antibodies Directed Against these Proteins
  FILE REFERENCE: 21402-138
  CURRENT APPLICATION NUMBER: US/09/970,944
  CURRENT FILING DATE: 2002-05-02
  PRIOR APPLICATION NUMBER: 60/237,862
  PRIOR FILING DATE: 2000-10-04
  NUMBER OF SEQ ID NOS: 62
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Caenorhabditis elegans
US-09-970-944-17
```

```
85.9%; Score 249; DB 10; Length 931;
 Query Match
  Best Local Similarity 82.0%; Pred. No. 3.5e-19;
           41; Conservative
                                6; Mismatches
                                                 3; Indels
                                                               0; Gaps
                                                                           0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             Db
         264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 10
US-09-972-211-121
; Sequence 121, Application US/09972211
; Publication No. US20040048245A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A
 APPLICANT: Taupier Jr, Raymond J
  APPLICANT: Burgess, Catherine E
  APPLICANT: Zerhusen, Bryan D
  APPLICANT: Mezes, Peter S
  APPLICANT: Rastelli, Luca
;
 APPLICANT: Malyankar, Uriel M
  APPLICANT: Grosse, William M
; APPLICANT: Alsobrook II, John P
  APPLICANT: Lepley, Denise M
  APPLICANT: Spytek, Kimberly Ann
  APPLICANT: Li, Li
  APPLICANT: Edinger, Shlomit
;
  APPLICANT: Gerlach, Valerie
;
  APPLICANT: Ellerman, Karen
  APPLICANT: MacDougall, John R
  APPLICANT: Gunther, Erik
  APPLICANT: Millet, Isabelle
;
  APPLICANT: Stone, David J
  APPLICANT: Smithson, Glennda
APPLICANT: Szekeres Jr, Edward S
  TITLE OF INVENTION: No. US20040048245A1el Human Proteins, Polynucleotides
Encoding Them And
  TITLE OF INVENTION: Methods Of Using The Same
  FILE REFERENCE: 21402-141
  CURRENT APPLICATION NUMBER: US/09/972,211
  CURRENT FILING DATE: 2001-10-05
  PRIOR APPLICATION NUMBER: 60/238,325
  PRIOR FILING DATE: 2000-10-05
  PRIOR APPLICATION NUMBER: 60/238,323
  PRIOR FILING DATE: 2000-10-05
  PRIOR APPLICATION NUMBER: 60/238,400
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,397
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,401
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,379
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,402
  PRIOR FILING DATE: 2000-10-06
```

PRIOR APPLICATION NUMBER: 30/238,384

```
PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,373
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,372
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,383
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,382
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/275,892
  PRIOR FILING DATE: 2001-03-14
  PRIOR APPLICATION NUMBER: 60/296,860
  PRIOR FILING DATE: 2001-06-08
;
  NUMBER OF SEQ ID NOS: 198
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 121
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Mus musculus
US-09-972-211-121
                         85.9%; Score 249; DB 11;
                                                    Length 931;
  Query Match
  Best Local Similarity 82.0%; Pred. No. 3.5e-19;
                                6; Mismatches
                                                 3; Indels
                                                                  Gaps
 Matches
           41; Conservative
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 11
US-09-972-211-122
; Sequence 122, Application US/09972211
; Publication No. US20040048245A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A
  APPLICANT: Taupier Jr, Raymond J
  APPLICANT: Burgess, Catherine E
              Zerhusen, Bryan D
  APPLICANT:
  APPLICANT: Mezes, Peter S
  APPLICANT:
              Rastelli, Luca
              Malyankar, Uriel M
  APPLICANT:
;
              Grosse, William M
  APPLICANT:
;
  APPLICANT: Alsobrook II, John P
  APPLICANT: Lepley, Denise M
;
  APPLICANT:
              Spytek, Kimberly Ann
  APPLICANT: Li, Li
;
  APPLICANT: Edinger, Shlomit
              Gerlach, Valerie
  APPLICANT:
;
              Ellerman, Karen
  APPLICANT:
;
  APPLICANT: MacDougall, John R
              Gunther, Erik
  APPLICANT:
 APPLICANT:
              Millet, Isabelle
; APPLICANT:
              Stone, David J
              Smithson, Glennda
; APPLICANT:
; APPLICANT: Szekeres Jr, Edward S
```

```
TITLE OF INVENTION: No. US20040048245A1el Human Proteins, Polynucleotides
Encoding Them And
  TITLE OF INVENTION: Methods Of Using The Same
  FILE REFERENCE: 21402-141
  CURRENT APPLICATION NUMBER: US/09/972,211
  CURRENT FILING DATE: 2001-10-05
  PRIOR APPLICATION NUMBER: 60/238,325
  PRIOR FILING DATE: 2000-10-05
  PRIOR APPLICATION NUMBER: 60/238,323
  PRIOR FILING DATE: 2000-10-05
  PRIOR APPLICATION NUMBER: 60/238,400
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,397
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,401
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,379
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,402
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 30/238,384
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,373
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,372
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,383
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/238,382
;
  PRIOR FILING DATE: 2000-10-06
  PRIOR APPLICATION NUMBER: 60/275,892
  PRIOR FILING DATE: 2001-03-14
  PRIOR APPLICATION NUMBER: 60/296,860
  PRIOR FILING DATE: 2001-06-08
  NUMBER OF SEQ ID NOS: 198
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 122
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-972-211-122
 Query Match
                         85.9%;
                                 Score 249; DB 11; Length 931;
 Best Local Similarity 82.0%; Pred. No. 3.5e-19;
           41; Conservative
                                6; Mismatches
 Matches
                                                 3; Indels
                                                               0; Gaps
                                                                           0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
              264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 12
US-09-972-211-125
; Sequence 125, Application US/09972211
; Publication No. US20040048245A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A
```

```
APPLICANT: Taupier Jr, Raymond J
  APPLICANT: Burgess, Catherine E
  APPLICANT: Zerhusen, Bryan D
  APPLICANT: Mezes, Peter S
  APPLICANT: Rastelli, Luca
   APPLICANT: Malyankar, Uriel M
  APPLICANT: Grosse, William M
  APPLICANT: Alsobrook II, John P
  APPLICANT: Lepley, Denise M
  APPLICANT: Spytek, Kimberly Ann
  APPLICANT: Li, Li
  APPLICANT: Edinger, Shlomit
  APPLICANT: Gerlach, Valerie
  APPLICANT: Ellerman, Karen
  APPLICANT: MacDougall, John R
  APPLICANT: Gunther, Erik
  APPLICANT: Millet, Isabelle
  APPLICANT: Stone, David J
  APPLICANT: Smithson, Glennda
  APPLICANT: Szekeres Jr, Edward S
   TITLE OF INVENTION: No. US20040048245A1el Human Proteins, Polynucleotides
Encoding Them And
  TITLE OF INVENTION: Methods Of Using The Same
   FILE REFERENCE: 21402-141
   CURRENT APPLICATION NUMBER: US/09/972,211
   CURRENT FILING DATE: 2001-10-05
   PRIOR APPLICATION NUMBER: 60/238,325
   PRIOR FILING DATE: 2000-10-05
   PRIOR APPLICATION NUMBER: 60/238,323
   PRIOR FILING DATE: 2000-10-05
   PRIOR APPLICATION NUMBER: 60/238,400
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,397
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,401
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,379
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,402
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 30/238,384
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,373
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,372
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,383
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/238,382
   PRIOR FILING DATE: 2000-10-06
   PRIOR APPLICATION NUMBER: 60/275,892
   PRIOR FILING DATE: 2001-03-14
   PRIOR APPLICATION NUMBER: 60/296,860
   PRIOR FILING DATE: 2001-06-08
   NUMBER OF SEQ ID NOS: 198
   SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 125
```

```
LENGTH: 931
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-972-211-125
                         85.9%; Score 249; DB 11; Length 931;
  Query Match
  Best Local Similarity 82.0%; Pred. No. 3.5e-19;
           41; Conservative
                               6; Mismatches
                                                               0; Gaps
                                                                          0;
                                                 3; Indels
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
             Dh
         264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 13
US-10-087-684-35
; Sequence 35, Application US/10087684
; Publication No. US20040029116A1
; GENERAL INFORMATION:
  APPLICANT: Edinger, Shlomit R.
  APPLICANT: MacDougall, John R.
; APPLICANT: Millet, Isabelle
  APPLICANT: Ellerman, Karen
  APPLICANT: Stone, David J.
 APPLICANT: Grosse, William M.
 APPLICANT: Lepley, Denise M.
  APPLICANT: Rieger, Daniel K.
  APPLICANT: Burgess, Cathereine E.
; APPLICANT: Casman, Stacie, J.
; APPLICANT: Spytek, Kimberly A.
  APPLICANT: Boldog, Ferenc L.
  APPLICANT: Li, Li
  APPLICANT: Padigaru, Muralidhara
  APPLICANT: Mishra, Vishnu
  APPLICANT: Shenoy, Suresh G. APPLICANT: Rastelli, Luca
  APPLICANT: Tchernev, Velizar T.
  APPLICANT: Vernet, Corine A.M.
  APPLICANT: Zerhusen, Bryan D.
  APPLICANT: Malyankar, Uriel M.
  APPLICANT: Guo, Xiaojia
  APPLICANT: Miller, Charles E.
  APPLICANT: Gangolli, Esha A.
  TITLE OF INVENTION: PROTEINS AND NUCLEIC ACIDS ENCODING SAME
  FILE REFERENCE: 21402-214 CIP
  CURRENT APPLICATION NUMBER: US/10/087,684
  CURRENT FILING DATE: 2003-03-10
  PRIOR APPLICATION NUMBER: 60/253,834
  PRIOR FILING DATE: 2000-11-29
  PRIOR APPLICATION NUMBER: 60/250,926
  PRIOR FILING DATE: 2000-11-30
;
  PRIOR APPLICATION NUMBER: 60/264,180
  PRIOR FILING DATE: 2001-01-25
  PRIOR APPLICATION NUMBER: 60/274,194
 PRIOR FILING DATE: 2001-03-08
   PRIOR APPLICATION NUMBER: 60/313,656
   PRIOR FILING DATE: 2001-08-20
```

```
PRIOR APPLICATION NUMBER: 60/327,456
  PRIOR FILING DATE: 2001-10-05
  NUMBER OF SEQ ID NOS: 220
  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 35
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Mus musculus
US-10-087-684-35
 Query Match
                         85.9%; Score 249; DB 15; Length 931;
 Best Local Similarity 82.0%; Pred. No. 3.5e-19;
                               6; Mismatches
 Matches
           41; Conservative
                                                 3; Indels
                                                               0; Gaps
                                                                           0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             Db
         264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 14
US-10-087-684-36
; Sequence 36, Application US/10087684
; Publication No. US20040029116A1
; GENERAL INFORMATION:
 APPLICANT: Edinger, Shlomit R.
  APPLICANT: MacDougall, John R.
  APPLICANT: Millet, Isabelle
  APPLICANT:
              Ellerman, Karen
              Stone, David J.
  APPLICANT:
  APPLICANT: Grosse, William M.
              Lepley, Denise M.
  APPLICANT:
  APPLICANT:
              Rieger, Daniel K.
  APPLICANT:
              Burgess, Cathereine E.
              Casman, Stacie, J.
  APPLICANT:
              Spytek, Kimberly A.
  APPLICANT:
  APPLICANT:
              Boldog, Ferenc L.
  APPLICANT:
             Li, Li
  APPLICANT:
             Padigaru, Muralidhara
  APPLICANT:
              Mishra, Vishnu
  APPLICANT:
              Shenoy, Suresh G.
              Rastelli, Luca
  APPLICANT:
              Tchernev, Velizar T.
  APPLICANT:
              Vernet, Corine A.M.
  APPLICANT:
              Zerhusen, Bryan D.
  APPLICANT:
              Malyankar, Uriel M.
  APPLICANT:
 APPLICANT:
              Guo, Xiaojia
  APPLICANT: Miller, Charles E.
  APPLICANT: Gangolli, Esha A.
  TITLE OF INVENTION: PROTEINS AND NUCLEIC ACIDS ENCODING SAME
  FILE REFERENCE: 21402-214 CIP
  CURRENT APPLICATION NUMBER: US/10/087.684
  CURRENT FILING DATE: 2003-03-10
  PRIOR APPLICATION NUMBER: 60/253,834
  PRIOR FILING DATE: 2000-11-29
  PRIOR APPLICATION NUMBER: 60/250,926
  PRIOR FILING DATE: 2000-11-30
  PRIOR APPLICATION NUMBER: 60/264,180
```

```
PRIOR APPLICATION NUMBER: 60/274,194
  PRIOR FILING DATE: 2001-03-08
 PRIOR APPLICATION NUMBER: 60/313,656
 PRIOR FILING DATE: 2001-08-20
  PRIOR APPLICATION NUMBER: 60/327,456
  PRIOR FILING DATE: 2001-10-05
; NUMBER OF SEQ ID NOS: 220
  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 36
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-087-684-36
  Query Match
                        85.9%; Score 249; DB 15; Length 931;
  Best Local Similarity
                        82.0%; Pred. No. 3.5e-19;
                               6; Mismatches
                                                3; Indels
           41; Conservative
                                                                  Gaps
                                                                         0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 15
US-10-218-779-36
; Sequence 36, Application US/10218779
; Publication No. US20040029222A1
; GENERAL INFORMATION:
; APPLICANT: Edinger, Shlomit
 APPLICANT: MacDougall, John
; APPLICANT: Millet, Isabelle
 APPLICANT: Ellerman, Karen
 APPLICANT: Stone, David
  APPLICANT: Gerlach, Valerie
  APPLICANT: Grosse, William
;
 APPLICANT: Alsobrook II, John
;
 APPLICANT: Lepley, Denise
  APPLICANT: Rieger, Daniel
  APPLICANT: Burgess, Catherine
  APPLICANT: Casman, Stacie
;
  APPLICANT:
              Spytek, Kimberly
  APPLICANT:
              Boldog, Ferenc
  APPLICANT: Li, Li
;
  APPLICANT: Padigaru, Muralidhara
;
  APPLICANT: Mishra, Vishnu
  APPLICANT:
              Patturajan, Meera
  APPLICANT:
              Shenoy, Suresh
;
  APPLICANT:
              Rastelli, Luca
              Tchernev, Velizar
  APPLICANT:
;
  APPLICANT:
             Vernet, Corine
;
  APPLICANT:
             Zerhusen, Bryan
;
  APPLICANT:
             Malyankar, Uriel
 APPLICANT:
              Guo, Xiaojia
 APPLICANT:
              Miller, Charles
; APPLICANT:
              Gangolli, Esha
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
```

PRIOR FILING DATE: 2001-01-25

```
FILE REFERENCE: 21402-214
  CURRENT APPLICATION NUMBER: US/10/218,779
  CURRENT FILING DATE: 2002-08-14
  PRIOR APPLICATION NUMBER: 60/253,834
  PRIOR FILING DATE: 2000-11-29
  PRIOR APPLICATION NUMBER: 60/250,-926
  PRIOR FILING DATE: 2000-11-30
  PRIOR APPLICATION NUMBER: 60/264,180
  PRIOR FILING DATE: 2001-01-25
  PRIOR APPLICATION NUMBER: 60/313,656
 PRIOR FILING DATE: 2001-08-20
  PRIOR APPLICATION NUMBER: 60/327,456
  PRIOR FILING DATE: 2001-10-05
 NUMBER OF SEQ ID NOS: 216
 SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
   LENGTH: 931
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-218-779-36
                        85.9%; Score 249; DB 15; Length 931;
 Query Match
  Best Local Similarity 82.0%; Pred. No. 3.5e-19;
                                                             0; Gaps
 Matches 41; Conservative
                              6; Mismatches
                                               3; Indels
                                                                        0;
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qy
             264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
```

Search completed: March 1, 2005, 09:51:30 Job time: 9.62324 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2005, 08:41:47; Search time 9.14662 Seconds

(without alignments)

2799.282 Million cell updates/sec

Title: US-10-624-932-2 COPY 246 295

Perfect score: 290

Sequence: 1 STWTEWSVCSASCGRGWQKR.....NGGAFCEGQNVQKTACATLC 50

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_03:*

1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

D==1+		8				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	290	100.0	 898	 1	UN5A MOUSE	Q8k1s4 mus musculu
2	290	100.0	898	1	UN5A RAT	008721 rattus norv
3	249	85.9	931	1	UN5C CHICK	Q7t2z5 gallus gall
4	249	85.9	931	1	UN5C HUMAN	095185 homo sapien
5	249	85.9	931	1	UN5C MOUSE	008747 mus musculu
6	244	84.1	931	1	UN5C RAT	Q761x5 rattus norv
7	239	82.4	945	1	UN5B HUMAN	Q8izj1 homo sapien
8	239	82.4	953	1	UN5D HUMAN	Q6uxz4 homo sapien
9	238	82.1	945	1	UN5B MOUSE	Q8kls3 mus musculu
10	238	82.1	945	1	UN5B RAT	008722 rattus norv
11	238	82.1	956	1	UN5D MOUSE	Q8k1s2 mus musculu
12	219	75.5	943	1	UN5B XENLA	Q8jgt4 xenopus lae
1.3	148	51.0	335	2	Q8BVQ2	Q8bvq2 m mus muscu
14	148	51.0	844	2	Q8BXU8	Q8bxu8 m mus muscu
15	148	51.0	1074	1	SM5A_HUMAN	Q13591 homo sapien

16	148	51.0	1077	1	SM5A MOUSE	Q62217 mus musculu
17	147	50.7	1092	2	Q6UY12	Q6uy12 homo sapien
18	147	50.7	1093	1	SM5B HUMAN	Q9p283 homo sapien
19	147	50.7	1151	2	Q6DD89	Q6dd89 homo sapien
20	144	49.7	1388	2	Q7QKD0	Q7qkd0 anopheles g
21	143	49.3	478	2	Q8BVE5	Q8bve5 m mus muscu
22	143	49.3	632	2	Q6ZPQ8	Q6zpq8 mus musculu
23	143	49.3	1088	2	Q6PCK8	Q6pck8 xenopus lae
24	143	49.3	1093	1	SM5B MOUSE	Q60519 mus musculu
25	143	49.3	1122	2	Q7TT33	Q7tt33 mus musculu
26	143	49.3	1244	2	Q69YJ3	Q69yj3 homo sapien
27	143	49.3	2673	2	Q96sc3	Q96sc3 homo sapien
28	143	49.3	5636	2	Q96RW7	Q96rw7 homo sapien
29	139	47.9	1224	1	AT16 HUMAN	Q8te57 homo sapien
30	138.5	47.8	4998	2	Q8CG65	Q8cg65 mus musculu
31	137	47.2	584	1	CO8A HUMAN	P07357 homo sapien
32	136	46.9	769	2	Q8MRL5	Q8mrl5 drosophila
33	136	46.9	839	2	Q7YS95	Q7ys95 bos taurus
34	136	46.9	1059	2	Q9W493	Q9w493 drosophila
35	136	46.9	1081	2	Q9U631	Q9u631 drosophila
36	136	46.9	1091	2	Q7YU6 7	Q7yu67 drosophila
37	136	46.9	1093	2	Q9VTT0	Q9vtt0 drosophila
38	135.5	46.7	5141	2	Q700K0	Q700k0 rattus norv
39	132.5	45.7	1072	1	UNC5_DROME	Q95tu8 drosophila
40	132	45.5	833	2	Q8K3 8 4	Q8k384 mus musculu
41	132	45.5	837	1	ATS4_HUMAN	075173 homo sapien
42	132	45.5	837	2	Q6UWA8	Q6uwa8 homo sapien
43	132	45.5	845	2	Q8BNJ2	Q8bnj2 mus musculu
44	132	45.5	893	2	Q6A017	Q6a017 mus musculu
45	131	45.2	900	2	Q8K206	Q8k206 mus musculu

ALIGNMENTS

```
RESULT 1
UN5A MOUSE
ID
     UN5A MOUSE
                    STANDARD;
                                   PRT;
                                           898 AA.
AC
     Q8K1S4; Q6PEF7; Q80T71;
DT
     25-OCT-2004 (Rel. 45, Created)
DT
     25-OCT-2004 (Rel. 45, Last sequence update)
     25-OCT-2004 (Rel. 45, Last annotation update)
DT
     Netrin receptor UNC5A precursor (Unc-5 homolog A) (Unc-5 homolog 1).
DE
GN
    Name=Unc5a; Synonyms=Kiaa1976, Unc5h1;
OS
    Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
    NCBI_TaxID=10090;
OX
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1), AND TISSUE SPECIFICITY.
    MEDLINE=22239710; PubMed=12351186; DOI=10.1016/S0925-4773(02)00248-4;
RX
RA
     Engelkamp D.;
RT
     "Cloning of three mouse unc-5 genes and their expression patterns at
RT
    mid-gestation.";
RL.
    Mech. Dev. 118:191-197(2002).
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
```

```
RC
     TISSUE=Brain;
RX
    MEDLINE=22579291; PubMed=12693553;
RA
     Okazaki N., Kikuno R., Ohara R., Inamoto S., Aizawa H., Yuasa S.,
RA
     Nakajima D., Nagase T., Ohara O., Koga H.;
     "Prediction of the coding sequences of mouse homologues of KIAA gene:
RT
RT
     II. The complete nucleotide sequences of 400 mouse KIAA-homologous
RT
     cDNAs identified by screening of terminal sequences of cDNA clones
     randomly sampled from size-fractionated libraries.";
RT
RL
     DNA Res. 10:35-48(2003).
RN
     [3]
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
     STRAIN=C57BL/6; TISSUE=Brain;
RX
     MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. It also acts as a dependence receptor required for
CC
         apoptosis induction when not associated with netrin ligand (By
CC
         similarity).
CC
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC. Interacts
         with MAGED1. Interacts with PRKCABP, possibly mediating some
CC
CC
         interaction with PKC (By similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein. The interaction
CC
         with PRKCABP regulates its surface expression and leads to its
         removal from surface of neurons and growth cones (By similarity).
CC
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=3;
CC
CC
           IsoId=Q8K1S4-1; Sequence=Displayed;
CC
         Name=2;
CC
           IsoId=Q8K1S4-2; Sequence=VSP 011697;
CC
           Note=No experimental confirmation available;
CC
CC
           IsoId=Q8K1S4-3; Sequence=VSP 011696;
CC
           Note=No experimental confirmation available;
CC
     -!- TISSUE SPECIFICITY: Restricted to central nervous system.
```

```
CC
    -!- DOMAIN: The ZU5 domain mediates the interaction with MAGED1, which
CC
        participates in the induction of apoptosis (By similarity).
CC
    -!- PTM: Phosphorylated by PKC in vitro. Phosphorylated on cytoplasmic
CC
        tyrosine residues (By similarity).
CC
    -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
        cleavage does not take place when the receptor is associated with
CC
CC
        netrin ligand. Its cleavage by caspases is required to induce
CC
        apoptosis (By similarity).
CC
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
    ______
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
DR
    EMBL; AJ487852; CAD32250.1; -.
DR
    EMBL; AK122575; BAC65857.1; ALT INIT.
DR
    EMBL; BC058084; AAH58084.1; -.
DR
    HSSP; P07996; 1LSL.
DR
    MGD; MGI:894682; Unc5a.
    InterPro; IPR000488; Death.
DR
    InterPro; IPR011029; DEATH like.
DR
DR
    InterPro; IPR003599; Ig.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
DR
    Pfam; PF00047; ig; 1.
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
DR
DR
    PRINTS; PR01705; TSP1REPEAT.
DR
    SMART; SM00005; DEATH; 1.
DR
    SMART; SM00409; IG; 1.
    SMART; SM00209; TSP1; 2.
DR
    SMART; SM00218; ZU5; 1.
DR
DR
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
    PROSITE; PS50835; IG LIKE; 1.
    PROSITE; PS50092; TSP1; 2.
DR
KW
    Alternative splicing; Apoptosis; Developmental protein;
KW
    Immunoglobulin domain; Phosphorylation; Receptor; Repeat; Signal;
KW
    Transmembrane.
FT
    SIGNAL
                 1
                       25
                                Potential.
                26
FT
    CHAIN
                      898
                                Netrin receptor UNC5A.
                26
FT
    DOMAIN
                      361
                               Extracellular (Potential).
FT
    TRANSMEM
               362
                      382
                               Potential.
FT
    DOMAIN
               3.8.3
                      898
                               Cytoplasmic (Potential).
FT
    DOMAIN
                44
                      141
                                Iq-like.
FT
    DOMAIN
                155
                      234
                                Ig-like C2-type.
```

```
FT
     DOMAIN
                 242
                        296
                                  TSP type-1 1.
FΤ
                 298
                        350
                                  TSP type-1 2.
     DOMAIN
                 495
\mathbf{FT}
                        598
     DOMAIN
                                  ZU5.
                 817
                        897
FT
     DOMAIN
                                  Death.
    SITE
                 396
FT
                        397
                                  Cleavage (by caspase-3) (By similarity).
FT
     SITE
                 661
                        679
                                  Interaction with DCC (By similarity).
FT
     DISULFID
                 65
                        124
                                  By similarity.
FT
     DISULFID
                 170
                        221
                                  By similarity.
FT
     CARBOHYD
                 107
                        107
                                  N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                 218
                        218
                                  N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                 343
                        343
                                  N-linked (GlcNAc. . .) (Potential).
FT
    VARSPLIC
                        790
                                  Missing (in isoform 3).
                 1
FT
                                  /FTId=VSP 011696.
FT
    VARSPLIC
                241
                        296
                                  Missing (in isoform 2).
FT
                                  /FTId=VSP 011697.
FT
    CONFLICT
                217
                       217
                                  A \rightarrow P \text{ (in Ref. 3)}.
SQ
     SEQUENCE
               898 AA; 98856 MW; 59F04BA2E196C1DB CRC64;
  Query Match
                          100.0%; Score 290; DB 1; Length 898;
  Best Local Similarity
                         100.0%; Pred. No. 8.2e-26;
 Matches
           50; Conservative
                                0; Mismatches
                                                   0; Indels
                                                                 0;
                                                                     Gaps
                                                                             0;
Qу
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
         246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
RESULT 2
UN5A RAT
    UN5A RAT
                   STANDARD;
ID
                                   PRT;
                                          898 AA.
AC
    008721;
DT
     25-OCT-2004 (Rel. 45, Created)
    25-OCT-2004 (Rel. 45, Last sequence update)
DT
DT
    25-OCT-2004 (Rel. 45, Last annotation update)
    Netrin receptor UNC5A precursor (Unc-5 homolog A) (Unc-5 homolog 1).
GN
    Name=Unc5a; Synonyms=Unc5h1;
OS
    Rattus norvegicus (Rat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
    NCBI TaxID=10116;
RN
    [1]
RP
    SEQUENCE FROM N.A., FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP
    SPECIFICITY.
    TISSUE=Ventral spinal cord;
RC
RX
    MEDLINE=97271897; PubMed=9126742;
    Leonardo E.D., Hinck L., Masu M., Keino-Masu K., Ackerman S.L.,
RA
RA
    Tessier-Lavigne M.;
RT
    "Vertebrate homologues of C. elegans UNC-5 are candidate netrin
RT
    receptors.";
RL
    Nature 386:833-838(1997).
RN
    FUNCTION, AND INTERACTION WITH DCC.
RP
RX
    PubMed=10399920;
RA
    Hong K., Hinck L., Nishiyama M., Poo M.-M., Tessier-Lavigne M.,
RA
    Stein E.;
    "A ligand-gated association between cytoplasmic domains of UNC5 and
RT
    DCC family receptors converts netrin-induced growth cone attraction to
RT
```

```
RT
     repulsion.";
RL
     Cell 97:927-941(1999).
RN
RP
     TISSUE SPECIFICITY.
     PubMed=11472849;
RX
RA
     Barrett C., Guthrie S.;
     "Expression patterns of the netrin receptor UNC5H1 among developing
RT
RT
     motor neurons in the embryonic rat hindbrain.";
RL
     Mech. Dev. 106:163-166(2001).
RN
     [4]
RP
     FUNCTION.
RX
     PubMed=11387206; DOI=10.1093/emboj/20.11.2715;
RA
     Llambi F., Causeret F., Bloch-Gallego E., Mehlen P.;
RT
     "Netrin-1 acts as a survival factor via its receptors UNC5H and DCC.";
RL
     EMBO J. 20:2715-2722(2001).
RN
     [5]
RP
     FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAGED1.
RX
     PubMed=12598531; DOI=10.1074/jbc.M300415200;
     Williams M.E., Strickland P., Watanabe K., Hinck L.;
RA
     "UNC5H1 induces apoptosis via its juxtamembrane region through an
RT
RT
     interaction with NRAGE.";
RL
     J. Biol. Chem. 278:17483-17490(2003).
RN
     INTERACTION WITH PRKCABP, PHOSPHORYLATION, AND MUTAGENESIS OF
RP
RP
     896-ALA--CYS-898.
     PubMed=14672991; DOI=23/36/11279;
RX
RA
     Williams M.E., Wu S.C.-Y., McKenna W.L., Hinck L.;
     "Surface expression of the netrin receptor UNC5H1 is regulated through
RT
     a protein kinase C-interacting protein/protein kinase-dependent
RT
    mechanism.";
RL
     J. Neurosci. 23:11279-11288(2003).
CC
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. It also acts as a dependence receptor required for
CC
         apoptosis induction when not associated with netrin ligand.
CC
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC. Interacts
CC
         with MAGED1. Interacts with PRKCABP, possibly mediating some
CC
         interaction with PKC.
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein. The interaction
CC
         with PRKCABP regulates its surface expression and leads to its
CC
         removal from surface of neurons and growth cones.
CC
     -!- TISSUE SPECIFICITY: Mainly expressed in regions of differentiating
CC
         neurons. Expressed at early stages of neural tube development in
CC
         the ventral spinal cord. In developing hindbrain, it colocalizes
CC
         with a number of cranial motor neuron subpopulations from
CC
         embryonic E11 to E14, while DCC is expressed by motor neurons at
CC
         E12. Also expressed in non-neural structures, such as the basal
CC
         plane of the hindbrain and midbrain, in the developing
CC
         hypothalamus, thalamus and in the pallidium.
CC
     -!- DOMAIN: The ZU5 domain mediates the interaction with MAGED1, which
CC
         participates in the induction of apoptosis.
CC
     -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
         similarity). Phosphorylated by PKC in vitro.
CC
     -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
```

cleavage does not take place when the receptor is associated with

CC

```
CC
        netrin ligand. Its cleavage by caspases is required to induce
CC
        apoptosis.
   .-!- SIMILARITY: Belongs to the UNC-5 family.
    -!- SIMILARITY: Contains 1 death domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
DR
    EMBL; U87305; AAB57678.1; -.
    HSSP; P07996; 1LSL.
DR
    RGD; 621755; Unc5h1.
    InterPro; IPR000488; Death.
DR
    InterPro; IPR011029; DEATH like.
DR
    InterPro; IPR003599; Ig.
DR
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
DR
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
    Pfam; PF00047; ig; 1.
DR
    Pfam; PF00090; TSP 1; 2.
DR
DR
    Pfam; PF00791; ZU5; 1.
DR
    PRINTS; PR01705; TSP1REPEAT.
DR
    SMART; SM00005; DEATH; 1.
DR
    SMART; SM00409; IG; 1.
    SMART; SM00209; TSP1; 2.
DR
DR
    SMART; SM00218; ZU5; 1.
DR
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
    PROSITE; PS50835; IG LIKE; 1.
DR
    PROSITE; PS50092; TSP1; 2.
DR
KW
    Apoptosis; Developmental protein; Immunoglobulin domain;
KW
    Phosphorylation; Receptor; Repeat; Signal; Transmembrane.
FT
    SIGNAL
                 1
                       25
                                Potential.
                26
FT
    CHAIN
                       898
                                Netrin receptor UNC5A.
FT
    DOMAIN
                26
                       361
                                Extracellular (Potential).
FT
    TRANSMEM
                362
                      382
                                Potential.
FΤ
                383
                      898
                                Cytoplasmic (Potential).
    DOMAIN
FΤ
    DOMAIN
                44
                      141
                                Ig-like.
FT
                155
                      238
    DOMAIN
                                Ig-like C2-type.
FT
    DOMAIN
                242
                      296
                                TSP type-1 1.
FT
    DOMAIN
                298
                      350
                                TSP type-1 2.
                      598
FT
    DOMAIN
               495
                                ZU5.
FT
               817
                      897
    DOMAIN
FT
    SITE
               396
                      397
                                Cleavage (by caspase-3) (By similarity).
                661
FT
    SITE
                      679
                                Interaction with DCC (By similarity).
FT
    DISULFID
                65
                      124
                                By similarity.
FT
    DISULFID
                170
                       221
                                By similarity.
                                N-linked (GlcNAc. . .) (Potential).
FT
    CARBOHYD
                107
                      107
```

```
218
                                N-linked (GlcNAc. . .) (Potential).
FT
    CARBOHYD
    CARBOHYD
                      218
                                N-linked (GlcNAc. . .) (Potential).
FT
                343
                      343
FT
               896
                      898
                                Missing: Abolishes interaction with
                                PRKCABP.
FT
SO
    SEQUENCE 898 AA; 98840 MW; 7A3CBCB9E7ACA135 CRC64;
 Query Match
                        100.0%; Score 290; DB 1; Length 898;
 Best Local Similarity 100.0%; Pred. No. 8.2e-26;
           50; Conservative
                            0; Mismatches
                                                             0; Gaps
                                                                         0;
                                                0; Indels
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
             246 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 295
Db
RESULT 3
UN5C CHICK
    UN5C CHICK
                  STANDARD;
                               PRT; 931 AA.
    O7T2Z5;
AC
DT
    25-OCT-2004 (Rel. 45, Created)
    25-OCT-2004 (Rel. 45, Last sequence update)
    25-OCT-2004 (Rel. 45, Last annotation update)
DT
    Netrin receptor UNC5C precursor (Unc-5 homolog C) (Unc-5 homolog 3)
DE
    (cUNC-5H3).
GN
    Name=UNC5C;
OS
    Gallus gallus (Chicken).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
    Gallus.
OX
    NCBI TaxID=9031;
RN
    [1]
RP
    SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RX
    PubMed=12799087;
RA
    Guan W., Condic M.L.;
    "Characterization of Netrin-1, Neogenin and cUNC-5H3 expression during
RT
    chick dorsal root ganglia development.";
RT
    Gene Expr. Patterns 3:369-373(2003).
RL
    -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
CC
        axon repulsion of neuronal growth cones in the developing nervous
CC
        system upon ligand binding (By similarity).
    -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
CC
    -!- TISSUE SPECIFICITY: Restricted to proprioceptive neurons.
    -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
CC
        similarity).
CC
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
    ______
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
    the European Bioinformatics Institute. There are no restrictions on its
CC
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
```

```
CC
    or send an email to license@isb-sib.ch).
CC
     ______
DR
    EMBL; AY187310; AA067275.1; -.
    InterPro; IPR000488; Death.
DR
    InterPro; IPR007110; Ig-like.
DR
DR
    InterPro; IPR003598; Ig c2.
DR
    InterPro; IPR000884; TSP1.
    InterPro; IPR000906; ZU5.
DR
DR
    Pfam; PF00531; Death; 1.
DR
    Pfam; PF00047; ig; 1.
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
DR
    SMART; SM00005; DEATH; 1.
DR
    SMART; SM00408; IGc2; 1.
    SMART; SM00209; TSP1; 2.
DR
    SMART; SM00218; ZU5; 1.
DR
DR
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
    PROSITE; PS50835; IG LIKE; 1.
DR
    PROSITE; PS50092; TSP1; 2.
    Developmental protein; Immunoglobulin domain; Phosphorylation;
KW
KW
    Receptor; Repeat; Signal; Transmembrane.
FT
    SIGNAL
                 1
                       39
                                Potential.
FT
                 40
                       931
    CHAIN
                                Netrin receptor UNC5C.
FT
    DOMAIN
                 40
                       380
                                Extracellular (Potential).
FT
    TRANSMEM
                381
                       401
                                Potential.
FT
                402
                       931
                                Cytoplasmic (Potential).
    DOMAIN
FT
    DOMAIN
                 62
                       159
                                Iq-like.
                       256
                                Ig-like C2-type.
FT
    DOMAIN
                161
                260
                       314
                                TSP type-1 1.
FT
    DOMAIN
                                TSP type-1 2.
FT
    DOMAIN
                316
                       368
FT
    DOMAIN
                528
                       631
                                ZU5.
                850
FT
    DOMAIN
                       929
                                Death.
FT
                83
                      142
                                By similarity.
    DISULFID
FT
                188
    DISULFID
                       239
                                By similarity.
                                N-linked (GlcNAc. . .) (Potential).
FT
                236
                      236
    CARBOHYD
FT
                361
                                N-linked (GlcNAc. . .) (Potential).
    CARBOHYD
                       361
               931 AA; 102906 MW; 1E23A0D84F2E2C62 CRC64;
SQ
    SEQUENCE
                         85.9%; Score 249; DB 1; Length 931;
  Query Match
  Best Local Similarity 82.0%; Pred. No. 6.1e-21;
  Matches
           41; Conservative
                               5; Mismatches
                                                     Indels
                                                                  Gaps
                                                                          0;
Qу
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
             264 STWTEWSACNSRCGRGFQKRTRTCTNPAPLNGGAFCEGQNVQKIACTTLC 313
Db
RESULT 4
UN5C HUMAN
    UN5C HUMAN
                   STANDARD;
                                 PRT;
                                        931 AA.
    095185; Q8IUTO;
AC
DT
    25-OCT-2004 (Rel. 45, Created)
    25-OCT-2004 (Rel. 45, Last sequence update)
DT
DT
    25-OCT-2004 (Rel. 45, Last annotation update)
DE
    Netrin receptor UNC5C precursor (Unc-5 homolog C) (Unc-5 homolog 3).
GN
    Name=UNC5C; Synonyms=UNC5H3;
OS
    Homo sapiens (Human).
```

```
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
     NCBI TaxID=9606;
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1), AND TISSUE SPECIFICITY.
RC
     TISSUE=Brain;
RX
     MEDLINE=99000841; PubMed=9782087; DOI=10.1006/geno.1998.5425;
RA
     Ackerman S.L., Knowles B.B.;
     "Cloning and mapping of the UNC5C gene to human chromosome 4q21-q23.";
RT
RL
     Genomics 52:205-208(1998).
RN
     [2]
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
     TISSUE=Lung;
RX
     MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
RP
     DOWN-REGULATION IN CANCER.
     PubMed=12655055; DOI=10.1073/pnas.0738063100;
RX
     Thiebault K., Mazelin L., Pays L., Llambi F., Joly M.-O.,
RA
RA
     Scoazec J.-Y., Saurin J.-C., Romeo G., Mehlen P.;
     "The netrin-1 receptors UNC5H are putative tumor suppressors
RT
RT
     controlling cell death commitment.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 100:4173-4178(2003).
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. Also involved in corticospinal tract axon guidances
CC
         independently of DCC. It also acts as a dependence receptor
CC
         required for apoptosis induction when not associated with netrin
CC
         ligand (By similarity).
CC
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC (By
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=2;
CC
CC
           IsoId=095185-1; Sequence=Displayed;
```

```
CC
        Name=2;
          IsoId=095185-2; Sequence=VSP 011700, VSP 011701;
CC
CC
    -!- TISSUE SPECIFICITY: Mainly expressed in brain. Also expressed in
CC
        kidney. Not expressed in developing or adult lung.
CC
    -!- PTM: Phosphorylated on different cytoplasmic tyrosine residues.
CC
        Phosphorylation of Tyr-568 leads to an interaction with PTPN11
CC
        phosphatase, suggesting that its activity is regulated by
CC
        phosphorylation/dephosphorylation. Tyrosine phosphorylation is
CC
        netrin-dependent (By similarity).
CC
    -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
        cleavage does not take place when the receptor is associated with
CC
        netrin ligand. Its cleavage by caspases is required to induce
CC
        apoptosis (By similarity).
CC
    -!- MISCELLANEOUS: Down-regulated in multiple cancers including
CC
        colorectal, breast, ovary, uterus, stomach, lung, or kidney
CC
        cancers.
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
CC
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
    _____
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
    EMBL; AF055634; AAC67491.1; -.
DR
DR
    EMBL; BC041156; AAH41156.1; -.
DR
    HSSP; P07996; 1LSL.
DR
    Genew; HGNC:12569; UNC5C.
DR
    MIM; 603610; -.
    GO; GO:0005042; F:netrin receptor activity; TAS.
DR
    GO; GO:0007411; P:axon quidance; TAS.
DR
    GO; GO:0007420; P:brain development; TAS.
DR
DR
    InterPro; IPR000488; Death.
DR
    InterPro; IPR011029; DEATH like.
    InterPro; IPR007110; Iq-like.
DR
DR
    InterPro; IPR003598; Iq c2.
DR
    InterPro; IPR000884; TSP1.
    InterPro; IPR008085; TSP 1.
DR
DR
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
DR
    Pfam; PF00047; ig; 1.
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
    PRINTS; PR01705; TSP1REPEAT.
DR
    SMART; SM00005; DEATH; 1.
DR
DR
    SMART; SM00408; IGc2; 1.
DR
    SMART; SM00209; TSP1; 2.
DR
    SMART; SM00218; ZU5; 1.
DR
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
    PROSITE; PS50835; IG LIKE; 1.
```

```
PROSITE; PS50092; TSP1; 2.
DR
     Alternative splicing; Apoptosis; Developmental protein;
KW
     Immunoglobulin domain; Phosphorylation; Polymorphism; Receptor;
KW
     Repeat; Signal; Transmembrane.
KW
FT
     SIGNAL
                   1
                          40
                                   Potential.
FT
     CHAIN
                  41
                         931
                                   Netrin receptor UNC5C.
FT
     DOMAIN
                  41
                         380
                                   Extracellular (Potential).
                 381
FT
     TRANSMEM
                         401
                                   Potential.
FT
     DOMAIN
                 402
                         931
                                   Cytoplasmic (Potential).
FT
     DOMAIN
                  62
                        159
                                   Ig-like.
FT
     DOMAIN
                 161
                        256
                                   Ig-like C2-type.
                 260
                        314
FT
     DOMAIN
                                   TSP type-1 1.
FT
     DOMAIN
                 316
                        368
                                   TSP type-1 2.
FT
                 528
                        631
                                   ZU5.
     DOMAIN
FT
     DOMAIN
                 850
                        929
                                   Death.
                                   Cleavage (by caspase-3) (By similarity).
FT
     SITE
                 415
                        416
FT
     SITE
                 694
                        712
                                   Interaction with DCC (By similarity).
FT
                  83
     DISULFID
                        142
                                   By similarity.
\mathbf{FT}
     DISULFID
                 188
                        239
                                   By similarity.
\mathbf{FT}
     MOD RES
                 568
                        568
                                   Phosphotyrosine (By similarity).
\mathbf{FT}
     CARBOHYD
                 236
                        236
                                   N-linked (GlcNAc. . .) (Potential).
FT
                                   N-linked (GlcNAc. . .) (Potential).
     CARBOHYD
                 361
                        361
FT
     VARSPLIC
                 370
                        370
                                   T -> SFIYPISTEQRTQNEYGFSS (in isoform 2).
FT
                                   /FTId=VSP 011700.
FT
     VARSPLIC
                 579
                        931
                                  Missing (in isoform 2).
FT
                                   /FTId=VSP 011701.
FT
     VARIANT
                  37
                         37
                                   G -> V (in dbSNP:2306715).
FT
                                   /FTId=VAR 019731.
     VARIANT
FT
                 721
                        721
                                   T -> M (in dbSNP:2289043).
FT
                                   /FTId=VAR 019732.
FT
     CONFLICT
                 219
                        219
                                   T \rightarrow I (in Ref. 1).
FT
     CONFLICT
                 489
                        489
                                   S \rightarrow T \text{ (in Ref. 1).}
SQ
     SEQUENCE
                931 AA; 103101 MW; EFD71122C98DABB8 CRC64;
  Query Match
                          85.9%; Score 249; DB 1; Length 931;
  Best Local Similarity
                          82.0%; Pred. No. 6.1e-21;
  Matches
            41; Conservative
                                  6; Mismatches
                                                    3;
                                                       Indels
                                                                       Gaps
                                                                               0;
Qy
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGONVQKTACATLC 50
              Db
          264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 5
UN5C MOUSE
     UN5C MOUSE
                    STANDARD;
                                    PRT;
                                           931 AA.
AC
     008747; Q8CD16;
     25-OCT-2004 (Rel. 45, Created)
DT
DT
     25-OCT-2004 (Rel. 45, Last sequence update)
DT
     25-OCT-2004 (Rel. 45, Last annotation update)
     Netrin receptor UNC5C precursor (Unc-5 homolog C) (Unc-5 homolog 3)
DE
DE
     (Rostral cerebellar malformation protein).
GN
     Name=Unc5c; Synonyms=Rcm, Unc5h3;
os
     Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
     NCBI TaxID=10090;
```

```
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1), FUNCTION, DISEASE, AND TISSUE
RP
     SPECIFICITY.
RC
     STRAIN=C57B6/SJL;
RX
     MEDLINE=97271898; PubMed=9126743;
RA
     Ackerman S.L., Kozak L.P., Przyborski S.A., Rund L.A., Boyer B.B.,
RA
     Knowles B.B.;
RT
     "The mouse rostral cerebellar malformation gene encodes an UNC-5-like
RT
     protein.";
RL
     Nature 386:838-842(1997).
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
     STRAIN=C57BL/6J; TISSUE=Testis;
RX
     MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
     Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA
     Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA
     Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA
     Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA
RA
     Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA
     Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
     Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA
     Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA
     Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA
RA
     Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
     Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA
RA
     Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA
     Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA
     Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA
     Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA
     Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA
     Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
     Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA
RA
     Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA
     Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA
     Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA
     Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA
     Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kaqawa I.,
RA
     Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA
     Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA
     Birney E., Hayashizaki Y.;
RT
     "Analysis of the mouse transcriptome based on functional annotation of
RT
     60,770 full-length cDNAs.";
RL
     Nature 420:563-573(2002).
RN
RP
     FUNCTION, AND TISSUE SPECIFICITY.
RX
     PubMed=9389662;
     Przyborski S.A., Knowles B.B., Ackerman S.L.;
RA
RT
     "Embryonic phenotype of Unc5h3 mutant mice suggests chemorepulsion
RT
     during the formation of the rostral cerebellar boundary.";
RL
     Development 125:41-50(1998).
RN
     [4]
RΡ
     INTERACTION WITH DCC.
RX
     PubMed=10399920;
RA
     Hong K., Hinck L., Nishiyama M., Poo M.-M., Tessier-Lavigne M.,
     Stein E.;
RA
RT
     "A ligand-gated association between cytoplasmic domains of UNC5 and
     DCC family receptors converts netrin-induced growth cone attraction to
RT
```

```
RT
     repulsion.";
RL . Cell 97:927-941(1999).
RN
RP
     PHOSPHORYLATION SITE TYR-568, AND MUTAGENESIS OF TYR-568.
RX
     PubMed=11533026; DOI=10.1074/jbc.M103872200;
     Tong J., Killeen M., Steven R., Binns K.L., Culotti J., Pawson T.;
RT
     "Netrin stimulates tyrosine phosphorylation of the UNC-5 family of
RT
     netrin receptors and induces Shp2 binding to the RCM cytodomain.";
RL
     J. Biol. Chem. 276:40917-40925(2001).
RN
     [6]
RP
     FUNCTION.
RX
     PubMed=12451134; DOI=22/23/10346;
     Finger J.H., Bronson R.T., Harris B., Johnson K., Przyborski S.A.,
RA
RA
    Ackerman S.L.;
RT
     "The netrin 1 receptors Unc5h3 and Dcc are necessary at multiple
RT
     choice points for the guidance of corticospinal tract axons.";
RL
     J. Neurosci. 22:10346-10356(2002).
CC
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. Also involved in corticospinal tract axon guidances
CC
         independently of DCC. It also acts as a dependence receptor
CC
         required for apoptosis induction when not associated with netrin
CC
         ligand.
CC
    -!- SUBUNIT: Interacts with the cytoplasmic part of DCC.
CC
    -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=2;
CC
         Name=1;
           IsoId=008747-1; Sequence=Displayed;
CC
CC
         Name=2;
CC
           IsoId=008747-2; Sequence=VSP 011702;
CC
    -!- TISSUE SPECIFICITY: Mainly expressed in regions of differentiating
CC
         neurons. Highly expressed in brain and lung. Weakly expressed in
CC
         testis, ovary, spleen, thymus and bladder. Expressed at very low
CC
         level in kidney, intestine and salivary gland.
CC
    -!- PTM: Phosphorylated on different cytoplasmic tyrosine residues.
CC
         Phosphorylation of Tyr-568 leads to an interaction with PTPN11
CC
         phosphatase, suggesting that its activity is regulated by
CC
         phosphorylation/dephosphorylation. Tyrosine phosphorylation is
CC
         netrin-dependent.
CC
    -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
         cleavage does not take place when the receptor is associated with
CC
         netrin ligand. Its cleavage by caspases is required to induce
CC
         apoptosis (By similarity).
CC
    -!- DISEASE: Defects in Unc5c are the cause of rostral cerebellar
CC
         malformation (Rcm). Rcm is characterized by cerebellar and
CC
         midbrain defects, apparently as a result of abnormal neuronal
CC
        migration.
CC
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
```

```
This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
DR
    EMBL; U72634; AAB54103.1; -.
DR
    EMBL; AK031655; BAC27495.1; -.
DR
    HSSP; P07996; 1LSL.
DR
    MGD; MGI:1095412; Unc5c.
DR
    GO; GO:0005886; C:plasma membrane; IC.
    GO; GO:0005042; F:netrin receptor activity; IDA.
DR
    GO; GO:0005515; F:protein binding; IDA.
DR
    GO; GO:0007420; P:brain development; IMP.
DR
    GO; GO:0030334; P:regulation of cell migration; IMP.
DR
DR
    InterPro; IPR000488; Death.
    InterPro; IPR011029; DEATH like.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003598; Ig c2.
DR
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
DR
    InterPro; IPR000906; ZU5.
DR
DR
    Pfam; PF00531; Death; 1.
    Pfam; PF00047; iq; 1.
DR
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
DR
    PRINTS; PR01705; TSP1REPEAT.
    SMART; SM00005; DEATH; 1.
DR
DR
    SMART; SM00408; IGc2; 1.
    SMART; SM00209; TSP1; 2.
DR
DR
    SMART; SM00218; ZU5; 1.
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
DR
    PROSITE; PS50835; IG LIKE; 1.
    PROSITE; PS50092; TSP1; 2.
DR
KW
    Alternative splicing; Apoptosis; Developmental protein;
    Immunoglobulin domain; Phosphorylation; Receptor; Repeat; Signal;
KW
KW
    Transmembrane.
FT
    SIGNAL
                        40
                 1
                                 Potential.
FT
    CHAIN
                 41
                       931
                                 Netrin receptor UNC5C.
                       380
FT
    DOMAIN
                 41
                                 Extracellular (Potential).
                381
                       401
FT
    TRANSMEM
                                 Potential.
                402
                       931
                                 Cytoplasmic (Potential).
FT
    DOMAIN
                 62
                       159
                                 Iq-like.
FT
    DOMAIN
FT
                161
                       256
                                 Ig-like C2-type.
    DOMAIN
                       314
                                 TSP type-1 1.
FT
    DOMAIN
                260
FT
    DOMAIN
                 316
                       368
                                 TSP type-1 2.
                                 ZU5.
FT
    DOMAIN
                 528
                       631
                850
                       929
FT
    DOMAIN
FT
    SITE
                 415
                       416
                                 Cleavage (by caspase-3) (By similarity).
FT
    SITE
                 694
                       712
                                 Interaction with DCC (By similarity).
FT
    DISULFID
                 83
                       142
                                 By similarity.
                                  By similarity.
FT
    DISULFID
                 188
                       239
FT
    MOD RES
                 568
                       568
                                 Phosphotyrosine.
                                 N-linked (GlcNAc. . .) (Potential).
FT
    CARBOHYD
                 236
                       236
                                 N-linked (GlcNAc. . .) (Potential).
FT
    CARBOHYD
                 361
                       361
```

```
FT
     VARSPLIC
                 370
                        370
                                  A -> GFIYPISTEHRPQNEYGFSS (in isoform 2).
FT
                                  /FTId=VSP 011702.
FT
     MUTAGEN
                 568
                        568
                                  Y->F: Abolishes interaction with PTPN11,
FT
                                  leading to a increased level of
                                  phosphorylation.
FT
FT
     CONFLICT
                  16
                         16
                                  L \rightarrow I (in Ref. 2).
FT
     CONFLICT
                 733
                        733
                                  H \rightarrow R \text{ (in Ref. 2)}.
                                  S \rightarrow Y (in Ref. 2).
FT
     CONFLICT
                 924
                        924
SQ
     SEQUENCE
                931 AA;
                        103062 MW;
                                     8A5D951A4EECA179 CRC64;
  Query Match
                          85.9%;
                                  Score 249; DB 1; Length 931;
  Best Local Similarity
                          82.0%;
                                  Pred. No. 6.1e-21;
  Matches
            41; Conservative
                                 6; Mismatches
                                                    3; Indels
                                                                              0;
                                                                      Gaps
            1 STWTEWSVCSASCGRGWOKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qу
              Db
          264 STWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 6
UN5C RAT
ID
     UN5C RAT
                    STANDARD;
                                   PRT;
                                          931 AA.
AC
     Q761X5;
     25-OCT-2004 (Rel. 45, Created)
DT
     25-OCT-2004 (Rel. 45, Last sequence update)
DT
DT
     25-OCT-2004 (Rel. 45, Last annotation update)
     Netrin receptor UNC5C precursor (Unc-5 homolog C) (Unc-5 homolog 3).
DE
     Name=Unc5c; Synonyms=Unc5h3;
GN
os
     Rattus norvegicus (Rat).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
     NCBI TaxID=10116;
RN
RP
     SEQUENCE FROM N.A., AND DISEASE.
RX
     PubMed=15010202; DOI=10.1016/j.molbrainres.2003.12.003;
RA
     Kuramoto T., Kuwamura M., Serikawa T.;
RT
     "Rat neurological mutations cerebellar vermis defect and hobble are
RT
     caused by mutations in the netrin-1 receptor gene Unc5h3.";
RL
     Brain Res. Mol. Brain Res. 122:103-108(2004).
RN
RP
     FUNCTION.
RX
     PubMed=11387206; DOI=10.1093/emboj/20.11.2715;
RA
     Llambi F., Causeret F., Bloch-Gallego E., Mehlen P.;
RT
     "Netrin-1 acts as a survival factor via its receptors UNC5H and DCC.";
     EMBO J. 20:2715-2722(2001).
RL
CC
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
         caused by its association with DCC that may trigger signaling for
CC
CC
         repulsion. Also involved in corticospinal tract axon guidances
CC
         independently of DCC. It also acts as a dependence receptor
CC
         required for apoptosis induction when not associated with netrin
CC
         ligand.
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC (By
CC
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
     -!- TISSUE SPECIFICITY: Mainly expressed in brain. Also expressed in
```

```
CC
         kidney. Not expressed in developing or adult lung.
CC
     -!- PTM: Phosphorylated on different cytoplasmic tyrosine residues.
CC
         Phosphorylation of Tyr-568 leads to an interaction with PTPN11
         phosphatase, suggesting that its activity is regulated by
CC
CC
         phosphorylation/dephosphorylation. Tyrosine phosphorylation is
CC
         netrin-dependent (By similarity).
CC
     -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
         cleavage does not take place when the receptor is associated with
CC
         netrin ligand. Its cleavage by caspases is required to induce
        apoptosis.
CC
CC
     -!- DISEASE: Defects in Unc5c are the cause of cerebellar vermis
CC
         defect (cvd) and hobble (hob) phenotypes. Cvd and hob rats exhibit
CC
         cerebellar and midbrain defects, possibly as a result of abnormal
         neuronal migration, and exhibit laminar structure abnormalities in
CC
CC
         the fused cerebellar hemispheres and ectopic cerebellar tissues in
CC
         the cerebello-pontine junction.
CC
     -!- SIMILARITY: Belongs to the UNC-5 family.
     -!- SIMILARITY: Contains 1 death domain.
CC
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
     -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
CC
     -!- SIMILARITY: Contains 1 ZU5 domain.
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
     _____
CC
DR
    EMBL; AB118026; BAD05181.1; -.
DR
    RGD; 735109; Unc5c.
DR
    InterPro; IPR000488; Death.
DR
    InterPro; IPR011029; DEATH like.
    InterPro; IPR003599; Iq.
DR
DR
    InterPro; IPR007110; Iq-like.
DR
    InterPro; IPR003598; Iq c2.
DR
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
DR
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
DR
    Pfam; PF00047; ig; 1.
DR
     Pfam; PF00090; TSP 1; 2.
DR
     Pfam; PF00791; ZU5; 1.
DR
     PRINTS; PR01705; TSP1REPEAT.
DR
    SMART; SM00005; DEATH; 1.
DR
     SMART; SM00409; IG; 1.
DR
     SMART; SM00408; IGc2; 1.
DR
     SMART; SM00209; TSP1; 2.
     SMART; SM00218; ZU5; 1.
DR
DR
     PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
     PROSITE; PS50835; IG LIKE; 1.
DR
     PROSITE; PS50092; TSP1; 2.
KW
     Apoptosis; Developmental protein; Immunoglobulin domain;
KW
     Phosphorylation; Receptor; Repeat; Signal; Transmembrane.
FT
     SIGNAL
                         40
                                 Potential.
                  1
```

```
FT
    CHAIN
                 41
                        931
                                 Netrin receptor UNC5C.
                 41
                       380 .
FT
     DOMAIN
                                 Extracellular (Potential).
FT
    TRANSMEM
                 381
                        401
                                 Potential.
FT
    DOMAIN
                 402
                       931
                                 Cytoplasmic (Potential).
                       159
FT
    DOMAIN
                 62
                                 Iq-like.
FΤ
    DOMAIN
                161
                       256
                                 Ig-like C2-type.
FT
    DOMAIN
                260
                       314
                                 TSP type-1 1.
FT
                316
                       368
                                 TSP type-1 2.
    DOMAIN
FT
    DOMAIN
                 528
                       631
                                 ZU5.
FT
    DOMAIN
                850
                       929
                                 Death.
FT
    SITE
                415
                       416
                                 Cleavage (by caspase-3) (By similarity).
FT
    SITE
                694
                       712
                                 Interaction with DCC (By similarity).
FT
    DISULFID
                 83
                       142
                                 By similarity.
FT
    DISULFID
                188
                       239
                                 By similarity.
    MOD RES
                                 Phosphotyrosine (By similarity).
FT
                568
                       568
FT
    CARBOHYD
                236
                       236
                                 N-linked (GlcNAc. . .) (Potential).
FT
    CARBOHYD
                361
                       361
                                 N-linked (GlcNAc. . .) (Potential).
               931 AA; 103134 MW; 25B183A97BCB8401 CRC64;
SQ
     SEQUENCE
 Query Match
                         84.1%; Score 244; DB 1; Length 931;
  Best Local Similarity
                         80.0%; Pred. No. 2.4e-20;
 Matches
          40; Conservative
                                6; Mismatches
                                                  4; Indels
                                                                    Gaps
Qу
           1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
         264 STWAEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLC 313
RESULT 7
UN5B HUMAN
ID
    UN5B HUMAN
                   STANDARD;
                                  PRT;
                                         945 AA.
     Q8IZJ1; Q86SN3; Q8N1Y2; Q9H9F3;
AC
DT
     25-OCT-2004 (Rel. 45, Created)
     25-OCT-2004 (Rel. 45, Last sequence update)
DT
    25-OCT-2004 (Rel. 45, Last annotation update)
DE
    Netrin receptor UNC5B precursor (Unc-5 homolog B) (Unc-5 homolog 2)
DE
     (p53-regulated receptor for death and life protein 1)
DE
     (UNQ1883/PRO4326).
GN
    Name=UNC5B; Synonyms=P53RDL1, UNC5H2;
OS
    Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 2), TISSUE SPECIFICITY, AND INTERACTION
RP
    WITH GNAI2.
RC
    TISSUE=Lung;
ŔХ
    MEDLINE=22246081; PubMed=12359238; DOI=10.1016/S0006-291X(02)02277-5;
RA
     Komatsuzaki K., Dalvin S., Kinane T.B.;
RT
     "Modulation of G(ialpha(2)) signaling by the axonal guidance molecule
RT
     UNC5H2.";
RL
     Biochem. Biophys. Res. Commun. 297:898-905(2002).
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1), FUNCTION, AND MUTAGENESIS OF ASP-412.
RX
     PubMed=12598906; DOI=10.1038/ncb943;
RA
     Tanikawa C., Matsuda K., Fukuda S., Nakamura Y., Arakawa H.;
RT
     "p53RDL1 regulates of p53-dependent apoptosis.";
```

```
Nat. Cell Biol. 5:216-223(2003).
RL
RN
     [3]
     SEQUENCE FROM N.A. (ISOFORM 1).
RP
     MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RX
     Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
RA
RA
     Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA
     Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
     Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA
     Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA
     Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA
     Vandlen R., Watanabe C., Wieand D., Woods K., Xie M.-H., Yansura D.,
RA
     Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA
RA
     Godowski P., Gray A.;
     "The secreted protein discovery initiative (SPDI), a large-scale
RT
RT
     effort to identify novel human secreted and transmembrane proteins: a
RT
     bioinformatics assessment.";
RL
     Genome Res. 13:2265-2270(2003).
RN
RP
     SEQUENCE OF 361-945 FROM N.A.
RC
     TISSUE=Amygdala, and Teratocarcinoma;
RX
     PubMed=14702039; DOI=10.1038/ng1285;
RA
    Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA
     Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
     Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA
RA
     Yamamoto J.-I., Saito K., Kawai Y., Isono Y., Nakamura Y.,
RA
     Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M.,
RA ·
     Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H.,
     Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E.,
RA
ŔĀ
     Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M.,
RA
     Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K.,
RA
     Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y.,
RA
     Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T.,
RA
     Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O.,
RA
     Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA
     Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
     Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA
RA
     Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA
     Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA
     Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA
     Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA
     Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA
     Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
     Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA
RA
     Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA
     Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA
     Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
     Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA
     Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA
     Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RA
     "Complete sequencing and characterization of 21,243 full-length human
RT
RT
     cDNAs.";
     Nat. Genet. 36:40-45(2004).
RL
RN
RP
     DOWN-REGULATION IN CANCER.
     PubMed=12655055; DOI=10.1073/pnas.0738063100;
RX
     Thiebault K., Mazelin L., Pays L., Llambi F., Joly M.-O.,
RA
RA
     Scoazec J.-Y., Saurin J.-C., Romeo G., Mehlen P.;
```

```
"The netrin-1 receptors UNC5H are putative tumor suppressors
     controlling cell death commitment.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 100:4173-4178(2003).
RL
CC
    -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
        axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. It also acts as a dependence receptor required for
CC
        apoptosis induction when not associated with netrin ligand.
    -!- SUBUNIT: Interacts with the cytoplasmic part of DCC (By
CC
CC
        similarity). Interacts with GNAI2 via its cytoplasmic part.
CC
    -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=1;
          IsoId=Q8IZJ1-1; Sequence=Displayed;
CC
CC
        Name=2;
CC
          IsoId=Q8IZJ1-2; Sequence=VSP 011698;
    -!- TISSUE SPECIFICITY: Highly expressed in brain. Also expressed at
CC
        lower level in developing lung, cartilage, kidney and
CC
CC
        hematopoietic and immune tissues.
CC
    -!- INDUCTION: By p53/TP53.
    -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
CC
        similarity).
CC
    -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
        cleavage does not take place when the receptor is associated with
CC
        netrin ligand. Its cleavage by caspases is required to induce
CC
        apoptosis.
CC
    -!- MISCELLANEOUS: Down-regulated in multiple cancers including
CC
        colorectal, breast, ovary, uterus, stomach, lung, or kidney
CC
        cancers.
CC
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    -----
DR
    EMBL; AY126437; AAM95701.1; -.
DR
    EMBL; AB096256; BAC57998.1; -.
DR
    EMBL; AY358351; AAQ88717.1; -.
    EMBL; AK022859; BAB14276.1; ALT INIT.
DR
    EMBL; AK094595; BAC04382.1; ALT INIT.
DR
    HSSP; P07996; 1LSL.
DR
DR
    Genew; HGNC:12568; UNC5B.
DR
    MIM; 607870; -.
    InterPro; IPR000488; Death.
DR
DR
    InterPro; IPR011029; DEATH like.
    InterPro; IPR007110; Ig-like.
DR
```

```
DR
     InterPro; IPR003598; Ig c2.
     InterPro; IPR000884; TSP1.
DR
DR
     InterPro; IPR008085; TSP 1.
DR
     InterPro; IPR000906; ZU5.
DR
     Pfam; PF00531; Death; 1.
DR
     Pfam; PF00047; iq; 1.
DR
     Pfam; PF00090; TSP 1; 2.
     Pfam; PF00791; ZU5; 1.
DR
     PRINTS; PR01705; TSP1REPEAT.
DR
DR
     SMART; SM00005; DEATH; 1.
DR
     SMART; SM00408; IGc2; 1.
DR
     SMART; SM00209; TSP1; 2.
DR
     SMART; SM00218; ZU5; 1.
     PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
     PROSITE; PS50835; IG LIKE; 1.
DR
     PROSITE; PS50092; TSP1; 2.
DR
KW
     Alternative splicing; Apoptosis; Developmental protein;
KW
     Immunoglobulin domain; Phosphorylation; Polymorphism; Receptor;
KW
     Repeat; Signal; Transmembrane.
FT
     SIGNAL
                   1
                         26
                                   Potential.
FΤ
     CHAIN
                  27
                        945
                                   Netrin receptor UNC5B.
FT
     DOMAIN
                  27
                        377
                                   Extracellular (Potential).
FT
     TRANSMEM
                 378
                        398
                                   Potential.
FT
     DOMAIN
                 399
                        945
                                   Cytoplasmic (Potential).
\mathbf{FT}
     DOMAIN
                  48
                        145
                                   Ig-like.
                                   Ig-like C2-type.
     DOMAIN
                 147
                        242
FT
     DOMAIN
                 246
                        300
                                   TSP type-1 1.
                                   TSP type-1 2.
FT
     DOMAIN
                 302
                        354
FT
     DOMAIN
                 541
                        644
                                   ZU5.
FT
     DOMAIN
                 865
                        943
                                   Death.
FT
     SITE
                 412
                        413
                                   Cleavage (by caspase-3).
\mathbf{FT}
     SITE
                 707
                        725
                                   Interaction with DCC (By similarity).
FT
     DISULFID
                  69
                        128
                                   By similarity.
FT
     DISULFID
                 174
                        225
                                   By similarity.
FT
     CARBOHYD
                 222
                        222
                                   N-linked (GlcNAc. . .) (Potential).
FT
                 347
                        347
                                   N-linked (GlcNAc. . .) (Potential).
     CARBOHYD
FT
     VARSPLIC
                 356
                        367
                                   NKKTLSDPNSHL -> M (in isoform 2).
FT
                                 /FTId=VSP 011698.
FT
    VARIANT
                 516
                                   A \rightarrow T \text{ (in dbSNP:} 10509332).
                        516
FT
                                   /FTId=VAR 019730.
FT
     MUTAGEN
                 412
                        412
                                   D->N: Abolishes cleavage by caspase-3 and
FT
                                   subsequent induction of apoptosis.
FT
     CONFLICT
                 483
                        483
                                   K \rightarrow E \text{ (in Ref. 3).}
FT
     CONFLICT
                 851
                        851
                                   L -> P (in Ref. 3; BAB14276).
SO
     SEQUENCE
                945 AA; 103637 MW;
                                      56064E335F323447 CRC64;
  Query Match
                          82.4%;
                                   Score 239; DB 1; Length 945;
  Best Local Similarity
                          78.0%; Pred. No. 9.4e-20;
 Matches
            39; Conservative
                                  4; Mismatches
                                                    7; Indels
                                                                               0;
                                                                       Gaps
Qу
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
          250 SSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQAFQKTACTTIC 299
```

RESULT 8 UN5D HUMAN

```
UN5D HUMAN
                    STANDARD;
                                   PRT;
ID
                                          953 AA.
    Q6UXZ4; Q8WYP7;
AC
     25-OCT-2004 (Rel. 45, Created)
DT
    25-OCT-2004 (Rel. 45, Last sequence update)
DT
    25-OCT-2004 (Rel. 45, Last annotation update)
DT
    Netrin receptor UNC5D precursor (Unc-5 homolog D) (Unc-5 homolog 4)
DE
     (UNQ6012/PRO34692).
    Name=UNC5D; Synonyms=KIAA1777, UNC5H4;
GN
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A. (ISOFORM 1).
RX
    MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA
    Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
RA
    Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA
    Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA
    Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA
    Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
    Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA
RA
    Vandlen R., Watanabe C., Wieand D., Woods K., Xie M.-H., Yansura D.,
RA
    Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA
    Godowski P., Gray A.;
RT
     "The secreted protein discovery initiative (SPDI), a large-scale
    effort to identify novel human secreted and transmembrane proteins: a
RT
    bioinformatics assessment.";
RL
    Genome Res. 13:2265-2270(2003).
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
    TISSUE=Brain;
RA
    Nakajima D., Nakayama M., Nagase T., Ohara O.;
RT
     "Identification of unc5H4 gene.";
RL
     Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
CC
    -!- FUNCTION: Receptor for netrin. May be involved in axon guidance by
CC
         mediating axon repulsion of neuronal growth cones in the
CC
         developing nervous system upon ligand binding. Axon repulsion in
CC
         growth cones may be caused by its association with DCC that may
CC
         trigger signaling for repulsion. It also acts as a dependence
CÇ
         receptor required for apoptosis induction when not associated with
CC
         netrin ligand (By similarity).
CC
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC (By
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
     -!- ALTERNATIVE PRODUCTS:
CÇ
         Event=Alternative splicing; Named isoforms=2;
CC
CC
           IsoId=Q6UXZ4-1; Sequence=Displayed;
CC
         Name=2;
CC
           IsoId=Q6UXZ4-2; Sequence=VSP 011703;
CC
           Note=No experimental confirmation available;
CC
     -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
         similarity).
CC
     -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
         cleavage does not take place when the receptor is associated with
CC
         netrin ligand. Its cleavage by caspases is required to induce
CC
         apoptosis (By similarity).
```

```
-!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
DR
    EMBL; AB055056; BAB83663.1; -.
DR
    EMBL; AY358147; AAQ88514.1; -.
DR
    HSSP; P07996; 1LSL.
DR
    Genew; HGNC:18634; UNC5D.
DR
    InterPro; IPR000488; Death.
DR
    InterPro; IPR011029; DEATH like.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003598; Ig_c2.
DR
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
    Pfam; PF00047; ig; 1.
DR
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
DR
    PRINTS; PR01705; TSP1REPEAT.
DR
    SMART; SM00005; DEATH; 1.
DR
    SMART; SM00408; IGc2; 1.
DR
    SMART; SM00209; TSP1; 2.
DR
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
    PROSITE; PS50835; IG LIKE; 1.
    PROSITE; PS50092; TSP1; 2.
DR
KW
    Alternative splicing; Apoptosis; Developmental protein;
KW
    Immunoglobulin domain; Phosphorylation; Receptor; Repeat; Signal;
KW
    Transmembrane.
FT
    SIGNAL
                  1
                       32
                                 Potential.
FT
    CHAÌN
                 33
                       953
                                Netrin receptor UNC5D.
FT
                       379
                                 Extracellular (Potential).
    DOMAIN
                 33
FT
    TRANSMEM
                380
                       400
                                 Potential.
\mathbf{FT}
    DOMAIN
                401
                       953
                                Cytoplasmic (Potential).
FT
                 54
                       151
    DOMAIN
                                Ig-like.
FT
    DOMAIN
                153
                       244
                                 Ig-like C2-type.
FT
                252
                       306
                                 TSP type-1 1.
    DOMAIN
FT
                308
                       360
                                 TSP type-1 2.
    DOMAIN
FT
                540
                       642
                                 ZU5.
    DOMAIN
FT
    DOMAIN
                859
                       936
                                 Death.
FT
    SITE
                416
                       417
                                 Cleavage (by caspase-3) (By similarity).
FT
    SITE
                703
                       721
                                 Interaction with DCC (By similarity).
FT
    DISULFID
                75
                      134
                                 By similarity.
FT
    DISULFID
                180
                       231
                                 By similarity.
FT
    CARBOHYD
                117
                       117
                                N-linked (GlcNAc. . .) (Potential).
FT
    CARBOHYD
                228
                       228
                                N-linked (GlcNAc. . .) (Potential).
```

```
353
                        353
                                  N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                 376
                        376
                                  N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
     VARSPLIC
                  1
                         34
                                  MGRAAATAGGGGGARRWLPWLGLCFWAAGTAAAR -> MIL
FT
FT
                                  VLVKALSDVCAGTSGFLLDFSSQTSP (in isoform
FT
                                  2).
FT
                                  /FTId=VSP 011703.
SQ
     SEQUENCE
                953 AA;
                         105879 MW; 5F893B9DF746F731 CRC64;
                                 Score 239; DB 1; Length 953;
  Query Match
                          82.4%;
  Best Local Similarity
                          76.0%;
                                 Pred. No. 9.4e-20;
                                 5; Mismatches
 Matches
           38; Conservative
                                                  7; Indels
                                                                    Gaps
                                                                             0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
Qу
              Db
          256 SSWTEWSACNVRCGRGWQKRSRTCTNPAPLNGGAFCEGMSVQKITCTSLC 305
RESULT 9
UN5B MOUSE
ID
     UN5B MOUSE
                    STANDARD;
                                  PRT;
                                          945 AA.
AC
     Q8K1S3; Q6PFH0; Q80Y85; Q9D398;
DT
     25-OCT-2004 (Rel. 45, Created)
DT
     25-OCT-2004 (Rel. 45, Last sequence update)
DT
     25-OCT-2004 (Rel. 45, Last annotation update)
DE
     Netrin receptor UNC5B precursor (Unc-5 homolog B) (Unc-5 homolog 2).
     Name=Unc5b; Synonyms=Unc5h2;
os
     Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
     NCBI TaxID=10090;
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1), AND TISSUE SPECIFICITY.
RX
     MEDLINE=22239710; PubMed=12351186; DOI=10.1016/S0925-4773(02)00248-4;
RA
     Engelkamp D.;
RT
     "Cloning of three mouse unc-5 genes and their expression patterns at
RT
     mid-gestation.";
RL
     Mech. Dev. 118:191-197(2002).
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1).
RC
     STRAIN=C57BL/6J; TISSUE=Medulla oblongata;
     MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA
     Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA
     Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA
     Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA
     Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA
     Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA
     Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
RA
     Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA
     Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
     Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA
RA
     Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
     Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA
RA
     Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA
     Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA
     Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA
     Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA
     Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
```

```
Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA
RA
    Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA
    Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA
    Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA
    Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA
    Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
    Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA
RA
    Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA
    Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA.
    Birney E., Hayashizaki Y.;
RT
     "Analysis of the mouse transcriptome based on functional annotation of
RT
     60,770 full-length cDNAs.";
    Nature 420:563-573(2002).
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
    STRAIN=C57BL/6; TISSUE=Brain;
RX
    MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
    Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
RT
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
     [4]
RP
    TISSUE SPECIFICITY.
RX
    PubMed=12799072;
RA
    Dalvin S., Anselmo M.A., Prodhan P., Komatsuzaki K., Schnitzer J.J.,
RA
     Kinane T.B.;
RT
     "Expression of Netrin-1 and its two receptors DCC and UNC5H2 in the
RT
     developing mouse lung.";
RL
    Gene Expr. Patterns 3:279-283(2003).
CC
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. It also acts as a dependence receptor required for
CC
         apoptosis induction when not associated with netrin ligand (By
CC
         similarity).
CC
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC. Interacts
CC
         with GNAI2 via its cytoplasmic part (By similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=2;
```

```
CC
        Name=1;
CC .
          IsoId=Q8K1S3-1; Sequence=Displayed;
CC
        Name=2;
          IsoId=Q8K1S3-2; Sequence=VSP 011699;
CC
    -!- TISSUE SPECIFICITY: Highly expressed in brain. Expressed in lung
CC
CC
        during late development. Expressed during early blood vessel
CC
        formation, in the semicircular canal and in a dorsal to ventral
        gradient in the retina.
CC
    -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
        similarity).
CC
    -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
        cleavage does not take place when the receptor is associated with
CC
CC
        netrin ligand. Its cleavage by caspases is required to induce
CC
        apoptosis (By similarity).
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
CC
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC
    _____
CC
DR
    EMBL; AJ487853; CAD32251.1; -.
DR
    EMBL; AK018177; BAB31108.1; -.
DR
    EMBL; BC048162; AAH48162.1; ALT INIT.
DR
    EMBL; BC057560; AAH57560.1; -.
DR
    HSSP; P07996; 1LSL.
    MGD; MGI:894703; Unc5b.
DR
    InterPro; IPR000488; Death.
DR
DR
    InterPro; IPR011029; DEATH like.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003598; Ig c2.
    InterPro; IPR000884; TSP1.
DR
DR
    InterPro; IPR008085; TSP 1.
DR
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
DR
    Pfam; PF00047; ig; 1.
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
DR
    PRINTS; PR01705; TSP1REPEAT.
    SMART; SM00005; DEATH; 1.
    SMART; SM00408; IGc2; 1.
DR
    SMART; SM00209; TSP1; 2.
DR
    SMART; SM00218; ZU5; 1.
DR
    PROSITE; PS50017; DEATH DOMAIN; 1.
DR
    PROSITE; PS50835; IG LIKE; 1.
DR
    PROSITE; PS50092; TSP1; 2.
DR
    Alternative splicing; Apoptosis; Developmental protein;
KW
    Immunoglobulin domain; Phosphorylation; Receptor; Repeat; Signal;
KW
    Transmembrane.
KW
```

```
FT
     SIGNAL
                   1
                         26
                                   Potential.
                  27
                        945
                                   Netrin receptor UNC5B.
FT
     CHAIN
                  27
                        377
                                   Extracellular (Potential).
FT
     DOMAIN
                 378
                        398
FT
     TRANSMEM
                                   Potential.
                 399
                        945
FT
     DOMAIN
                                   Cytoplasmic (Potential).
FT
     DOMAIN
                  48
                        145
                                   Iq-like.
FT
                 153
                        242
                                   Ig-like C2-type.
     DOMAIN
                                   TSP type-1 1.
FT
     DOMAIN
                 246
                        300
                 302
                        354
                                   TSP type-1 2.
FT
     DOMAIN
                 541
                                   ZU5.
FT
     DOMAIN
                        644
                 865
                        943
                                   Death.
FT
     DOMAIN
     SITE
                 412
                        413
                                   Cleavage (by caspase-3) (By similarity).
FT
FT
                 707
                        725
                                   Interaction with DCC (By similarity).
     SITE
                                   By similarity.
FT
     DISULFID
                  69
                        128
FT
     DISULFID
                 174
                        225
                                   By similarity.
FT
     CARBOHYD
                 222
                        222
                                   N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                 347
                        347
                                   N-linked (GlcNAc. . .) (Potential).
FΤ
     VARSPLIC
                 356
                        367
                                   NQRTLNDPKSHP -> T (in isoform 2).
FT
                                   /FTId=VSP 011699.
FT
     CONFLICT
                 238
                        238
                                   T \rightarrow A \text{ (in Ref. 2)}.
FT
     CONFLICT
                 394
                        394
                                   V \rightarrow E \text{ (in Ref. 2)}.
FT
     CONFLICT
                 679
                        679
                                   T \rightarrow S \text{ (in Ref. 2).}
FT
     CONFLICT
                 874
                        874
                                   N \rightarrow D (in Ref. 2).
SQ
     SEQUENCE
                945 AA; 103738 MW; 80E896F0F0E06012 CRC64;
  Query Match
                          82.1%;
                                  Score 238; DB 1; Length 945;
 Best Local Similarity
                          78.0%; Pred. No. 1.2e-19;
 Matches
            39; Conservative
                                  4; Mismatches
                                                    7; Indels
                                                                   0;
                                                                       Gaps
                                                                                0;
Qу
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
          250 SSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQAFQKTACTTVC 299
RESULT 10
UN5B RAT
ID
     UN5B RAT
                    STANDARD;
                                    PRT;
                                           945 AA.
AC
     008722;
DT
     25-OCT-2004 (Rel. 45, Created)
DT
     25-OCT-2004 (Rel. 45, Last sequence update)
     25-OCT-2004 (Rel. 45, Last annotation update)
DE
     Netrin receptor UNC5B precursor (Unc-5 homolog B) (Unc-5 homolog 2).
GN
     Name=Unc5b; Synonyms=Unc5h2;
OS
     Rattus norvegicus (Rat).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX
     NCBI TaxID=10116;
RN
RP
     SEQUENCE FROM N.A., FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP
     SPECIFICITY.
     MEDLINE=97271897; PubMed=9126742;
RX
     Leonardo E.D., Hinck L., Masu M., Keino-Masu K., Ackerman S.L.,
RA
RA
     Tessier-Lavigne M.;
RT
     "Vertebrate homologues of C. elegans UNC-5 are candidate netrin
RT
     receptors.";
RL
     Nature 386:833-838(1997).
RN
     [2]
```

```
RP
     FUNCTION, AND INTERACTION WITH DCC.
RX
     PubMed=10399920;
     Hong K., Hinck L., Nishiyama M., Poo M.-M., Tessier-Lavigne M.,
RA
RA
     Stein E.;
RT
     "A ligand-gated association between cytoplasmic domains of UNC5 and
RT
     DCC family receptors converts netrin-induced growth cone attraction to
RT
     repulsion.";
     Cell 97:927-941(1999).
RL
RN
     FUNCTION, AND MUTAGENESIS OF ASP-412.
RP
RX
     PubMed=11387206; DOI=10.1093/emboj/20.11.2715;
     Llambi F., Causeret F., Bloch-Gallego E., Mehlen P.;
     "Netrin-1 acts as a survival factor via its receptors UNC5H and DCC.";
RT
     EMBO J. 20:2715-2722(2001).
RL
CC
     -!- FUNCTION: Receptor for netrin required for axon quidance. Mediates
CC
         axon repulsion of neuronal growth cones in the developing nervous
CC
         system upon ligand binding. Axon repulsion in growth cones may be
CC
         caused by its association with DCC that may trigger signaling for
CC
         repulsion. It also acts as a dependence receptor required for
CC
         apoptosis induction when not associated with netrin ligand.
CC
     -!- SUBUNIT: Interacts with GNAI2 via its cytoplasmic part (By
CC
         similarity). Interacts with the cytoplasmic part of DCC.
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein.
     -!- TISSUE SPECIFICITY: Mainly expressed in regions of differentiating
CC
CC
         neurons. Expressed in the developing sensory ganglia that flank
CC
         the spinal cord from E12, peaking at E14. Expressed in the roof
CC
         plate region of the spinal cord from E14.
CC
     -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
         similarity).
CC
     -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
         cleavage does not take place when the receptor is associated with
CC
         netrin ligand. Its cleavage by caspases is required to induce
CC
         apoptosis.
CC
     -!- SIMILARITY: Belongs to the UNC-5 family.
CC
     -!- SIMILARITY: Contains 1 death domain.
CC
     -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
     -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
     -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
     -!- SIMILARITY: Contains 1 ZU5 domain.
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
     modified and this statement is not removed. Usage by and for commercial
CC
CC
    .entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; U87306; AAB57679.1; -.
     HSSP; P07996; 1LSL.
DR
DR
     RGD; 621756; Unc5h2.
     InterPro; IPR000488; Death.
DR
DR
     InterPro; IPR011029; DEATH like.
DR
     InterPro; IPR007110; Iq-like.
     InterPro; IPR003598; Iq c2.
DR
     InterPro; IPR000884; TSP1.
DR
     InterPro; IPR008085; TSP 1.
```

```
InterPro; IPR000906; ZU5.
DR
DR
     Pfam; PF00531; Death; 1.
DR
     Pfam; PF00047; ig; 1.
DR
     Pfam; PF00090; TSP 1; 2.
DR
     Pfam; PF00791; ZU5; 1.
DR
     PRINTS; PR01705; TSP1REPEAT.
DR
     SMART; SM00005; DEATH; 1.
     SMART; SM00408; IGc2; 1.
DR
     SMART; SM00209; TSP1; 2.
DR
     SMART; SM00218; ZU5; 1.
DR
DR
     PROSITE; PS50017; DEATH DOMAIN; 1.
DR
     PROSITE; PS50835; IG LIKE; 1.
DR
     PROSITE; PS50092; TSP1; 2.
KW
     Apoptosis; Developmental protein; Immunoglobulin domain;
     Phosphorylation; Receptor; Repeat; Signal; Transmembrane.
KW
FT
     SIGNAL
                   1
                         26
                                   Potential.
\mathbf{FT}
     CHAIN
                  27
                        945
                                   Netrin receptor UNC5B.
FT
     DOMAIN
                  27
                        377
                                   Extracellular (Potential).
FT
     TRANSMEM
                 378
                        398
                                   Potential.
FT
     DOMAIN
                 399
                        945
                                   Cytoplasmic (Potential).
F.T
     DOMAIN
                  48
                        145
                                   Ig-like.
FT
     DOMAIN
                 153
                        242
                                   Ig-like C2-type.
FT
     DOMAIN
                 246
                        300
                                   TSP type-1 1.
\mathbf{FT}
     DOMAIN
                 302
                        354
                                   TSP type-1 2.
FT
     DOMAIN
                 541
                        644
                                   ZU5.
FT
     DOMAIN
                 865
                        943
                                   Death.
FT
     SITE
                 412
                        413
                                   Cleavage (by caspase-3).
                 707
FT
     SITE
                        725
                                   Interaction with DCC.
FT
     DISULFID
                  69
                        128
                                   By similarity.
FT
     DISULFID
                 174
                        225
                                   By similarity.
FT
     CARBOHYD
                 222
                        222
                                  N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                 347
                        347
                                   N-linked (GlcNAc. . .) (Potential).
FT
     MUTAGEN
                 412
                        412
                                   D->N: Abolishes cleavage by caspase-3 and
FT
                                   subsequent induction of apoptosis.
SQ
     SEQUENCE
                        103520 MW;
                                      6E9C2A262E560B9B CRC64;
                945 AA;
                                   Score 238; DB 1; Length 945;
  Query Match
                          82.1%;
  Best Local Similarity
                          78.0%;
                                   Pred. No. 1.2e-19;
  Matches
                Conservative
            39;
                                  4;
                                     Mismatches
                                                    7;
                                                        Indels
                                                                       Gaps
                                                                               0;
            1 STWTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTACATLC 50
              Db
          250 SSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQACQKTACTTVC 299
RESULT 11
UN5D MOUSE
ID
     UN5D MOUSE
                    STANDARD;
                                    PRT;
                                           956 AA.
AC
     Q8K1S2;
DT
     25-OCT-2004 (Rel. 45, Created)
     25-OCT-2004 (Rel. 45, Last sequence update)
DT
DT
     25-OCT-2004 (Rel. 45, Last annotation update)
DE
     Netrin receptor UNC5D precursor (Unc-5 homolog D) (Unc-5 homolog 4).
GN
     Name=Unc5d; Synonyms=Unc5h4;
os
     Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
```

```
NCBI TaxID=10090;
OX
RN
     [1]
     SEQUENCE FROM N.A., AND TISSUE SPECIFICTY.
RP
RX
     MEDLINE=22239710; PubMed=12351186; DOI=10.1016/S0925-4773(02)00248-4;
RA
RT
     "Cloning of three mouse Unc5 genes and their expression patterns at
RT
     mid-gestation.";
     Mech. Dev. 118:191-197(2002).
RL
CC
     -!- FUNCTION: Receptor for netrin involved in cell migration. May be
CC
         involved in axon guidance by mediating axon repulsion of neuronal
CC
         growth cones in the developing nervous system upon ligand binding.
CC
         Axon repulsion in growth cones may be caused by its association
CC
         with DCC that may trigger signaling for repulsion. It also acts as
CC
         a dependence receptor required for apoptosis induction when not
CC
        associated with netrin ligand (By similarity).
CC
     -!- SUBUNIT: Interacts with the cytoplasmic part of DCC (By
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC
     -!- TISSUE SPECIFICITY: Expressed in developing limb and mammary
CC
         gland.
CC
     -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
         similarity).
CC
     -!- PTM: Proteolytically cleaved by caspases during apoptosis. The
CC
         cleavage does not take place when the receptor is associated with
CC
         netrin ligand. Its cleavage by caspases is required to induce
CC
         apoptosis (By similarity).
CC
     -!- SIMILARITY: Belongs to the UNC-5 family.
CC
     -!- SIMILARITY: Contains 1 death domain.
CC
     -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
     -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC
     -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
     -!- SIMILARITY: Contains 1 ZU5 domain.
CC
     _____
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; AJ487854; CAD32252.1; -.
DR
     HSSP; P07996; 1LSL.
DR
     MGD; MGI:2389364; Unc5d.
DR
     InterPro; IPR000488; Death.
DR
     InterPro; IPR011029; DEATH like.
     InterPro; IPR007110; Ig-like.
DR
DR
     InterPro; IPR003598; Ig c2.
DR
     InterPro; IPR000884; TSP1.
DR
     InterPro; IPR008085; TSP 1.
DR
     InterPro; IPR000906; ZU5.
     Pfam; PF00531; Death; 1.
DR
DR
     Pfam; PF00047; ig; 1.
DR
     Pfam; PF00090; TSP 1; 2.
     Pfam; PF00791; ZU5; 1.
DR
     PRINTS; PR01705; TSP1REPEAT.
DR
     SMART; SM00005; DEATH; 1.
DR
```

```
SMART; SM00408; IGc2; 1.
DR
DR
     SMART; SM00209; TSP1; 2.
     PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
     PROSITE; PS50835; IG LIKE; 1.
DR
     PROSITE; PS50092; TSP1; 2.
DR
     Apoptosis; Developmental protein; Immunoglobulin domain;
KW
     Phosphorylation; Receptor; Repeat; Signal; Transmembrane.
KW
FT
     SIGNAL
                   1
                        30
                                  Potential.
FT
     CHAIN
                  31
                        956
                                  Netrin receptor UNC5D.
                                  Extracellular (Potential).
                  31
FT
     DOMAIN
                        382
FT
     TRANSMEM
                 383
                        403
                                  Potential.
FT
     DOMAIN
                 404
                        956
                                  Cytoplasmic (Potential).
FT
     DOMAIN
                  52
                        149
                                  Iq-like.
FT
FT
     DOMAIN
                 151
                        242
                                  Iq-like C2-type.
                                  TSP type-1 1.
     DOMAIN
                 250
                        304
FT
     DOMAIN
                 306
                        358
                                  TSP type-1 2.
FT
     DOMAIN
                 543
                        645
                                  ZU5.
FT
     DOMAIN
                 862
                        939
\mathbf{FT}
     SITE
                 419
                        420
                                  Cleavage (by caspase-3) (By similarity).
FT
     SITE
                 706
                        724
                                  Interaction with DCC (By similarity).
FT
     DISULFID
                 73
                        132
                                  By similarity.
FT
     DISULFID
                 178
                        229
                                  By similarity.
FT
    CARBOHYD
                 115
                        115
                                  N-linked (GlcNAc. . .) (Potential).
\mathbf{FT}
                 226
                        226
                                  N-linked (GlcNAc. . .) (Potential).
    CARBOHYD
FT
     CARBOHYD
                 351
                        351
                                  N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                 379
                        379
                                  N-linked (GlcNAc. . .) (Potential).
     SEQUENCE
                956 AA; 106351 MW; DFDF07839C10C68D CRC64;
SQ
  Query Match
                          82.1%; Score 238; DB 1; Length 956;
  Best Local Similarity
                         76.0%; Pred. No. 1.2e-19;
  Matches
           38; Conservative
                                 4; Mismatches
                                                  8; Indels
                                                                             0;
                                                                     Gaps
            1 STWTEWSVCSASCGRGWOKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qy
              Db
          254 SSWTEWSACNVRCGRGWQKRSRTCTNPAPLNGGAFCEGMSVQKITCTALC 303
RESULT 12
UN5B XENLA
                                   PRT:
     UN5B XENLA
                    STANDARD;
                                          943 AA.
AC
     O8JGT4;
DT
     25-OCT-2004 (Rel. 45, Created)
DT
     25-OCT-2004 (Rel. 45, Last sequence update)
     25-OCT-2004 (Rel. 45, Last annotation update)
DT
     Netrin receptor UNC5B precursor (UNC-5 homolog) (Protein XUNC-5).
DE
os
     Xenopus laevis (African clawed frog).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC
     Xenopodinae; Xenopus.
     NCBI TaxID=8355;
OX
RN
     [1]
     SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RP
     MEDLINE=22239703; PubMed=12351179; DOI=10.1016/S0925-4773(02)00215-0;
RX
     Anderson R.B., Holt C.E.;
RT
     "Expression of UNC-5 in the developing Xenopus visual system.";
RL
     Mech. Dev. 118:157-160(2002).
CC
     -!- FUNCTION: Receptor for netrin required for axon guidance. Mediates
```

```
axon repulsion of neuronal growth cones in the developing nervous
CC
        system upon ligand binding (By similarity).
CC
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
    -!- TISSUE SPECIFICITY: In the developing visual system, it is
CC
        expressed within the developing optic vesicles and later become
CC
CC
        restricted to the dorsal ciliary marginal zone, a site of
CC
        retinoblast proliferation and differentiation.
CC
    -!- PTM: Phosphorylated on cytoplasmic tyrosine residues (By
CC
        similarity).
CC
    -!- SIMILARITY: Belongs to the UNC-5 family.
CC
    -!- SIMILARITY: Contains 1 death domain.
    -!- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.
CC
    -!- SIMILARITY: Contains 1 immunoglobulin-like domain.
    -!- SIMILARITY: Contains 2 TSP type-1 domains.
CC
CC
    -!- SIMILARITY: Contains 1 ZU5 domain.
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
DR
    EMBL; AY099459; AAM34486.1; -.
    HSSP; P07996; 1LSL.
DR
    InterPro; IPR000488; Death.
    InterPro; IPR011029; DEATH like.
DR
    InterPro; IPR007110; Ig-like.
DR
DR
    InterPro; IPR003598; Ig c2.
DR
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
DR
    InterPro; IPR000906; ZU5.
DR
    Pfam; PF00531; Death; 1.
DR
    Pfam; PF00047; ig; 1.
DR
    Pfam; PF00090; TSP 1; 2.
DR
    Pfam; PF00791; ZU5; 1.
DR
    PRINTS; PR01705; TSP1REPEAT.
DR
    SMART; SM00005; DEATH; 1.
DR
    SMART; SM00408; IGc2; 1.
DR
    SMART; SM00209; TSP1; 2.
    SMART; SM00218; ZU5; 1.
DR
    PROSITE; PS50017; DEATH DOMAIN; FALSE NEG.
DR
    PROSITE; PS50835; IG LIKE; 1.
DR
    PROSITE; PS50092; TSP1; 2.
KW
    Developmental protein; Immunoglobulin domain; Phosphorylation;
KW
    Receptor; Repeat; Signal; Transmembrane.
FT
    SIGNAL
                  1
                        30
                                 Potential.
FT
    CHAIN
                 31
                       943
                                 Netrin receptor UNC5B.
FT
                                 Extracellular (Potential).
    DOMAIN
                 31
                       380
FT
    TRANSMEM
                381
                       401
                                 Potential.
FT
    DOMAIN
                402
                       943
                                 Cytoplasmic (Potential).
FT
    DOMAIN
                 51
                       148
                                Ig-like.
FT
    DOMAIN
                150
                       245
                                 Iq-like C2-type.
                249
                                 TSP type-1 1.
    DOMAIN
                       303
FT
                305
                       357
                                 TSP type-1 2.
    DOMAIN
FT
    DOMAIN
                540
                       643
                                 ZU5.
```

```
863
FT
     DOMAIN
                       941
                                 Death.
                 7.2
                                 By similarity.
FT
     DISULFID
                       131
                177
                       228
                                 By similarity.
FT
     DISULFID .
                                 N-linked (GlcNAc. . .) (Potential).
FT
                225
                       225
     CARBOHYD
                350
                                 N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                       350
               943 AA; 105083 MW; A024E24A7EDB6175 CRC64;
SO
     SEQUENCE
                         75.5%; Score 219; DB 1; Length 943;
  Query Match
 Best Local Similarity
                         70.0%; Pred. No. 2.2e-17;
                                5; Mismatches 10; Indels
 Matches
           35; Conservative
                                                                0; Gaps
                                                                            0;
            1 STWTEWSVCSASCGRGWOKRSRSCTNPAPLNGGAFCEGONVOKTACATLC 50
Qу
              Db
          253 SSWTEWSPCNNRCGHGWQKRTRTCTNPAPLNGGTMCEGQQYQKFACNTMC 302
RESULT 13
08BV02
ID
     Q8BVQ2
                PRELIMINARY;
                                  PRT:
                                         335 AA.
AC
     Q8BVQ2;
DT
     01-MAR-2003 (TrEMBLrel. 23, Created)
     01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DΤ
     01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
DE
    Mus musculus adult male testis cDNA, RIKEN full-length enriched
DE
    library, clone:4932412F09 product:sema domain, seven thrombospondin
DE
     repeats (type 1 and type 1-like), transmembrane domain (TM) and short
     cytoplasmic domain, (semaphorin) 5A, full insert sequence.
DE
OS
    Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Testis;
    MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RX
RA
    Carninci P., Hayashizaki Y.;
RT
     "High-efficiency full-length cDNA cloning.";
RL
    Meth. Enzymol. 303:19-44(1999).
RN
     [2]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Testis;
    MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RX
RA
     RIKEN FANTOM Consortium;
RT
     "Functional annotation of a full-length mouse cDNA collection.";
RL
     Nature 409:685-690(2001).
RN
     [3].
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Testis;
RA
     The FANTOM Consortium,
     the RIKEN Genome Exploration Research Group Phase I & II Team;
RA
RT
     "Analysis of the mouse transcriptome based on functional annotation of
RT
     60,770 full-length cDNAs.";
RL
     Nature 420:563-573(2002).
RN
     [4]
RP
     SEQUENCE FROM N.A.
     STRAIN=C57BL/6J; TISSUE=Testis;
RC
    MEDLINE=20499374; PubMed=11042159; DOI=10.1101/qr.145100;
RX
```

```
Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA
     Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RA
     "Normalization and subtraction of cap-trapper-selected cDNAs to
RT
     prepare full-length cDNA libraries for rapid discovery of new genes.";
RT
RL
     Genome Res. 10:1617-1630(2000).
RN
     [5]
RP
     SEQUENCE FROM N.A.
     STRAIN=C57BL/6J; TISSUE=Testis;
RC
     MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RX
     Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA
     Konno H., Akiyama J., Nishi K., Kitsunai T., Tashiro H., Itoh M.,
RA
     Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA
RA
     Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
     Fujiwake S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA
     Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA
     Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RA
RT
     "RIKEN integrated sequence analysis (RISA) system-384-format
RT
     sequencing pipeline with 384 multicapillary sequencer.";
RL
     Genome Res. 10:1757-1771(2000).
RN
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Testis;
RA
     Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
RA
     Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,
RA
     Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
RA
     Hori F., Imotani K., Ishii Y., Itoh M., Kagawa I., Kasukawa T.,
RA
     Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,
     Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,
RA
RA
     Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
RA
     Saito R., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,
RA
     Sasaki D., Shibata K., Shinagawa A., Shiraki T., Sogabe Y., Tagami M.,
RA
     Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,
RA
     Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.;
RL
     Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
DR
     EMBL; AK077021; BAC36572.1; -.
DR
     HSSP; P07996; 1LSL.
DR
     GO; GO:0016021; C:integral to membrane; IEA.
DR
     InterPro; IPR000884; TSP1.
DR
     InterPro; IPR008085; TSP 1.
DR
     Pfam; PF00090; TSP 1; 4.
     PRINTS; PR01705; TSP1REPEAT.
DR
     SMART; SM00209; TSP1; 4.
DR
     PROSITE; PS50092; TSP1; 4.
KW
     Transmembrane.
SO
     SEQUENCE
                335 AA;
                         37185 MW; A6A451219EFC530D CRC64;
                          51.0%;
                                  Score 148; DB 2; Length 335;
  Query Match
  Best Local Similarity
                          54.5%;
                                  Pred. No. 2.1e-09;
  Matches
            24; Conservative
                                 6; Mismatches
                                                                 0;
                                                                             0;
                                                  14; Indels
                                                                     Gaps
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qу
              92 WTSWSPCSTTCGIGFQVRQRSCSNPTPRHGGRVCVGQNREERYC 135
```

Db

```
ID
     Q8BXU8
                 PRELIMINARY;
                                   PRT;
                                          844 AA.
AC
     O8BXU8;
DT
     01-MAR-2003 (TrEMBLrel. 23, Created)
     01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
DT
     01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE
    Mus musculus 7 days neonate cerebellum cDNA, RIKEN full-length
     enriched library, clone: A730090007 product: sema domain, seven
DE
DE
     thrombospondin repeats (type 1 and type 1-like), transmembrane domain
DE
     (TM) and short cytoplasmic domain, (semaphorin) 5A, full insert
DE
     sequence.
os
    Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
     NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Cerebellum;
RX
    MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA
    Carninci P., Hayashizaki Y.;
RT
     "High-efficiency full-length cDNA cloning.";
RL
    Meth. Enzymol. 303:19-44(1999).
RN
     [2]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Cerebellum;
    MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA
     RIKEN FANTOM Consortium;
RT
     "Functional annotation of a full-length mouse cDNA collection.";
RL
     Nature 409:685-690(2001).
RN
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Cerebellum;
RA
     The FANTOM Consortium,
     the RIKEN Genome Exploration Research Group Phase I & II Team;
RA
RT
     "Analysis of the mouse transcriptome based on functional annotation of
     60,770 full-length cDNAs.";
RT
RL
    Nature 420:563-573(2002).
RN
     [4]
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=C57BL/6J; TISSUE=Cerebellum;
    MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA
     Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA
     Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT
     "Normalization and subtraction of cap-trapper-selected cDNAs to
·RT
     prepare full-length cDNA libraries for rapid discovery of new genes.";
RL
     Genome Res. 10:1617-1630(2000).
RN
     [5]
RP
     SEQUENCE FROM N.A.
     STRAIN=C57BL/6J; TISSUE=Cerebellum;
RC
     MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RX
     Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA
     Konno H., Akiyama J., Nishi K., Kitsunai T., Tashiro H., Itoh M.,
RA
RA
     Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
     Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA
     Fujiwake S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA
     Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
     Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RA
RT
     "RIKEN integrated sequence analysis (RISA) system-384-format
```

```
sequencing pipeline with 384 multicapillary sequencer.";
RT
RL
     Genome Res. 10:1757-1771(2000).
RN
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Cerebellum;
RA
     Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
     Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,
RA
     Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
RA
     Hori F., Imotani K., Ishii Y., Itoh M., Kagawa I., Kasukawa T.,
RA
RA
     Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,
RA
     Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,
     Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
RA
RA
     Saito R., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,
     Sasaki D., Shibata K., Shinagawa A., Shiraki T., Sogabe Y., Tagami M.,
RA
RA ·
     Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,
RA
     Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.;
RL
     Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
DR
     EMBL; AK043386; BAC31531.1; -.
DR
     HSSP; P07996; 1LSL.
DR
     GO; GO:0016021; C:integral to membrane; IEA.
DR
     GO; GO:0004872; F:receptor activity; IEA.
DR
     GO; GO:0007275; P:development; IEA.
DR
     InterPro; IPR003659; Plexin-like.
DR
     InterPro; IPR002165; Plexin repeat.
DR
     InterPro; IPR001627; Sema.
     InterPro; IPR000884; TSP1.
DR
     InterPro; IPR008085; TSP 1.
DR
     Pfam; PF01437; PSI; 1.
DR
     Pfam; PF01403; Sema; 1.
DR
     Pfam; PF00090; TSP 1; 4.
DR
     PRINTS; PR01705; TSP1REPEAT.
DR
     SMART; SM00423; PSI; 1.
DR
     SMART; SM00630; Sema; 1.
DR
     SMART; SM00209; TSP1; 4.
DR
     PROSITE; PS50092; TSP1; 4.
KW
     Transmembrane.
SO
     SEQUENCE
               844 AA; 94673 MW; 19D4D8DAB36FBEA5 CRC64;
  Query Match
                          51.0%;
                                 Score 148; DB 2;
                                                    Length 844;
  Best Local Similarity
                          54.5%; Pred. No. 5e-09;
  Matches
           24; Conservative
                                 6; Mismatches
                                                 14; Indels
                                                                 0; Gaps
                                                                             0;
            3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
Qу
              601 WTSWSPCSTTCGIGFQVRQRSCSNPTPRHGGRVCVGQNREERYC 644
RESULT 15
SM5A HUMAN
     SM5A HUMAN
                    STANDARD;
                                   PRT; 1074 AA.
ID
AC
     Q13591; 060408;
DT
     30-MAY-2000 (Rel. 39, Created)
DT
     30-MAY-2000 (Rel. 39, Last sequence update)
     25-OCT-2004 (Rel. 45, Last annotation update)
     Semaphorin 5A precursor (Semaphorin F) (Sema F).
GN
     Name=SEMA5A; Synonyms=SEMAF;
OS
     Homo sapiens (Human).
```

```
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RΡ
    SEQUENCE FROM N.A.
RX
    MEDLINE=98125554; PubMed=9464278; DOI=10.1006/bbrc.1997.8027;
    Simmons A.D., Puschel A.W., McPherson J.D., Overhauser J., Lovett M.;
RA
RT
     "Molecular cloning and mapping of human semaphorin F from the Cri-du-
RT
    chat candidate interval.";
RL
    Biochem. Biophys. Res. Commun. 242:685-691(1998).
RN
    SEQUENCE OF 1-494 FROM N.A.
RP
    Kalicki J., Harmon G.;
RA
RL
    Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN
     [3]
RP
    INTERACTION WITH PLXNB3.
    PubMed=15218527; DOI=10.1038/sj.embor.7400189;
RX
RA
    Artigiani S., Conrotto P., Fazzari P., Gilestro G.F., Barberis D.,
RA
    Giordano S., Comoglio P.M., Tamagnone L.;
RT
    "Plexin-B3 is a functional receptor for semaphorin 5A.";
RL
    EMBO Rep. 5:710-714(2004).
CC
    -!- FUNCTION: May act as positive axonal guidance cues.
CC
    -!- SUBUNIT: Binds PLXNB3.
    -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
CC
    -!- SIMILARITY: Belongs to the semaphorin family.
    -!- SIMILARITY: Contains 1 Sema domain.
CC
    -!- SIMILARITY: Contains 7 TSP type-1 domains.
CC
    ______
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
DR
    EMBL; U52840; AAC09473.1; -.
DR
    EMBL; AC004615; AAC14668.1; -.
DR
    PIR; JC5928; JC5928.
DR
    HSSP; P07996; 1LSL.
    Genew; HGNC:10736; SEMA5A.
DR
    GO; GO:0007155; P:cell adhesion; TAS.
DR
    GO; GO:0007267; P:cell-cell signaling; TAS.
DR
    GO; GO:0007399; P:neurogenesis; TAS.
DR
    InterPro; IPR003659; Plexin-like.
DR
    InterPro; IPR002165; Plexin repeat.
DR
    InterPro; IPR001627; Sema.
    InterPro; IPR000884; TSP1.
DR
    InterPro; IPR008085; TSP 1.
    Pfam; PF01437; PSI; 1.
DR
DR
    Pfam; PF01403; Sema; 1.
    Pfam; PF00090; TSP 1; 6.
DR
    PRINTS; PR01705; TSP1REPEAT.
DR
DR
    SMART; SM00423; PSI; 1.
    SMART; SM00630; Sema; 1.
DR
    SMART; SM00209; TSP1; 6.
DR ·
    PROSITE; PS51004; SEMA; 1.
```

```
DR
     PROSITE; PS50092; TSP1; 6.
KW
     Developmental protein; Glycoprotein; Multigene family; Neurogenesis;
KW
     Repeat; Signal; Transmembrane.
FT
     SIGNAL
                           22
                    1
                                    Potential.
FT
     CHAIN
                        1074
                                    Semaphorin 5A.
                   23
FT
     DOMAIN
                   23
                         968
                                    Extracellular (Potential).
FT
     TRANSMEM
                  969
                         989
                                    Potential.
FT
                  990
                        1074
                                    Cytoplasmic (Potential).
     DOMAIN
FT
     DOMAIN
                   35
                         484
                                    Sema.
FT
                  540
                         593
                                    TSP type-1 1.
     DOMAIN
FT
                  595
                         651
                                    TSP type-1 2.
     DOMAIN
     DOMAIN
                  653
                         702
                                    TSP type-1 3.
FT
FT
     DOMAIN
                  707
                         765
                                    TSP type-1 4.
FT
     DOMAIN
                  784
                         839
                                    TSP type-1 5.
FT
     DOMAIN
                  841
                         896
                                    TSP type-1 6.
                  897
FT
     DOMAIN
                         944
                                    TSP type-1 7.
FT
     DISULFID
                  104
                         114
                                    By similarity.
FT
     DISULFID
                  131
                         140
                                    By similarity.
FT
     DISULFID
                  278
                         320
                                    By similarity.
FT
     DISULFID
                  487
                         504
                                    By similarity.
FT
     DISULFID
                  496
                         513
                                    By similarity.
FT
     CARBOHYD
                  142
                         142
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  168
                         168
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  227
                         227
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  277
                         277
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  323
                         323
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  367
                         367
                                    N-linked (GlcNAc. . .) (Potential).
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  437
                         437
FT
     CARBOHYD
                  536
                         536
                                    N-linked (GlcNAc. . .) (Potential).
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CARBOHYD
                  591
                         591
FT
     CARBOHYD
                  717
                         717
                                    N-linked (GlcNAc. . .) (Potential).
FΤ
     CARBOHYD
                  933
                         933
                                    N-linked (GlcNAc. . .) (Potential).
FT
     CONFLICT
                   56
                          56
                                    A \rightarrow V (in Ref. 2).
FT
     CONFLICT
                  149
                         149
                                    A \rightarrow T (in Ref. 2).
FT
     CONFLICT
                  382
                         382
                                    V \rightarrow M \text{ (in Ref. 2).}
                                    S \rightarrow R \text{ (in Ref. 2).}
\Gamma T
                         494
     CONFLICT
                  494
SO
     SEQUENCE
                 1074 AA; 120570 MW; EE3DB763CBE29407 CRC64;
  Query Match
                            51.0%;
                                    Score 148; DB 1; Length 1074;
  Best Local Similarity
                            54.5%;
                                    Pred. No. 6.2e-09;
  Matches
            24;
                  Conservative
                                       Mismatches
                                                      14; Indels
                                                                      0;
                                                                          Gaps
                                                                                   0;
Qу
             3 WTEWSVCSASCGRGWQKRSRSCTNPAPLNGGAFCEGQNVQKTAC 46
               11 11 11 :11 1:1 1 111:11 1 :11 1 111 :: 1
          601 WTSWSPCSTTCGIGFQVRQRSCSNPTPRHGGRVCVGQNREERYC 644
```

Search completed: March 1, 2005, 09:03:37

Job time : 11.1466 secs